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…life for none of us has been a crystal stair, but we must keep moving. We must keep 
going. And so, if you can’t fly, run. If you can’t run, walk. If you can’t walk, crawl. But 
by all means, keep moving. 
 


























This is dedicated to 
the women who always believed in me, inspired me to work hard no matter the 
circumstances, and taught me to enjoy life, 
my mother Betty, grandmother Mary, and granny Lerlean. 
 







 Many people have been involved in the journey I began upon my matriculation at 
Georgia Tech. First I would like to express gratitude to my advisor, Dr. Facundo M. 
Fernández. You have been an excellent mentor and extremely supportive of my many 
endeavors. I knew the first time I met with you that you were THE advisor for me, and I 
could not be happier that the both of us choosing each other worked out so well. Thank 
you for your professional guidance and financial support in pursuing my dissertation 
research. Additionally, I would like to thank my committee members Dr. Julia Kubanek, 
Dr. Lawrence Bottomley, Dr. John F. McDonald, and Dr. Mark Styczynski. I am very 
appreciative of your advisement, the collaborations that were fostered, and your interest 
in my graduate education and research in addition to my career goals.  
All teams are essentially dynamic, and the Fernández research group has been no 
different. Yet, despite changes, the morale and support of our group have remained 
outstandingly static. I would not have made it to this point without my fellow comrades. I 
would like to thank past group members Dr. Manshui Zhou, Dr. Asiri Galhena, Dr. Glenn 
Davis, Dana Hostetler, Deanna Snyder, Dr. Arti Navare, Dr. Mark Kwasnik, Dr. Leonard 
Nyadong, Adam Kaylor, Dr. María Eugenia Monge, Dr. Jennifer Pittman, Dr. Prabha 
Dwivedi, Dr. M. Julía Culzoni, and Dr. Chaminda Gamage. Manshui, thank you for 
teaching me when I first joined the group and passing the metabolomics torch to me. 
Glenn, your endless support, friendship, and still being available for words of 
encouragement means the most. Maru, I could write so much, but thank you—thank you 
for constantly pushing me to be a better scientist and for being one of the best friends I 
 vi 
have. And of course I would like to thank my current group members Rachel Bennett 
Stryffeler, Joel Keelor, José Pérez, Eric Parker, Xiaoling Zang, Scott Hogan, Dr. Martin 
Paine, Dr. Jay Forsythe, Dr. Matthew Bernier, Dr. David Gaul, Danning Huang, JasLynn 
Murphy, and my undergraduate student Laura Winalski. Rachel and Joel, you have been 
the best. It was just us for so long—I am going to miss the bond we share. Eric, take care 
of Xiaoling; keep her safe. El Capitan (Marty), you will always be my dumpling daddy. 
And Laura, you were the breath of fresh air that I needed to get to the end. Seeing science 
and research through your eyes brought me back to the joy and excitement I experienced 
when I first set foot in a research lab—one of the main reasons I pursued a doctoral 
degree. You are going to climb major heights and break down barriers, and I wish you 
nothing but the best. 
My LSU family has continued to have my best interest at heart despite the 
hundreds of miles that separate us. I owe many thanks to my forever mentor Dr. Isiah M. 
Warner. Dr. Warner has exemplified the true meaning of mentorship—always providing 
honest advice and recommendations, absolute support, professional opportunities that 
have aided in my growth as a scientific researcher, and welcoming me into his family. Dr. 
Warner, you have inspired me to follow my passions, and I hope that I can fill your big 
shoes one day. The Office of Strategic Initiatives staff has been just as wonderful—Dr. 
Monica Sylvain, Lisa Swilley, Dr. Karin H. DeGravelles, Dr. Ginger (Powe) Redd, 
Dionne Sibley, and Melissa Crawford—in addition to Gretchen Schneider and Dr. Graca 
Vicente from the IMSD program. I was groomed well for graduate school success, and I 
am happy that I continue to be a source of encouragement and inspiration for the many 
students who followed suit after.  
 vii 
Finally, I would like to thank my family and loved ones— the people who really 
never forget to remind me of the magnitude of my accomplishments. My mother, Betty J. 
London, has always inspired and encouraged me to dream big and work hard. Your faith 
in my capabilities never cease to amaze me. My interest in research sparked because of 
the unfortunate tragedy that uprooted our lives, and I am glad that we now have 
something great to show for it. I would not be here without you. My grandmother, Mary 
L. Jones, embodies what it means to be a strong female. You carry the weight of the 
world on your shoulders, but maintain a spirit of perseverance. Our conversations are a 
source of motivation, and I am glad that I make you proud. My brother, Christopher 
“Jamaal” Eruchalu, is the male version of myself. I love and adore it. I feel as though I 
am getting the chance to see myself grow and mature and venture out into the world 
again. I am glad that I can always count on you no matter what. Know that the world is 
ours for the taking. Kristen, you have positively impacted all aspects of my life and I do 
not know where I would be without that. Every time I see my precious niece Natalie, I 
am reminded of the hard-working example I have to set and the mindset of passionately 
achieving goals and having compassion (among other things) that she has to see and 
experience. We are destined for greatness, and Natalie is as well. Sakina, hopefully you 
now know that I am not like Tommy, and I have a j-o-b. I love that you believe in me and 
just assume that I can do whatever I put my mind to; where would I be without that? I 
hope that when we reminisce on this phase of my life in the future, I have achieved an 
accomplishment of which my godchildren Jordan, Jayden, and Julia can be proud. Tiana, 
it has been nearly 2 decades—almost our whole lives. You have been supportive and 
available for every single thing with which I have had to deal, and I am more grateful 
 viii 
than you will ever know. We have to show Taran that anything is possible if he puts his 
mind to it. Chloe, we are all we have, and I have finally made it to the end. You are my 
never-ending source of encouragement and my pick me up when I am down. Meagan, Dr. 
Christina M. Jones has arrived. You claimed it before anyone else. You kept me excited 
about the outcome throughout this entire process—you are my rock. You, Chloe, and I 
have without a doubt made the best of our situations and are aiming for the clouds. Dr. 
Lauren A. Austin, venimus, vidimus, vicimus—we came, we saw, we conquered. I knew I 
had a partner when I met you during that visitation weekend. We have shared so many 
experiences, and you have reveled in all of my successes—for which I am eternally 
grateful. There is never a worry when you are present because of that take-charge attitude 
of yours and your unwavering support. I am following your trek and joining the 
ranks…we made it. And of course, I would also like to thank the rest of my family. You 
have all played a role in this achievement. We must celebrate and let the good times roll. 
I am a person of faith, and I would be remiss if that was not acknowledged. God 








TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS v 
LIST OF TABLES xvi 
LIST OF FIGURES xix 
LIST OF SYMBOLS xxviii 
LIST OF ABBREVIATIONS xxx 
SUMMARY xxxv 
CHAPTER 1. UNTARGETED METABOLIC FINGERPRINTING: AN  
OVERVIEW 1 
1.1 Abstract 1 
1.2 An Origin Tale of Metabolomics 2 
1.3 Primary Analytical Platforms for Metabolic Fingerprinting 8 
1.3.1 Mass Spectrometry 8  
1.3.1.1 Gas Chromatography-Mass Spectrometry 8 
1.3.1.2 Liquid Chromatography-Mass Spectrometry 10 
1.3.1.3 Capillary Electrophoresis-Mass Spectrometry 13 
1.3.1.4 Direct Infusion and Ambient Ionization Mass  
Spectrometry 14 
1.3.2 Nuclear Magnetic Resonance Spectroscopy 16 
1.4 Biological Applications of Metabolic Fingerprinting 18 
1.4.1 Metabolomics in Oncology (Oncometabolomics) 18 
1.4.2 Metabolomics in Chemical Ecology (Ecometabolomics) 21 
1.5 Traditional Mass Spectrometry-Based Untargeted Metabolomics 
Workflow 23 
 x 
1.5.1 Experimental Design 23 
1.5.2 Biological Sample Preparation 25 
1.5.3 Data Analysis and Metabolic Feature Extraction 27 
1.5.4 Pattern Recognition by Multivariate Analysis 28 
1.5.5 Metabolite Identification and Pathway Mapping 29 
1.6 Conclusion 30 
1.7 References 32 
PART I: APPLICATIONS OF MASS SPECTROMETRY-BASED  
UNTARGETED METABOLOMICS 46 
CHAPTER 2. ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY- 
MASS SPECTROMETRY SERUM METABOLOMICS DETECTION OF  
PROSTATE CANCER 47 
2.1 Abstract 47 
2.2 Prostate Cancer Detection 48 
2.2.1 Current Diagnostic Methodology 48 
2.2.2 Overview of Metabolic Prostate Cancer Detection 49 
2.3 Experimental Details 50 
2.3.1 Chemicals 50 
2.3.2 Patient Cohort Description 51 
2.3.3 Sample Preparation and Ultra Performance Liquid  
Chromatography-Mass Spectrometry Protocols 52 
2.3.4 Data Analysis 53 
2.3.5 Discriminant Metabolite Identification Procedure 55 
2.4 Prostate Cancer Detection Performance of the In Vitro Diagnostic 
Multivariate Assay 56 
2.5 In Vitro Diagnostic Multivariate Assay Versus Prostate Specific  
Antigen Diagnosis 63 
 
 xi 
2.6 In Vitro Diagnostic Multivariate Assay Potential in Clinical  
Applications 65 
2.7 Identification of Metabolites Used in the In Vitro Diagnostic  
Multivariate Assay 71 
2.8 Biological Relevance of the In Vitro Diagnostic Multivariate Assay 
Metabolites 74 
2.9 Conclusion 81 
2.10 References 83 
CHAPTER 3. ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY- 
MASS SPECTROMETRY SERUM METABOLOMICS DETECTION  
OF EARLY-STAGE OVARIAN CANCER 91 
3.1 Abstract 91 
3.2 Ovarian Cancer 93 
3.2.1 Overview 93 
3.2.2 Current Diagnostic Methodology 93 
3.2.3 Dicer-Pten Double Knockout Mouse Model 94 
3.2.4 Metabolic Ovarian Cancer Detection 95 
3.3 Experimental Details 96 
3.3.1 Chemicals 96 
3.3.2 Dicer-Pten Double Knockout Mice 97 
3.3.3 Human Cohort Description 98 
3.3.4 Serum Sample Preparation and Experimental Design 98 
3.3.5 Metabolic Profiling via Ultra Performance Liquid  
Chromatography-Mass Spectrometry 99 
3.3.6 Data Analysis for Dicer-Pten Double Knockout Mouse Model 
Study 100 
3.3.7 Data Analysis for Human Cohort Study 101 
3.3.8 Discriminant Feature Identification Procedure 104 
 xii 
3.4 Metabolomic Serum Profiling Detects Early-Stage High-Grade  
Serous Ovarian Cancer in a Mouse Model 106 
3.4.1 Double Knockout Mice Cohort 106 
3.4.2 Multivariate Classification Performance 110 
3.4.3 Discriminant Metabolite Identification 115 
3.4.4 High Grade Serous Carcinoma-related Metabolic Alterations 123 
3.4.4.1 Fatty Acids and Derivatives 124 
3.4.4.2 Phospholipids 125 
3.4.4.3 Sphingoid Bases 127 
3.4.4.4 Bile Acids, Alcohols, & Derivatives 128 
3.4.4.5 Peptides 129 
3.4.4.6 Phytochemicals – Terpenes 129 
3.4.4.7 Phytochemicals – Lignans 130 
3.5 Ultra Performance Liquid Chromatography-Mass Spectrometry 
Characterization of Serum Metabolic Phenotypes of an  
Early-Stage Ovarian Cancer Pilot Patient Cohort 131 
3.5.1 Multivariate Classification Performance 131 
3.5.2 Discriminant Metabolite Identification and Biological  
Relevance 136 
3.5.3 Discriminant Metabolite Differences Between Early-Stage  
Papillary Serous and Endometrioid Ovarian Carcinoma 144 
3.6 Conclusion 146 
3.7 References 148 
PART II: CHALLENGES IN MASS SPECTROMETRY-BASED  
UNTARGETED METABOLOMICS 158 
CHAPTER 4. METABOLOMICS AND PROTEOMICS REVEAL  
METABOLIC IMPACTS OF CHEMICALLY MEDIATED  
COMPETITION ON MARINE PLANKTON 159 
4.1 Abstract 159 
 xiii 
4.2 Marine Plankton Competition 160 
4.2.1 Chemically Mediated Competition 160 
4.2.2 Karenia brevis 161 
4.2.3 Omics Integration 161 
4.3 Experimental Methods 162 
4.3.1 Ultra Performance Liquid Chromatography-Mass  
Spectrometry Data Acquisition 162 
4.3.2 Ultra Performance Liquid Chromatography-Mass  
    Spectrometry Data Processing 163 
4.3.3 Metabolomics Statistical Analyses 164 
4.3.4 Metabolite Annotation 165 
4.3.5 Protein Sample Preparation 167 
4.3.6 Mass Spectrometry-Based Proteomics 167 
4.3.7 Protein Database Searching and Mass Spectrometry Data  
 Interpretation 168 
4.4 Karenia brevis Allelopathy Impacts Competitor Metabolism 169 
4.5 Response of Asterionellopsis glacialis to Allelopathy 178 
4.6 Response of Thalassiosira pseudonana to Allelopathy 180 
4.6.1 Cell Protection Pathways Impacted 186 
4.6.2 Cells in Crisis 188 
4.7 Conclusion 189 
4.8 References 191 
CHAPTER 5. TRANSMISSION MODE DIRECT ANALYSIS IN REAL  
TIME MASS SPECTROMETRY FOR FAST UNTARGETED  
METABOLIC FINGERPRINTING 197 
5.1 Abstract 197 
5.2 Metabolic Fingerprinting by Direct Analysis in Real Time Mass 
Spectrometry 198 
 xiv 
5.2.1 Direct Analysis in Real Time 198 
5.2.2 Direct Analysis in Real Time in Metabolomics 200 
5.2.3 Ion Mobility Spectrometry 201 
5.3 Experimental Details 203 
5.3.1 Transmission Mode Direct Analysis in Real Time Metabolic  
Fingerprinting Method Development 203 
5.3.1.1 Chemicals 203 
5.3.1.2 Serum Sample Preparation 204 
5.3.1.3 Mass Spectrometry Instrumentation 204 
5.3.1.4 Direct Analysis in Real Time Setup 205 
5.3.2. Application of Transmission Mode Direct Analysis in Real  
Time Metabolic Fingerprinting for Cystic Fibrosis Detection 209 
5.3.2.1 Chemicals 209 
5.3.2.2 Exhaled Breath Condensate Sample Collection and 
Preparation 209 
5.3.2.3 Traveling Wave Ion Mobility Mass Spectrometry  
Instrumentation 209 
5.3.2.4 Transmission Mode Direct Analysis in Real Time  
Setup 210 
5.3.2.5 Data Analysis 211 
5.4 Optimization of Transmission Mode Direct Analysis in Real Time 
Experimental Variables  212 
5.5 Comparison of Probe Mode Direct Analysis in Real Time and 
Transmission Mode Direct Analysis in Real Time 228 
5.6 Transmission Mode Direct Analysis in Real Time Tandem Mass 
Spectrometry 231 
5.7 Application of Transmission Mode Direct Analysis in Real Time 
Metabolic Fingerprinting 235 
5.8 Conclusion 244 
 xv 
5.9 References 245 
CHAPTER 6. CONCLUSIONS AND OUTLOOK 250 
6.1 Abstract 250 
6.2 Ultra Performance Liquid Chromatography-Mass Spectrometry  
Serum Metabolomics for Cancer Detection 250 
6.2.1 Summary of Accomplishments 250 
6.2.2 Moving Forward 252 
6.3 Metabolic Impacts of Chemically Mediated Competition on  
Marine Plankton 255 
6.3.1 Summary of Accomplishments 255 
6.3.2 Moving Forward 255 
6.4 Transmission Mode Direct Analysis in Real Time for Metabolic 
Fingerprinting 257 
6.4.1 Summary of Accomplishments 257 
6.4.2 Moving Forward 257 
6.5 References 259 
VITA   260 
 xvi 
LIST OF TABLES 
Page 
Table 2.1  63 
Gleason scores for PCa patients. 
Table 2.2  66 
Discriminant feature (sub)panels for PCa detection. 
Table 2.3  69 
IVDMIA performance for identified metabolites. 
Table 2.4  75 
Results for the chemical identification workflow for various discriminant features. 
Metabolites confirmed by retention time matching with commercially-available 
standards are highlighted in bold font. 
Table 3.1  109 
Early-Stage Tumor Dicer-Pten Double Knockout Mice and Control Mice 
Characteristics. 
Table 3.2  118 
Confirmed and Tentative Metabolites Identified as Discriminatory Between 
Early-Stage Tumor Dicer-Pten Double Knockout Mice and Control Mice. 
Metabolites confirmed by retention time matching with commercially-available 
standards are highlighted in bold font. 
Table 3.3  120 
Exogenous Metabolites or Metabolites Not Reported in Mammals Identified as 
Discriminatory Between Early-Stage Tumor Dicer-Pten DKO and Control Mice. 
Table 3.4  138 
Confirmed and Tentative Metabolites Identified as Discriminatory Between 
Early-Stage Ovarian Cancer Patients and Healthy Individuals. Metabolites 
confirmed by Tandem MS experiments are highlighted in bold font. 
Table 3.5  140 
Metabolites Not Reported in Mammals Identified as Discriminatory Between 
Early-Stage OC Patients and Healthy Individuals. 
Table 3.6  144 




Table 4.1  174 
Metabolic pathways and cellular functions from Biological Process and Molecular 
Function Gene Ontology categories for proteins in Thalassiosira pseudonana 
whose concentrations increased (red triangle) or decreased (blue triangle) in 
response to Karenia brevis allelopathy. 
Table 4.2  175 
Candidate metabolites tentatively identified by NMR spectra and UPLC-MS to 
increase in concentration (red arrows) or decrease in concentration (blue arrows) 
in Thalassiosira pseudonana exposed to Karenia brevis. 
Table 4.3  179 
Candidate metabolites tentatively identified from UPLC-MS data of 
Asterionellopsis glacialis exposed to Karenia brevis allelopathy. 
Table 4.4  183 
Candidate metabolites identified from 1H and HSQC NMR spectra of 
Thalassiosira pseudonana exposed to Karenia brevis allelopathy. Chemical shifts 
in bold indicate observed signals in T. pseudonana extracts, while non-bold shifts 
indicate signals not observed due to overlap in that spectral region. 
Table 4.5  184 
Candidate metabolites tentatively identified from UPLC-MS data of Thalassiosira 
pseudonana exposed to Karenia brevis allelopathy. 
Dataset 4.1 
Spectral counts, Qspec statistics, and functional annotations of proteins identified 
in all proteomic experiments on Asterionellopsis glacialis. 
Dataset 4.2 
Spectral counts, Qspec statistics, and functional annotations of proteins identified 
in all proteomic experiments on Tha;assiosira pseudonana. 
Table 5.1  215 
Tentative annotation of peaks selected from the chemically derivatized human 
blood serum mass spectrum shown in Figure 5.2 via accurate mass measurements 
with a mass tolerance of 10 mDa and a relative intensity cutoff of 1% of the base 
peak. 
Table 5.2  229 
Reproducibility comparison between automated PM- and TM-DART 
experiments. The absolute intensities of [M+H]+ quinine ions were monitored (n = 
3) at concentrations of 10 and 15 µM. No outliers were removed from the 
datasets. 
Table 5.3  233 
Elemental formula result generated by SmartFormula from the full DART MS 
scan of the [M+H]+ D-erythro-sphingosine ion. 
 xviii 
Table 5.4  234 
Elemental formula results generated by SmartFormula 3D from the 10 eV MS/MS 
scan of D-erythro-sphingosine. The [M+H]+ ion was identified. 
Table 5.5  241 
Tentative Metabolites Identified as Discriminatory Between Cystic Fibrosis 
Patients and Healthy Controls. 
 xix 
LIST OF FIGURES 
Page 
Figure 1.1 3 
Omics Cascade. Metabolomics is the last level of the omics cascade and is more  
directly related to cellular phenotype. 
Figure 1.2 12 
Comparison of base peak chromatograms from LC-MS untargeted plasma 
metabolite profiling. An increase in resolution was observed with UPLC-MS 
analysis along with a 3-fold reduction in analysis time. The three circled peaks 
represent common ions detected in both LC-MS methods for comparison of 
separation performance. 
Figure 1.3 24 
A typical untargeted metabolomics workflow. 
Figure 2.1 57 
Evolution of classification accuracy for a validation sample subset consisting of 
10% of the training samples as a function of the number of features retained. The 
minimum discriminant feature set that maximizes classification accuracy is 
highlighted with a dashed line. 
Figure 2.2 58 
Visualization of the PCa metabolic scores obtained by SVMs in one out of 10 
iterative model validations based on 40 discriminant features. Green circles 
correspond to PCa patients in the training set, black triangles correspond to 
controls in the training set, red circles correspond to PCa patients in the test set 
built for the iteration shown, and blue triangles correspond to healthy individuals 
in the test set. The dotted line shows the projection of the separating hyperplane: 
𝒘𝒙′ + 𝑏 = 0. 
Figure 2.3 59 
Visualization of the PCa metabolic scores obtained by SVMs in 9 out of 10 model 
validation iterations. Green circles correspond to PCa patients in the training set, 
black triangles correspond to controls in the training set, red circles correspond to 
PCa patients in the test set, and blue triangles correspond to healthy individuals in 
the test set. The dotted line shows the projection of the separating hyperplane: 





Figure 2.4 61 
Fold change of average peak areas of each discriminant feature. Positive fold 
changes are calculated as the ratio of average peak areas between PCa patients 
and healthy individuals, and negative fold changes are calculated as the negative 
ratio of average peak areas between healthy individuals and PCa patients. 
Features are labeled with their codes. 
Figure 2.5 62 
Principal Component Analysis (PCA). A: PCA score plot using only the 40 
discriminant features obtained by RFE-SVMs. B: Loadings plot obtained for PC3 
using the 40 discriminant features, each labeled with their code. C: PCA score 
plot of the initial set of 480 features. Samples from PCa patients are illustrated 
with red circles and samples from healthy individuals are illustrated with blue 
circles. 
Figure 2.6 65 
Comparison of IVDMIA vs. PSA diagnosis performance for 62 PCa patients. 
True positive and false negative outputs are highlighted in red and black, 
respectively. The cutoff point of 4.0 ng mL-1 used in PSA-based diagnosis is 
indicated with a dotted line. The IVDMIA score output is presented as box plots 
in the figure, each of which is generated by results obtained for each of the 10 test 
sets where each sample was selected for validation. No comparison is shown for 2 
of the 64 PCa samples as they were not randomly selected in any of the 10 cross-
validation iterations. 
Figure 2.7 70 
Weights for the 40 discriminant metabolic features in panel A. Metabolic features 
are labeled with their codes. 
Figure 2.8 71 
Weights for the discriminant metabolic features from panels A-G (indicated in 
Table 2.2) obtained by the classification model using the total cohort. 
Figure 2.9 72 
Base peak intensity chromatograms obtained for typical serum samples from a 
patient with PCa (A) and a healthy individual (B). (C): Extracted ion 
chromatogram for m/z 187.0968 ± 0.0050 generated from a PCa patient sample 
(red line) and a healthy individual (black line). These were generated from the 
data shown in A and B, respectively. (D): Adduct ion analysis for discriminant 
feature at m/z 187.0968. Mass errors are calculated with respect to the theoretical 
values for azelaic acid (C9H16O4). Tandem MS spectrum for the m/z 187.0968 
precursor ion using a collision cell voltage of 15 V. The matching of tandem MS 
fragmentation patterns between the experimental spectrum and the metabolite 
candidate is illustrated by the mass errors calculated as differences with the values 
in the METLIN database. 
 
 xxi 
Figure 3.1 106 
Early- and late-stage high-grade serous carcinomas (HGSCs) in DKO mice (Dicer 
flox/flox Pten flox/flox Amhr2 cre/+). (A): Early fallopian tube tumors (yellow arrows) 
formed in a 6.8-month-old DKO mouse used in this study with normal ovaries 
(white arrowheads) and uterus (green arrows). (B): Massive fallopian tube tumors 
that engulfed the ovaries in a 10.7-month-old DKO mouse with late-stage 
HGSCs. 
Figure 3.2 107 
Principal Component Analysis (PCA) scores plot of early-stage tumor Dicer-Pten 
DKO (red circles), late-stage tumor Dicer-Pten DKO mice (green triangles), and 
control mice (blue squares). The model consisted of 2 PCs with 30.70% total 
captured variance. 
Figure 3.3 111 
Orthogonal projection to latent structures-discriminant analysis (oPLS-DA) 
models of early-stage tumor (ET) Dicer-Pten DKO (red circles) vs. control mice 
(blue squares). (A): oPLS-DA calibration scores plot using the total initial set of 
934 spectral features. The model consisted of 3 LVs with 35.35% and 93.64% 
total captured X- and Y-block variances, respectively. The cross-validated 
accuracy, sensitivity, and specificity were 76%, 68%, and 83%, respectively. (B): 
The corresponding ET cross-validated prediction plot for (A). There were 5 
misclassified mice. (C): oPLS-DA calibration scores plot using the 18 
discriminant metabolic feature panel obtained from genetic algorithm variable 
selection. The model consisted of 2 LVs with 33.12% and 98.30% total captured 
X- and Y-block variances, respectively. The accuracy, sensitivity, and specificity 
were all 100%. (D): The corresponding ET cross-validated prediction plot for (C). 
There were no misclassified mice. 
Figure 3.4 113 
Discriminatory spectral features having statistically significant univariate changes 
between early-stage tumor (ET) Dicer-Pten DKO mice (n = 14) and control (C) 
mice (n = 11). P-values were calculated using the Mann-Whitney U test. Box 
plots with mean (square), median, upper and lower quartile, outliers, and 
minimum and maximum (whiskers) data values are displayed. Feature ID 
numbers are indicated on top of each case. 
Figure 3.5 114 
Principal Component Analysis (PCA) of early-stage tumor Dicer-Pten DKO (red 
circles) and control mice (blue squares). (A): PCA scores plot using the initial set 
of 934 spectral features. The model consisted of 3 PCs with 46.43% total captured 
variance. (B): PCA scores plot using the 18 discriminant feature panel obtained 
from genetic algorithm variable selection. The model consisted of 3 PCs with 
53.49% total captured variance. 
 
 xxii 
Figure 3.6 116 
Typical total ion chromatograms obtained for serum samples from (A) a control 
mouse and (B) a Dicer-Pten early-stage tumor DKO mouse. (C): Extracted ion 
chromatogram for m/z 452.2779 ± 0.0050 generated from a control mouse sample 
(blue line) and a Dicer-Pten early-stage tumor DKO mouse (red line). These were 
generated from the data shown in A and B, respectively. (D): Mass spectrum for 
the discriminant metabolic feature with m/z 452.2779. (E): Tandem MS spectrum 
for the m/z 452.2779 precursor ion using a collision cell voltage of 30 V. The 
matching of the experimental tandem MS fragmentation pattern with the 
metabolite candidate is illustrated by the mass errors calculated as differences 
with the values in the MassBank database, in addition to manual fragment 
analysis. 
Figure 3.7 123 
Overview of key altered metabolic/catabolic pathways observed in early-stage 
tumor (ET) Dicer-Pten DKO mice. Arrows are colored based on their 
corresponding altered pathways and represent both direct and indirect 
relationships between metabolites/metabolite classes. Metabolites from the 18 
discriminant feature subset are italicized, and their corresponding metabolite class 
is in bold. Metabolites in red text have increased levels in ET DKO mice, while 
those in blue text have decreased levels in ET DKO mice. Metabolite 
relationships were derived from Kyoto Encyclopedia of Genes and Genomes, 
MetaCyc, and existing scientific literature. 
Figure 3.8 132 
Evolution of classification accuracy, sensitivity, and specificity resulting from the 
recursive feature elimination (RFE) method using (A) all features and (B) the 
initial curated 25 discriminant feature set. The minimum discriminant feature set 
that maximizes the model performance characteristic is highlighted with a red 
dashed line. Accuracy values are represented by the green traces, sensitivity 
values are represented by the blue traces, and specificity values are represented by 
the black traces. 
Figure 3.9 133 
Visualization of ovarian cancer (OC) detection scores obtained by SVMs using 
the 22-feature discriminant panel. Black squares correspond to the healthy women 
and red triangles correspond to the early-stage OC patients. The dotted line shows 






Figure 3.10 135 
Orthogonal projection to latent structures-discriminant analysis (oPLS-DA) cross-
validated (CV) prediction plots of early-stage ovarian cancer (OC) patients (red 
triangles) and healthy women (black squares). (A): OC CV prediction plot for the 
oPLS-DA model using the initial set of 371 spectral features. The cross-validated 
accuracy, sensitivity, and specificity of the model were 49%, 64%, and 34%, 
respectively. There were 32 misclassified samples. (B) OC CV prediction plot for 
the oPLS-DA model using the 22 discriminant feature panel. The cross-validated 
accuracy, sensitivity, and specificity of the model were 94%, 97%, and 91%, 
respectively. There were 4 misclassified samples. 
Figure 3.11 137 
Fold change of average peak areas of each discriminant feature. Fold changes are 
calculated as the base 2 logarithm of the average peak area ratios for early-stage 
ovarian cancer samples and healthy women samples. Features are labeled with 
their codes. Features with statistically significant (p ≤ 0.05) fold changes 
(calculated using Mann-Whitney U test) are additionally labeled with asterisks. 
Figure 3.12 146 
Discriminatory spectral features having statistically significant univariate changes 
between papillary serous ovarian cancer (S) patients (n = 12) and endometrioid 
ovarian cancer (E) patients (n = 12). P values were calculated using the 
Mann−Whitney U test. Box plots with mean (square), median, upper and lower 
quartile, outliers, and minimum and maximum (whiskers) data values are 
displayed. Feature ID numbers are indicated on top of each case. Fold change was 
calculated as the base 2 logarithm of the average peak area ratios for early-stage 
papillary serous ovarian cancer samples and early-stage endometrioid ovarian 
cancer samples. 
Figure 4.1 170 
Effects of exposure to exudates of live Karenia brevis on the growth of 
Asterionellopsis glacialis and Thalassiosira pseudonana. (A) A. glacialis (red) in 
vivo and T. pseudonana (blue) in vivo fluorescence (arrow indicates day of 
harvest for metabolomics and proteomics). The solid lines indicate fluorescence 
of diatom-only controls, and the dashed lines indicate fluorescence of diatoms 
exposed to K. brevis. Initial K. brevis (red open circles for A. glacialis 
experiment; blue open circles for T. pseudonana experiment) concentrations from 
cultures used to fill dialysis tubes (n = 1), final concentrations from experimental 
flasks at time of harvest (n = 15). (B) Calculated percent growth of competitors A. 
glacialis (red) and T. pseudonana (blue) relative to their own controls after 8 and 
6 days exposure to K. brevis, respectively. The dotted line indicates growth 
equivalent to control. n = 15. P < 0.0001 indicated by asterisk (*), unpaired t-test. 




Figure 4.2 171 
Orthogonal projection to latent structures-discriminant analysis (oPLS-DA) shows 
effects of Karenia brevis allelopathy on the metabolomes of competitor diatoms. 
oPLS-DA calibration scores plot of (A) UPLC-MS metabolic features and (B) 1H 
NMR spectral data for Thalassiosira pseudonana exposed to K. brevis (filled 
squares) or dilute media control (empty squares) with cross-validated accuracies 
of 87% and 100%, respectively. oPLS-DA calibration scores plot of (C) UPLC-
MS metabolic features and (D) 1H NMR spectral data for Asterionellopsis 
glacialis exposed to live K. brevis (filled circles) or dilute media controls (empty 
circles) with cross-validated accuracies of 57% and 63%, respectively. 
Figure 4.3 172 
Principal component analysis (PCA) shows effects of Karenia brevis allelopathy 
on the metabolomes of competitor diatoms. PCA scores plot of (A) UPLC-MS 
metabolic features and (B) 1H NMR spectral data for Thalassiosira pseudonana 
exposed to K. brevis (filled squares) or dilute media control (empty squares) 
showing significant separation along the 2nd and 1st principal components, 
respectively (MS: unpaired t-test, n = 30, p = 0.002; NMR: unpaired t-test, n = 9-
14, p < 0.0001). PCA scores plot of (C) UPLC-MS metabolic features and (D) 1H 
NMR spectral data for Asterionellopsis glacialis exposed to live K. brevis (filled 
circles) or dilute media controls (empty circles) with only the 1H NMR spectral 
data showing significant separation (5th principal component, unpaired t-test, n = 
9-11, p = 0.033). 
Figure 4.4 181 
Network of cellular pathways, enzymes, and metabolites in the diatom 
Thalassiosira pseudonana impacted by exposure to Karenia brevis allelopathy, 
derived from NMR and MS metabolomics and proteomics. Pathways and 
metabolites enhanced by allelopathy are indicated by red arrows and compound 
names, respectively. Blue arrows and compound names denote pathways and 
metabolites that were suppressed by allelopathy. 
Figure 5.1 203 
TWIMS schematic. A traveling voltage wave (T-wave) applied to a series of 
electrically connected ring electrodes (stacked ring ion guide: SRIG) pushes ions 
through the device. For a given wave speed and magnitude, ions carried forward 
by the T-wave have short drift times (red), while ions that roll over the T-wave 
take longer to exit the device (blue). RF, radiofrequency. 
Figure 5.2 206 
Photograph of the automated PM-DART MS system. 
Figure 5.3 207 
Photograph of the automated TM-DART system. The top panel displays the 
module used to hold the stainless steel mesh strip or discs, as well as a stainless 
steel mesh strip. The bottom panel shows the automated TM system during an 
analysis placed between the DART ion source and the GIST inlet. 
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Figure 5.4 213 
Microscopic image of a dried, derivatized human serum sample (a) before and (b) 
after TM-DART analysis with the (c) corresponding background-corrected 
positive ion mode mass spectrum in the 50 – 850 m/z range. The inset details the 
signals observed upon zooming into the baseline. 
Figure 5.5 218 
Total ion chronogram observed during TM-DART analyses of a derivatized 
serum sample showing an increase in the abundance of detected ions for each 
successive analysis prior to sample introduction method modification. 
Figure 5.6 218 
Thermal IR images of the TM-DART ion source and sampling module assembly 
during the analysis of a derivatized serum samples. The DART cap (1) in the IR 
images rests in close proximity of the module (2) where the sample is spotted for 
analysis. Two previously-analyzed mesh holder samples positions (3) are shown 
on the left, and two mesh positions in the queue (4), waiting to be analyzed, on 
the right. The color scale displays the measure temperature in Celsius. The set 
DART temperature was 250 °C. 
Figure 5.7 221 
Extracted ion chronograms for selected reagent water cluster ions present in the 
DART ionization regions for a period of ~50 minutes after application of high 
voltage to the discharge electrode. No signals for reagent ions with m/z lower than 
~75 were observed. 
Figure 5.8 223 
Effect of serum sample deposition strategy (A: liquid sample; B: sample dried 
with heated N2 from DART source; C: self-dried sample) on sensitivity and 
reproducibility of successive TM-DART analyses for mass spectrometric signals 
at m/z = 315.1042, C13H23O5Si2, m/z = 416.2246, C19H38NO5Si2, (top panel) and 
signals at m/z = 640.3391, C33H54N3O4Si3, m/z = 714.3601, C29H60N7O6Si4, 
(bottom panel). 
Figure 5.9 224 
The sensitivity of TM-DART MS analysis is influenced by the position of the SS 
mesh substrate in the ionization region. Two parameters (a) determine this 
position: the distance from the GIST to the SS mesh (i) and the distance from the 
mesh to the DART cap (ii). The effect of varying distance “i” on the sensitivity 
for untargeted metabolic profiling of derivatized serum is displayed in (b). 
Figure 5.10 225 
Effect of helium gas temperature on TM-DART MS sensitivity for untargeted 
metabolic profiling of derivatized serum: (a) absolute intensities of monitored 
signals in the low mass range and (b) absolute intensities of monitored signals at 
higher masses. Intensities were monitored at DART set temperatures of 100, 150, 
200, 250, 300, 350, and 400 °C. 
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Figure 5.11 227 
Effect of ramping the set helium gas temperature on intensities of monitored mass 
spectrometric signals in the low (top panel) and high (bottom panel) mass ranges. 
The set helium gas temperature was ramped from 150 °C to 450 °C over 3 
minutes. 
Figure 5.12 228 
Effect of helium gas flow rate on TM-DART MS sensitivity for untargeted 
metabolic profiling of derivatized serum: (a) absolute intensities for selected ions 
below m/z = 600, (b) absolute intensities for selected ions above m/z = 600. 
Intensities were monitored at flow rates of 0.50, 0.75, 1.00, 1.25, and 1.50 L min-
1. 
Figure 5.13 230 
Signal linearity for TM-DART (left) and PM-DART (right). The absolute 
intensity of the [M+H]+ quinine ion was monitored (n = 3) for 1 (PM), 10, 15, 25, 
75 (TM), 100 (TM), and 150 (TM) µM solutions. The experimental data was 
linearly fitted to a 𝑦 = 𝑚𝑥 + 𝑏 model.  The regression parameters for each DART 
operational mode are displayed within each panel. 
Figure 5.14 231 
Extracted ion chronograms of the [M+H]+ (m/z 325.1920) ion observed during 
TM-DART (top panel) and PM-DART (bottom panel) analysis of a 15 µM 
quinine solution. 
Figure 5.15 232 
TM-DART full scan MS (a) and 30 eV product ion spectrum (b) for D-erythro-
sphingosine. The quadrupole-selected precursor ion was m/z 300.2919. 
Figure 5.16 237 
Orthogonal projection to latent structures-discriminant analysis (oPLS-DA) 
models for the discrimination of CF patients (orange circles) from healthy 
controls (black squares).  (a): oPLS-DA calibration scores plot using the total 
initial set of 66 spectral features.  The model consisted of 2 LVs with 46.43% and 
93.79% total captured X- and Y-block variances, respectively. The cross-
validated accuracy, sensitivity, and specificity were 88%, 100%, and 75%, 
respectively.  (b): The corresponding CF cross-validated prediction plot for (a).  
There was 1 misclassified CF EBC sample.  (c): oPLS-DA calibration scores plot 
using the 9 discriminant metabolic feature panel obtained from genetic algorithm 
variable selection.  The model consisted of 2 LVs with 84.24% and 94.29% total 
captured X- and Y-block variances, respectively.  The accuracy, sensitivity, and 
specificity were all 100%.  (d): The corresponding CF cross-validated prediction 




Figure 5.17 238 
Principal Component Analysis (PCA) of cystic fibrosis (CF) patients (orange 
circles) and healthy controls (black squares).  (a): PCA scores plot using the initial 
set of 66 spectral features.  The model consisted of 2 PCs with 72.89% total 
captured variance.  (b): PCA scores plot using the 9 discriminant feature panel 
obtained from genetic algorithm variable selection.  The model consisted of 2 PCs 
with 84.49% total captured variance. 
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Metabolomics is the methodical scientific study of biochemical processes 
associated with the metabolome—which comprises the entire collection of metabolites in 
any biological entity. Metabolome changes occur as a result of modifications in the 
genome and proteome, and are, therefore, directly related to cellular phenotype. Thus, 
metabolomic analysis is capable of providing a snapshot of cellular physiology. 
Untargeted metabolomics is an impartial, all-inclusive approach for detecting as many 
metabolites as possible without a priori knowledge of their identity. Hence, it is a 
valuable exploratory tool capable of providing extensive chemical information for 
discovery and hypothesis-generation regarding biochemical processes. Untargeted 
metabolomic analysis is the first step toward designing targeted assays to study specific 
metabolic pathways, detect clinical disease, or monitor environmental phenomena. A 
history of metabolomics and advances in the field corresponding to improved analytical 
technologies are described in Chapter 1 of this dissertation. Additionally, Chapter 1 
introduces the analytical workflows involved in untargeted metabolomics research to 
provide a foundation for Chapters 2 – 5. 
Part I of this dissertation which encompasses Chapters 2 – 3 describes the 
utilization of mass spectrometry (MS)-based untargeted metabolomic analysis to acquire 
new insight into cancer detection. There is a knowledge deficit regarding the biochemical 
processes of the origin and proliferative molecular mechanisms of many types of cancer 
which has also led to a shortage of sensitive and specific biomarkers. Prostate cancer 
(PCa) is the 2nd leading cause of cancer-related mortality in men worldwide. Although the 
 xxxvi 
introduction of prostate-specific antigen (PSA) screening has slightly decreased 
mortality, it is still a non-specific diagnostic serum marker as elevated concentrations are 
also indicative of benign prostatic hyperplasia and prostatitis. Chapter 2 describes the 
development of an in vitro diagnostic multivariate index assay (IVDMIA) for PCa 
prediction based on ultra performance liquid chromatography-mass spectrometry (UPLC-
MS) metabolic profiling of blood serum samples from 64 PCa patients and 50 healthy 
individuals. A panel of 40 metabolic spectral features was found to be differential with 
92.1% sensitivity, 94.3% specificity, and 93.0% accuracy. The performance of the 
IVDMIA was higher than the prevalent PSA test, thus, highlighting that a combination of 
multiple discriminant features yields higher predictive power for PCa detection than the 
univariate analysis of a single marker. Numerous discriminant metabolites were mapped 
in the steroid hormone biosynthesis pathway. The identification of fatty acids, amino 
acids, lysophospholipids, and bile acids provided further insights into the metabolic 
alterations associated with the disease.  
Chapter 3 describes two approaches that were taken to investigate metabolic 
patterns for early detection of ovarian cancer (OC). OC is the 5th leading cause of cancer-
related deaths for U.S. women. Due to the unavailability of reliable screening tests in 
clinical practice and the asymptomatic course through early stages of the disease, the 
majority of ovarian cancer cases are diagnosed as advanced, metastatic disease with poor 
survival. Early detection is thus crucial in reducing ovarian cancer mortality. First, Dicer-
Pten double knockout (DKO) mice that phenocopy many of the features of metastatic 
high-grade serous carcinoma (HGSC) observed in women were studied. HGSC is the 
most common and deadliest subtype that results in 90% of OC deaths. Using UPLC-MS, 
 xxxvii 
serum samples from 14 early-stage tumor DKO mice and 11 controls were analyzed in 
depth to screen for metabolic signatures capable of differentiating early-stage HGSC 
from controls. Iterative multivariate classification selected 18 metabolites that, when 
considered as a panel, yielded 100% accuracy, sensitivity, and specificity for 
classification. Altered metabolic pathways reflected in that panel included those of fatty 
acids, bile acids, glycerophospholipids, peptides, and some dietary phytochemicals. 
These alterations revealed impacts to cellular energy storage and membrane stability, as 
well as changes in defenses against oxidative stress, shedding new light on the metabolic 
alterations associated with early OC stages. In the second approach, serum metabolic 
phenotypes of an early-stage OC pilot patient cohort were characterized. Serum samples 
were collected from 24 early-stage OC patients and 40 healthy women, and subsequently 
analyzed using UPLC-MS. Multivariate statistical analysis employing support vector 
machine learning methods and recursive feature elimination selected a panel of 
metabolites that differentiated between age-matched samples with 100% cross-validated 
accuracy, sensitivity, and specificity. This small pilot study demonstrated that metabolic 
phenotypes may be useful for detecting early-stage OC and, thus, supports conducting 
larger, more comprehensive studies. 
Many challenges exist in the field of untargeted metabolomics. Part II of this 
dissertation which encompasses Chapters 4 – 5 focuses on two specific challenges. While 
metabolomic data may be used to generate hypothesis concerning biological processes, 
determining causal relationships within metabolic networks with only metabolomic data 
is impractical. Proteins play major roles in these networks; therefore, pairing 
metabolomic information with that acquired from proteomics gives a more 
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comprehensive snapshot of perturbations to metabolic pathways. Chapter 4 describes the 
integration of MS- and NMR-based metabolomics with proteomics analyses to 
investigate the role of chemically mediated ecological interactions between Karenia 
brevis and two diatom competitors, Asterionellopsis glacialis and Thalassiosira 
pseudonana. Karenia brevis is a toxic dinoflagellate known to exude allelopathic 
compounds that directly inhibit the growth of species with whom it competes for 
resources. This integrated systems biology approach showed that K. brevis allelopathy 
distinctively perturbed the metabolisms of these two competitors. A. glacialis had a more 
robust metabolic response to K. brevis allelopathy which may be a result of its repeated 
exposure to K. brevis blooms in the Gulf of Mexico. However, K. brevis allelopathy 
disrupted energy metabolism and obstructed cellular protection mechanisms including 
altering cell membrane components, inhibiting osmoregulation, and increasing oxidative 
stress in T. pseudonana. This work represents the first instance of metabolites and 
proteins measured simultaneously to understand the effects of allelopathy or in fact any 
form of competition and highlights the ability of systems biology to shed light onto the 
nature of complex ecological interactions.  
Chromatography is traditionally coupled to MS for untargeted metabolomics 
studies. While coupling chromatography to MS greatly enhances metabolome analysis 
due to the orthogonality of the techniques, the lengthy analysis times pose challenges for 
large metabolomics studies. Consequently, there is still a need for developing higher 
throughput MS approaches. A rapid metabolic fingerprinting method that utilizes a new 
transmission mode direct analysis in real time (TM-DART) ambient sampling technique 
is presented in Chapter 5. In this approach, the sample is deposited directly on a stainless 
 xxxix 
steel mesh that is held in the ionization region by a custom-built module. As a result, the 
DART plasma gas stream interacts with the sample in a flow-through fashion, which 
maximizes the sample-ionizing species interaction and minimizes variance in sample 
positioning. The optimization of TM-DART parameters directly affecting metabolite 
desorption and ionization, such as sample position and ionizing gas desorption 
temperature, was critical in achieving high sensitivity and detecting a broad mass range 
of metabolites. Ramping the ionizing gas desorption temperature further enhanced 
analysis by adding a simple separation dimension to this ambient approach. In terms of 
reproducibility, TM-DART compared favorably with traditional probe mode DART 
analysis, with coefficients of variation as low as 16%. The longer-lasting TM-DART 
signals enabled the acquisition of full scan and product ion accurate mass spectra in a 
single experiment, resulting in greater confidence in metabolite identification. TM-DART 
MS proved to be a powerful analytical technique for rapid metabolome analysis of human 
blood sera and was adapted for exhaled breath condensate (EBC) analysis. To determine 
the feasibility of utilizing TM-DART for metabolomics investigations, TM-DART was 
interfaced with traveling wave ion mobility spectrometry (TWIMS) time-of-flight (TOF) 
MS for the analysis of EBC samples from cystic fibrosis patients and healthy controls. 
TM-DART-TWIMS-TOF MS was able to successfully detect cystic fibrosis in this small 
sample cohort, thereby, demonstrating it can be employed for probing metabolome 
changes. 
Finally, in Chapter 6, a perspective on the presented work is provided along with 









Untargeted metabolomics is an impartial, all-inclusive approach for detecting as 
many metabolites as possible without a priori knowledge of their identity. This chapter 
presents an overview of untargeted mass spectrometry (MS)-based metabolomics which 
has become a valuable exploratory tool capable of providing extensive chemical 
information for discovery and hypothesis-generation studies regarding biochemical 
processes. Metabolomics is a recently emerging systems biology “omics” field that uses a 
holistic approach to comprehensively characterize the small molecule metabolites (< 
1500 Da) in biological systems. A history of metabolomics and advances in the field 
corresponding to improved analytical technologies are described. The metabolome is 
estimated to be comprised of thousands to tens of thousands of chemically diverse 
metabolites at varying concentrations. These investigations can be challenging, and the 
main analytical platforms employed for contemporary untargeted metabolomics are 
reviewed; primary focus is placed on MS-based methods as they are utilized for analyses 
throughout the subsequent chapters. Untargeted metabolomics requires unique 
methodologies for sample preparation and mass spectrometric analysis in addition to 






1.2 An Origin Tale of Metabolomics 
Metabolomics is the methodical scientific study of biochemical processes 
associated with the metabolome which comprises the entire collection of metabolites in 
any biological entity.  These metabolites are intermediates and end products of cellular 
metabolism.  Thus, metabolomics is critical for probing changes in metabolite levels and 
collecting pertinent metabolic pathway information in an effort to investigate the 
biochemical fingerprints specific to particular cellular processes. The total number of 
human metabolites is currently unknown, but 4,000 – 20,000 are estimated.1 Metabolome 
changes occur as a result of modifications in the genome and proteome, and are, 
therefore, directly related to cellular phenotype. Thus, metabolomic analysis is capable of 
providing a snapshot of cellular physiology (Figure 1.1). Metabolomic studies can be 
conducted in both targeted and untargeted manners.  Targeted metabolomics detects and 
measures known metabolites or metabolite classes. Conversely, untargeted 
metabolomics—fingerprinting (often interchanged with profiling)—is an impartial, all-
inclusive approach that detects as many metabolites as possible without a priori 
knowledge of their identity.2, 3 Although fingerprinting and profiling are used 
interchangeably, profiling classically refers to the quantitative analysis of a particular 
class of metabolites or a set of metabolites involved in a specific biochemical pathway.4 
Untargeted metabolomic (or metabolic) fingerprinting is a valuable exploratory tool 
capable of providing extensive chemical information for discovery and hypothesis-
generation studies concerning biochemical processes. Additionally, information acquired 
from metabolomics studies can be used to characterize disease states of organisms and 




Figure 1.1: Omics Cascade. Metabolomics is the last level of the omics cascade and is 
more directly related to cellular phenotype. 
 
 
Although metabolomics is still considered to be an emerging systems biology 
field, its origins can be traced back to traditional Chinese medicine. During 1500 – 2000 
BC, traditional Chinese doctors employed ants to determine if urine glucose levels were 
too high in patients—an indicator of the metabolic disease diabetes mellitus.5 These 
medical practitioners also detected diabetes by tasting urine for the sweetness associated 
with high glucose levels. While Chinese doctors did not have a name for this metabolic 
disease at that time, they recognized that characteristics of urine, a biological fluid 
containing many end and by-products of cellular metabolism, could be used to assess the 




















Ayurvedic medicine also noted that sweet-tasting urine was associated with certain 
diseases.5 Later in history (Middle Ages: 401 – 1500), ancient Greeks used ‘urine charts’ 
to link the tastes, smells, and colors of urine to medical illnesses.6 Although 
contemporary metabolomics involves more sophisticated technologies, these ancient 
doctors correlated chemical patterns to biological processes—a fundamental notion upon 
which metabolomics was founded. 
 The growth of chromatography aided in the advent of contemporary 
metabolomics. This family of analytical separation techniques allow for simultaneous 
detection of many metabolites. C. E. Dialgliesh developed a two-dimensional paper 
chromatography method to profile urinary indolic compounds; indolic compounds may 
have been associated with bladder cancer and could provide information regarding 
vitamin nutrition.7 From the late 1940s to early 1950s, Roger Williams and his research 
team utilized paper chromatography to acquire urinary and salivary metabolic 
fingerprints of many people.8, 9 Subsequently, Williams found that similar groups of 
people, such as alcoholics or individuals suffering from mental disorders, may have 
characteristic metabolic fingerprints.  Williams’ work was a tremendous effort—more 
than 200,000 paper chromatograms were analyzed.9 The availability of liquid 
chromatography (LC) and gas chromatography (GC) analytical separation techniques 
reduced the effort needed for such studies and, consequently, further expanded the field 
of metabolomics throughout the 1960s and 1970s.10-14 Linus Pauling and collaborators 
believed that “information about the genetic nature of an individual human being, as 
reflected in the rates of various chemical reactions that take place in his body, usually 
catalyzed by enzymes, could be obtained by the thorough quantitative analysis of body 
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fluids”.14 Pauling developed a GC method to investigate biological variability by 
quantifying metabolites in urine and breath vapor based on the idea that “thorough 
quantitative analysis of body fluids might permit differential diagnosis of many diseases 
in a more effective way”.14 Additionally, Malcolm et al. demonstrated that metabolic 
profiles acquired from cerebrospinal fluid may be useful for the diagnosis of neurological 
disorders/infections in infants after profiles showed qualitative and quantitative 
differences between infant sufferers and controls.12 Although GC and LC are very 
powerful separation techniques, neither has the ability to directly identify molecules in 
complex biological samples. LC was generally coupled to UV/UV-vis detectors and GC 
to flame ionization detectors, so analysis of chemical standards was required for 
metabolite identification. But, this changed when GC and LC techniques began to be 
coupled to mass spectrometry (MS) in the 1970s and 1980s. MS has undergone many 
technical advancements since the first modern-day mass spectrometers were created.15, 16 
These advancements greatly supported the expansion of contemporary metabolomics 
since numerous metabolites could be simultaneously detected and identified. E. C. and 
M. G. Horning developed GC-MS analysis methods to acquire urinary metabolic profiles 
of steroids, acids, and drug metabolites.17, 18 In fact, the Hornings coined the term 
‘metabolic profile’. It was their belief that metabolic profiles “may prove to be useful for 
characterizing both normal and pathologic states, for studies of drug metabolism and the 
effects of drugs on human metabolism, and for human developmental studies”.17 The 
development and commercialization of atmospheric pressure ionization (API) techniques, 
chiefly electrospray ionization (ESI)19 (for which Fenn shared the chemistry Nobel Prize 
in 2002) and atmospheric pressure chemical ionization (APCI),20 allowed for the mass 
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spectrometric analysis of a broad range of analytes with varying chemical moieties and 
masses, in addition to the coupling of LC to mass spectrometers. As a result, the usage of 
LC-MS for metabolomics studies began to be on par with GC-MS.21 In 1978, Henion 
presented research on the coupling of LC to MS to study drugs and their metabolites in 
biological matrices.22-24 Games et al. utilized a newly developed interface which coupled 
LC to MS to metabolically profile plants.25 In time, more and more clinical chemists 
began to realize the utility of chromatographic separation techniques coupled to MS for 
metabolic fingerprinting of biological samples and how impactful they could be for 
detection of inherited metabolic diseases and other diseases of interest.12, 26 Additionally, 
clinical chemists and other researchers began to use multivariate pattern recognition 
methods to analyze and assist in the interpretation of their metabolomic data sets.27-32 The 
importance of dimensionality reduction of the immense data sets and the need for sample 
class discrimination functions were recognized.  
 Concurrently with the development of GC-MS and LC-MS, advancements in 
nuclear magnetic resonance (NMR) spectroscopy instrumentation, first introduced in 
1946,33, 34 allowed for metabolite profiling of biological fluids.35, 36 During the 1980s, 1H-
NMR analysis of urine proved to be successful in detecting several inherited metabolic 
disorders, including maple syrup urine disease,37 methylmalonic academia,37, 38 and 
phenylketonuria.39 Nicholson et al. demonstrated that 1H-NMR blood plasma 
fingerprinting could be used to monitor diabetes patients when they were no longer 
undergoing insulin therapy.40 Similarly to hyphenated MS analysis techniques, 
contemporary metabolomics underwent tremendous growth once NMR spectroscopists 
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also began to use multivariate analysis techniques to interpret their substantial data sets.6, 
35 
 From the 1990s to present time, metabolic fingerprinting technologies have 
incorporated MS- or NMR-based analytical platforms with multivariate statistical 
analysis techniques. New approaches have appeared for metabolic fingerprinting, such as 
capillary electrophoresis (CE)-MS,41, 42 and improvements in chromatographic separation 
techniques, namely the development of ultra performance liquid chromatography 
(UPLC),43, 44 have broadened the scope of metabolome coverage.5 Although many 
technological advancements were made for comprehensive metabolite detection, a draft 
of the human metabolome was not made available to the scientific community until 
2007.45 David Wishart, along with numerous other scientists, catalogued more than 2,180 
detectable endogenous metabolites using MS and NMR data collected from urine, blood, 
and cerebrospinal fluid, in addition to analyzing chemical standards and gathering 
metabolite information from books, journal articles, and electronic databases over a span 
of multiple years. The resultant database, the Human Metabolome Database (HMDB), 
has been updated since 2007, and now houses biological information for more than 
40,000 metabolites. ‘Detected’ metabolites (those which have been experimentally 
confirmed) and ‘expected’ metabolites (“those for which biochemical pathways are 
known or human intake/exposure is frequent but the compound has yet to be detected in 
the body”) are included.46, 47 Moreover, the number of metabolites with biological fluid 
and tissue concentration data has greatly increased. The creation of HMDB has had a 
significant impact on metabolomics research— more than 1000 published scientific 
studies encompassing metabolomics, clinical biochemistry, and systems biology have 
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utilized the resources provided by the database.46 Additional free databases used for 
metabolomics research include METLIN,48 Kyoto Encyclopedia of Genes and Genomes 
(KEGG),49 Lipid Metabolites and Pathways Strategy (LIPID MAPS) Structure 
Database,50 and MetaCyc.51 
1.3 Primary Analytical Platforms for Metabolic Fingerprinting 
 Comprehensively fingerprinting the metabolome is difficult due to its complex, 
diverse nature— thousands of metabolites belonging to different chemical compound 
classes, such as lipids, amino acids, and saccharides, exist. Moreover, these metabolites 
have dynamic levels ranging from picomoles to millimoles.52 No singular analytical 
method can measure the thousands of metabolites estimated to be present in a biological 
system, as various analytical tools are successful in detecting different classes of 
metabolites. Although other analytical detection techniques are used for metabolomics 
research, such as ion mobility spectrometry,53 and electrochemical detection (ECD),54 
MS and NMR (discussed in sections 1.3.1 and 1.3.2, respectively) are the primary 
technologies. 
1.3.1 Mass Spectrometry 
1.3.1.1 Gas Chromatography-Mass Spectrometry 
The development of GC-MS was pivotal to the growth of metabolomics, and as 
such, is one of the most widely used analytical techniques for metabolomics studies. GC 
is typically coupled to MS via electron impact (EI) ionization. GC-MS is advantageous 
due to its high peak capacity, reproducible retention times, and ability to quantify 
metabolites.4, 55, 56 Additionally, metabolite fragmentation patterns acquired by GC-MS 
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can be precisely replicated as EI ionization leads to very reproducible fragment ions, 
thereby, facilitating accurate metabolite identification by comparison to readily available 
compound databases, such as the National Institute of Standards and Technology mass 
spectral library. However, GC-MS is best suited for the analysis of volatile and thermally 
stable analytes. Polar metabolites must be chemically modified through derivatization 
reactions to reduce polarity and increase their volatility. Typically, acidic hydrogens in –
COOH, -SH, -OH, and –NH functional groups are modified via alkylation, acylation, or 
silylation chemical derivatization reactions; additionally, carbonyl functional groups can 
be modified via methoximation derivatization reactions to inhibit enolization which can 
further complicate GC-MS analyses since multiple products would be present in resultant 
mass spectra.4, 57 Methoximation derivatization followed by silylation of metabolites has 
been performed to broaden metabolome coverage.58, 59 Nevertheless, chemical 
derivatization reactions can create undesirable artifacts and also have varying degrees of 
efficiency as sterically hindered analytes may only be partially derivatized.57, 60 
Moreover, added sample preparation steps decrease sample throughput for large 
metabolomics studies, thus, increasing analysis time. 
Technological innovation has led to the development of two-dimensional GC-MS 
systems (GC x GC-MS). Typically, cryogenic modulation is utilized to transfer samples 
from a non-polar column onto a second polar column for rapid separation.4, 61 In 
comparison to GC-MS, GC x GC-MS has substantial increases in peak capacity, 
chromatographic resolution, and sensitivity, thus, making it more suitable for metabolic 
profiling of complex biological samples.61 Habram et al. demonstrated that GC x GC-MS 
analysis lowered detection limits of small hydrocarbons by a maximum factor of 27.62 
10 
 
For a metabolomics study on spleen tissue extracts, Welthagen et al. determined that GC 
x GC-MS detected 2.4 times the number of metabolites than GC-MS.63 GC x GC-MS has 
been used to metabolically profile urine of infants to determine organic acids capable of 
diagnosing inborn errors of metabolism64 and to explore metabolic differences in 
fermenting and respiring yeast cells.65 
1.3.1.2 Liquid Chromatography-Mass Spectrometry 
Although many of the first metabolomics studies utilized GC-MS, the growth and 
availability of high performance (HP) LC-MS aided in the expansion of this scientific 
field of study and is still one of the primary analysis methods used. While HPLC-MS has 
lower chromatographic resolution than GC-MS, a broad range of metabolite classes 
across a wide mass range can be detected with HPLC-MS by choosing optimal stationary 
and mobile phases.56 Moreover, there is no need to derivatize metabolites prior to 
analysis. The separation of intermediate polar to nonpolar metabolites can be achieved by 
reversed phase LC-MS with C18 stationary phases being the most common. Hydrophilic 
interaction chromatography (HILIC) has been developed for the analysis of polar 
metabolites since they are not retained on reversed-phase LC-MS columns and elute with 
the solvent front.66 Tolstikov et al. developed a HILIC-MS method that separated and 
detected highly polar metabolites in phloem exudates from petioles of Cucurbita maxima 
leaves.67 They obtained the best separation of metabolites in the plant samples using an 
amide stationary phase. Oligosaccharides, glycosides, amino sugars, amino acids, and 
sugar nucleotides were detected. Reversed-phase ion-pairing LC-MS is typically used to 
detect charged metabolites;68 however, unpaired ion-pair reagents can contaminate mass 
spectrometers and reduce the sensitivity and repeatability of LC-MS analyses.55 Luo et al. 
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employed tributylammonium acetate as an ion pair modifier in reversed-phase LC-MS to 
identify intracellular metabolites involved in the central carbon metabolism (including 
glycolysis, the pentose phosphate pathway, and the tricarboxylic acid cycle) of 
Escherichia coli.68 Sugar phosphates, nucleotides, and carboxylic acids were separated 
and detected. LC is primarily coupled to MS via ESI, a soft ionization technique that can 
be negatively impacted by matrix effects of complex biological samples.69, 70 For 









Figure 1.2: Comparison of base peak chromatograms from LC-MS untargeted plasma 
metabolite profiling. An increase in resolution was observed with UPLC-MS analysis 
along with a 3-fold reduction in analysis time. The three circled peaks represent common 
ions detected in both LC-MS methods for comparison of separation performance.  
Reprinted with permission from ref 73. Copyright 2009 American Chemical Society. 
 
 
The introduction of UPLC-MS in 200443 greatly impacted LC-MS-based 
metabolomics.55, 71 UPLC-MS utilizes 1.0 – 1.7 µm porous column particles, and, 
subsequently, requires instrumentation that can operate in the 6000 – 15000 psi pressure 
range.43 Typical peak widths are 1 – 2 s and result in a 3 – 5 fold sensitivity increase 
when compared to HPLC-MS using 3 µm particle columns.43 Moreover, increased peak 
capacity allows for higher chromatographic resolution as spectral overlap is significantly 
reduced. Rapid UPLC-MS analyses can be achieved without resolution losses which 
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increases the throughput of metabolomics studies.43, 72 Evans et al. reduced LC-MS run 
time almost 3-fold when switching from HPLC-MS to UPLC-MS for the analysis of 
plasma metabolites, while still experiencing gains in chromatographic resolution (Figure 
1.2).73 This advantage allowed for two UPLC-MS data acquisitions (positive and 
negative ESI modes) in less time than a single HPLC-MS method with better precision. 
While analyzing the urine of Zucker rats, Wilson and coworkers detected ~1,500 ionic 
species during a 10 min HPLC-MS analysis, and over 5,000 ionic species in a 5 min 
UPLC-MS analysis.74 A 1 min UPLC-MS analysis detected 1,000 ionic species, thereby, 
demonstrating that UPLC-MS can achieve similar results as HPLC-MS, but on a much 
shorter time scale. UPLC-MS has been used for metabolic profiling of human and animal 
tissues,75 determining metabolic markers for hepatitis B detection76 and hepatotoxicity.77 
1.3.1.3 Capillary Electrophoresis-Mass Spectrometry 
The first reported use of CE-MS for metabolomics research was in 2000.41 CE 
separations are rapid and require little or no sample pretreatment.78 Moreover, organic 
solvent consumption is extremely low or nonexistent and simple fused-silica capillaries 
are used instead of expensive LC columns.78 CE is typically interfaced to MS via ESI79-81 
which is not a trivial feat owing to the low effluent flow rates from the capillary, the need 
to maintain electrical contact for electrophoretic current, and the usage of electrolytes in 
the buffer used during analyses.82 CE-MS has been used to acquire metabolic fingerprints 
of human colon cancer cells,83 and for the discovery of metabolic biomarkers for diabetic 
nephropathy.84 Soga et al. employed CE-MS for serum metabolomics research that 
showed γ-glutamyl dipeptides may be potential biomarkers for liver diseases.85 The γ-
glutamyl dipeptides indicated reduced glutathione production. Although CE-MS is 
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capable of detecting a wide range of metabolites, it is best suited for the analysis of water 
soluble, charged metabolites. While reversed-phase ion-pairing LC-MS is capable of 
detecting charged metabolites, CE has less of a negative impact on the MS system.55 
Furthermore, CE has a higher theoretical separation efficiency than HPLC.55, 56 CE is 
capable of analyzing metabolites in individual cells or very small sample volumes (nL up 
to a few µL).78 Nemes et al. used CE-MS for metabolic profiling of six different neuron 
types from the Aplysia californica central nervous system.86 They detected more than 300 
distinct metabolites from a single neuron and were able to detect chemical similarities 
among some neuron types. The fused-silica capillaries used for CE-MS analysis can be 
coated to reduce electroosmotic flow, and, thus, enhance the separation windows for 
specific metabolite types. Ramautar et al. used coated polybrene-dextran sulfate-
polybrene coated CE capillaries to ensure a larger separation window for cationic 
metabolites in urine would be achieved.87 But, CE-MS can suffer from low repeatability 
when bare fused-silica capillaries are used as temperature changes cause deviations in 
migration times.82 To circumvent this disadvantage, a genetic algorithm that aligns CE-
MS data using accurate mass information has been designed.88 Using murine urine 
samples analyzed by CE-MS, the algorithm showed a significant reduction in the 
migration time drift.  
1.3.1.4 Direct Infusion and Ambient Ionization Mass Spectrometry 
Direct infusion MS (DIMS) is a high-throughput MS analytical approach that 
involves infusing/injecting a sample directly into the ionization source of a mass 
spectrometer without employing chromatography. Since typical analysis times are no 
longer than a few minutes, DIMS is able to fingerprint a large set of samples rapidly.89 
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Furthermore, short analysis times ensure that instruments are stable over the duration of 
all experiments, and reduced technical variability improves the subsequent multivariate 
analysis.90 Lin et al. compared DIMS and UPLC-MS for a kidney cancer serum 
biomarker discovery metabolomics study.91 Twenty-three metabolites were found as 
potential biomarkers by DIMS analysis, while UPLC-MS analysis discovered 48. Still, 
DIMS had comparable multivariate classification and prediction capabilities as UPLC-
MS, but only consumed ~5% of the analysis time. The authors demonstrated that DIMS 
has the potential to be a rapid diagnostic method, while UPLC-MS can be used limitedly 
when a comprehensive biomarker screening is needed. Mas et al. compared DIMS to GC-
MS for metabolic profiling of yeast mutants and found that the data acquired from both 
methods was complementary.92 GC-MS mainly detected amino acids and was well-suited 
for the classification of mutants with altered nitrogen regulation, while DIMS performed 
well at classifying mutants involved in the regulation of phospholipid metabolism. DIMS 
is used with API sources, however, ESI is the primary ionization technique used.4, 89 
Although DIMS is advantageous as a rapid analysis technique for metabolomics studies, 
it does have disadvantages. Isomeric species cannot be distinguished since they have the 
same mass, and there is a possibility for in-source fragmentation to occur as well as the 
formation of adducts.4 Furthermore, DIMS suffers from ion suppression because all 
components of the sample are introduced to the ionization source at the same time.  
Although DIMS is a rapid analysis method, sample preparation is still needed 
before metabolomics experiments are conducted to ensure the metabolites are in a liquid 
state. With the introduction of desorption electrospray ionization (DESI)93 in late 2004 
and direct analysis in real time (DART)94 in early 2005, a new subfield of analytical 
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MS—ambient ionization MS—was established. Ambient ionization MS analysis is 
conducted in open-air and entails minimal-to-no sample preparation. Ambient ionization 
MS is used to analyze samples in solid, liquid, and gaseous states. The lack of sample 
pretreatment gives ambient ionization techniques an advantageous edge for metabolomics 
research since precious samples remain in their original states. Additionally, these 
techniques are high-throughput MS analyses, given that there is a lack of 
chromatographic separation and the analysis time is mainly influenced by the time 
needed to place the sample in the ionization region of the assembled instrumentation. 
Although ambient ionization MS is a recent subfield of MS, most ambient MS ionization 
methods rely on adaptations of ESI and APCI ionization mechanisms. Ambient MS has 
been utilized for metabolomics research. Cajka et al. determined the origin of selected 
beers using DART-MS metabolomic fingerprinting.95 Pan et al. analyzed urinary 
metabolites by DESI-MS to identify patients with inborn errors of metabolism.96   
1.3.2 Nuclear Magnetic Resonance Spectroscopy 
The advancements in NMR analysis of biological fluids35 aided in the growth of 
metabolomics; consequently, NMR remains one of the primary analytical platforms used 
for metabolomics research. NMR analysis is rapid, highly reproducible, and non-
destructive, thereby, allowing samples to be analyzed in their crude form. Furthermore, 
NMR provides structural information for the detected metabolites. Unlike MS, NMR is 
not discriminatory toward certain metabolites. Its sensitivity is not dependent upon the 
chemical polarity of metabolites and, as such, can be used for broad metabolome 
coverage.97 McClay et al. used 1H NMR as a metabolomics screening tool for the 
identification of plasma and urinary biomarkers for chronic obstructive pulmonary 
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disease in addition to identifying metabolites associated with baseline lung function.98 
Samuelsson et al. used NMR-based metabolomics to study metabolic responses of 
rainbow trout exposed to the synthetic contraceptive estrogen ethinylestradiol.99 Despite 
the advantages of NMR, it is still a less sensitive detection method than MS. NMR is able 
to detect nanogram quantities, while MS has detection limits ranging from femtograms to 
pictograms.100-102 Furthermore, the complexity of biological samples leads to major 
spectral overlap of NMR signals from many metabolites, especially in the aliphatic 
region. 1H J-resolved NMR spectroscopy and two-dimensional methods (e.g. correlation 
spectroscopy, total correlation spectroscopy, or heteronuclear single quantum conherence 
spectroscopy) have been developed to increase the resolution and sensitivity of NMR 
analysis. J-resolved NMR separates metabolite chemical shifts and J-coupling into two 
dimensions, thereby, reducing spectral congestion and increasing metabolite 
specificity.103 Viant demonstrated how J-resolved NMR increases the amount of 
extractable metabolic information from NMR spectra through the investigation of 
embryogenesis in an established fish model for developmental toxicology.104 
Metabolomics studies also combine both NMR and MS approaches to broaden 
metabolome coverage as these detection platforms can complement each other. 1H NMR 
and UPLC-MS analyses have been used to determine the geographical origins of 
differing herbal medicines and to identify the primary and secondary metabolites 






1.4 Biological Applications of Metabolic Fingerprinting 
Metabolomics has been used for a wide variety of biological applications. Those 
highlighted in Sections 1.4.1 and 1.4.2 are directly related to the work presented in this 
dissertation. 
1.4.1 Metabolomics in Oncology (Oncometabolomics) 
Cancer is currently the 2nd leading cause of death in the United States but is 
expected to surpass heart disease as the leading cause within the next few years.106, 107 In 
the US alone, 1 in 4 deaths is due to cancer.106 Although the cancer death rate has been 
declining for nearly 2 decades, more than 1.6 million new cancer cases and 589,430 
cancer deaths are estimated to occur in 2015.107 Although early diagnosis leads to 
improved prognosis, there is a knowledge deficit regarding the biochemical processes of 
the origin and proliferative molecular mechanisms of many types of cancers which has 
also led to a shortage of sensitive and specific cancer biomarkers.108, 109 Researchers have 
looked to proteins for biomarker discovery for over a century. Yet, less than 10 proteins 
have progressed to FDA-approved cancer diagnostic tests.109 Recently, metabolomics has 
become more attractive for cancer research due to the development of technologies that 
can discriminate metabolic fingerprints among healthy, precancerous, and cancerous cells 
or tissues.110 Modern interest in oncometabolomics stemmed from the late 1980s claim 
that cancer could be identified by NMR spectra of blood samples;111 however, this study 
was found to be falsified and consequently tainted the field of metabolomics.112 Yet, the 
notion that metabolomics could aid in understanding and detecting cancer persisted.112 
Changes in metabolite levels occur after modifications of the genome and proteome 
linked to cancer-associated biochemical reactions, yet still before cell morphologic 
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changes associated with cancer.113 Therefore, examining the metabolome is appealing for 
early diagnostics of cancer since this analysis should detect the initial stages of 
carcinogenesis, as well as the observation of cancerous effects and subsequent therapeutic 
intervention.55 Moreover, metabolomics could aid in the understanding of the 
mechanisms of cancer development and proliferation. 
While traditional biomarker discovery studies focused on finding one marker for 
disease, biomarker panels which are typically sought after in metabolomics research have 
the potential to give better sensitivity and/or specificity than single biomarkers alone. It 
has been shown, for example, that combinations of known bladder cancer biomarkers can 
increase diagnostic sensitivity on average to 91 – 98%.114 For brain cancer,  Florian et al. 
demonstrated that in vitro NMR and HPLC metabolic profiles could distinguish between 
three types of human brain and nervous system tumors (meningiomas, neuroblastomas, 
and glioblastomas) using biomarker panels.115 Discriminant metabolites from NMR 
analysis included alanine, glutamate, creatine, phosphorylcholine, and threonine, while 
HPLC analysis showed that taurine, γ-aminobutyric acid, and serine discriminated among 
the 3 tumor types. These early findings demonstrated that metabolomics has potential for 
the development of brain cancer tumor lineage diagnosis.115 Maxwell et al. found that 1H 
NMR metabolomic profiles had 85% accuracy when used to differentiate meningiomas 
from other brain tumors.116 This accuracy was increased to 89% when only creatine and 
glutamine signals from the spectra were used for classification. Additionally, inositol 
levels significantly correlated with glioma grade. For colorectal cancer, Qiu et al. found 
that 5 metabolites associated with perturbations of glycolysis, arginine and proline 
metabolism, fatty acid metabolism, and oleamide metabolism were linked to colorectal 
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cancer morbidity using GC-MS and UPLC-MS serum metabolomic profiles.117 Nishiumi 
et al. employed GC-MS based serum metabolomic fingerprinting to create a prediction 
model for colorectal cancer based on levels of 2-hydroxybutyrate, aspartic acid, 
kynurenine, and cystamine.118 Validation of the prediction model with test samples 
resulted in 83.1%, 81.0%, and 82.0% sensitivity, specificity, and accuracy, respectively. 
The model also detected early-stage colorectal cancer with 82.8% sensitivity. 
Metabolomics is actively used to understand the molecular mechanisms by which 
chemotherapeutic drugs attack and destroy cancerous cells in addition to assessing the 
efficacy of treatment. Corominas-Faja et al. found that metformin-treated breast cancer 
cells had significant accumulation of 5-formimino-tetrahydrofolate using UPLC-MS 
metabolic profiles.119 5-formimino-tetrahydrofolate carries activated one-carbon units 
that are essential for the de novo synthesis of purines and pyrimidines. Concurrently, de 
novo synthesis of glutathione, a folate-dependent pathway involved in one-carbon 
metabolism, was reduced in response to metformin. Activation of the DNA repair protein 
ATM kinase and the metabolic tumor suppressor AMPK were not observed after 
metformin treatment. The findings suggested for the first time that metformin can 
function as an antifolate chemotherapeutic agent that induces the ATM/AMPK tumor 
suppressor after modifying the flow of carbon through folate-related one-carbon 
metabolic pathways. Choline phospholipid metabolism is elevated in many cancers, and 
the increase of total choline-containing metabolites may be used as a predictive 
biomarker for monitoring treatment efficacy in targeted therapies.112, 120 Employing 
combined magnetic resonance imaging and three-dimensional spectroscopic imaging, 
Mueller-Lisse et al. studied the metabolic effects of hormone-deprivation therapy in 
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prostate cancer patients. There was a substantial time-dependent decrease of choline, 
creatine, citrate, and polyamines, which ultimately resulted in the complete loss of these 
metabolites in 25% of patients on long-term hormone-deprivation therapy. Residual 
prostate cancer could be detected by elevated choline levels (choline/creatine ratio ≥ 1.5). 
These findings provided both a measure to detect residual prostate cancer and a time-
course of metabolic response following hormone-deprivation therapy.121 Metabolomics is 
also used to determine molecular targets for new chemotherapies, specifically focusing 
on perturbed pathways involved in cancer growth, proliferation, and metastasis.112 Folger 
et al. developed a flux balance analysis model of cancer metabolism that captured the key 
metabolic alterations that occur across many cancer types—the first computational 
approach for interpreting the ever-growing body of metabolomics and proteomics data.122  
The model was used to predict 52 cytostatic chemotherapeutic targets, of which 60% are 
not currently targeted by known, approved, or experimental anticancer drugs. Potential 
selective treatments for specific cancers that depend on cancer type‐specific down-
regulation of gene expression and somatic mutations were also presented. 
1.4.2 Metabolomics in Chemical Ecology (Ecometabolomics) 
Chemical ecology is concerned with the chemical signals that organisms produce 
and of which they respond that lead to interactions amongst themselves. These 
chemically-mediated interactions have allowed researchers to become more 
knowledgeable of how organisms locate food and habitats, as well as avoid predators and 
pathogens, compete with each other, and mate.123, 124 These interactions can dramatically 
influence ecosystem structure.124, 125 Chemical ecology advancements have correlated to 
advancements in the sensitivities of analytical technologies which have allowed for the 
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discovery of many compounds utilized for chemical signaling.123, 124 The traditional 
analysis technique for the discovery of compounds used for chemical signaling is 
bioassay-guided fractionation. While bioassay-guided fractionation can be powerful, 
bioactivity resulting from unstable compounds cannot be traced back to its original 
molecular source. Furthermore, compounds that interact synergistically are not detected 
since individual fractions may have no effect on bioassays even though combined 
fractions may illicit a biochemical response.124 Bioassay-guided fractionation is also time 
consuming and not high-throughput. Although studies using metabolomics to gain 
knowledge regarding chemically-mediated interactions are scarce,1 researchers have 
begun to exploit the advantages that metabolomics has over the traditional bioassay-
guided fractionation. As all metabolites are measured at once, unstable compounds are 
more likely to be detected.1, 124 Moreover, metabolomic investigations can evaluate the 
different responses a particular species phenotype may have in response to chemically-
mediated interactions or environmental changes in addition to the metabolic pathways 
involved in those responses.1 Metabolomics has been used to explore the effect of 
drought on the growth on Oryza sativa,126 the global responses of Arabidopsis thaliana to 
nutritional stresses,127 and the impact of pollution exposure on the metabolism of Mytilus 
galloprovincialis.128 Metabolomics has been used to investigate the impact of biotic 
factors on organisms as well. Choi et al. found 5-caffeoylquinic acid, α-linolenic acid 
analogues, and sesqui- and diterpenoids were connected to the systemic acquired 
resistance of tobacco to tobacco mosaic virus. Before their metabolomics study, only 
genes and proteins involved in the systemic acquired resistance had been characterized.129 
Schroeder et al. found that pinoresinol, a plant lignan, is a minor component in the 
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defensive secretion produced by the glandular hairs of Pieris rapae, cabbage butterfly 
caterpillars.130 The caterpillars obtain pinoresinol, which is a deterrant to ants, from their 
food source—cabbage (Brassica oleracea). Pinoresinol proved to be more potent than 
mayolene-16, a primary component belonging to the mayolene group of lipids previously 
reported to be responsible for the action of the defensive secretion. Pieiris et al. used 
metabolomics to study the chemically-mediated interactions of the wood decay 
basidiomycete fungus Stereum hirsutum with its competitors Coprinus micaceus and 
Coprinus disseminates.131 There were increased levels of 3 metabolites including malic 
acid and 1,2-dihydroxyanthraquinone when S. hirsutum was overgrown by C. 
disseminates. When S. hirsutum interacted with C. micaceus, decreased levels of 7 
metabolites including 2-methyl-2, 3-dihydroxypropionic acid and pyridoxine were 
observed. 
1.5 Traditional Mass Spectrometry-Based Untargeted Metabolomics 
Workflow 
Traditional MS-based metabolomics research is performed using chromatography 
coupled to MS and results in complex three-dimensional data sets. A traditional MS-
based untargeted metabolomics workflow is shown in Figure 1.3. The steps involved are 
further described in Sections 1.5.1 – 1.5.5. 
1.5.1 Experimental Design 
Untargeted metabolomics is an impartial, all-inclusive approach for detecting as 
many metabolites as possible without a priori knowledge of their identity. These analyses 
are the first steps toward designing targeted assays to study specific metabolic pathways, 
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detect clinical disease, or monitor environmental phenomena; thus, the experimental 
design is of the utmost importance.132 Experimental details that should be established 
early include predetermined sample classes (e.g., cancer vs. non-cancer or exposed vs. 
control) in addition to the types of biological samples needed and the number of samples 
to be included in the study. Instrumentation needed for analyses should also be 
determined since its analytical sensitivity can influence sample preparation methods. An 
assessment of analytical sensitivity and repeatability during metabolomics studies is 
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While QCs can vary, it has been recommended that a pooling of all samples to be 
analyzed serve as the QC for metabolomics studies.134 Furthermore, experimental details 
must consider possible confounding factors such as age, gender, and ethnicity, to ensure 
that resultant multivariate analysis is not influenced by such variables.135, 136 Analysis 
methods should have limited technical variation; if technical variation exceeds the 
biological variation of the system under investigation, results from the ensuing study may 
be invalid as multivariate analysis methods could solely interpret technical variation and 
not useful biological information. Steps taken to ensure this include conducting replicate 
analyses, cleaning instrumentation between sample batches, and optimizing instrumental 
parameters before beginning any metabolomics study.134 
1.5.2 Biological Sample Preparation 
Many types of biological samples are used for metabolomics studies—serum,40, 77 
plasma,40, 99 urine,40, 64, 87 cerebrospinal fluid,12 exhaled breath condensate,137 and 
tissue.63, 75 As these sample matrices also contain proteins, the primary sample 
preparation method involved in metabolomics research is extraction of metabolites. 
Metabolite extraction is challenging due to the chemical diversity of the metabolome.100 
Typically, organic solvents are used to precipitate proteins by disrupting hydrogen 
bonding to water and, subsequently, extract soluble metabolites. However, these 
extraction methods may deplete certain metabolite levels, i.e. protein-bound metabolites, 
and suffer from matrix interference.100, 138 The solvent system used for metabolite 
extraction greatly impacts the type of metabolites detected during metabolomic 
analyses—polar solvents will extract polar metabolites and a nonpolar solvent system 
will be biased towards extracting nonpolar metabolites. Moreover, the solvent system 
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used should be able to reproducibly extract metabolites to ensure minimum technical 
variation in the resultant data. Testing 14 different metabolite extraction methods for 
reversed-phase LC-MS serum metabolomics, Want et al. found that utilizing methanol as 
the extraction solvent was the most effective, reproducible metabolite extraction 
method.139 The resultant serum extracts contained over 2,000 detected metabolic features 
and less than 2% residual protein. Furthermore, methanol extracted metabolites with 
varying degrees of hydrophobicity. Interestingly, combining all of the metabolite 
extraction methods resulted in the detection of over 10,000 unique metabolic features, 
thereby demonstrating that metabolite extraction procedures can bias the types of 
detected metabolites. Using 12 protocols to extract intracellular metabolites from Chinese 
hamster ovary cells, Dietmair et al. found that the concentration of extracted intracellular 
metabolites was highest with a cold 50:50 (v/v) mixture of acetonitrile and water.140 
Additionally, this method was able to fully extract/recover all analytes of an experimental 
chemical standard metabolite mixture. Metabolites can also be fractionated after proteins 
are eliminated; liquid-liquid extraction can be performed to further separate extracted 
metabolites into polar aqueous and lipophilic organic fractions.4 Masson et al. 
demonstrated that UPLC-MS metabolic profiling of polar and nonpolar liver tissue 
metabolite extracts benefitted from aqueous extraction with methanol/water followed by 
an organic extraction with dichloromethane/methanol; although, dried extracts had to be 
resuspended in methanol/water before UPLC-MS analysis.141 The median coefficients of 
variation for metabolic feature intensities of aqueous extracts was <20%, while it was 
<30% for organic extracts. As the primary aim of untargeted metabolomics is to detect as 
many metabolites as possible without a priori knowledge of their identity, metabolite 
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extraction protocols should be optimized before beginning a study to ensure broad 
metabolome coverage. 
1.5.3 Data Analysis and Metabolic Feature Extraction 
Resultant untargeted metabolomics data files contain three dimensions: (1) 
chromatographic retention time, (2) mass-to-charge ratio (m/z), and (3) abundance. The 
acquired data sets are mined to extract metabolic features (unique retention time, m/z 
pairs) across all analyzed samples. Metabolic feature lists can contain hundreds to 
thousands of features.142 The most commonly used open-source software tools to 
accomplish this are MZmine143 and XCMS,144 but vendor supplied software also exists 
for this purpose. These software tools support many MS data file types. Furthermore, 
they can be utilized for data visualization.  Data mining procedures generally include 
chromatogram alignment to eliminate retention time variation across analyses that may 
result from sample carryover or column degradation when conducting large studies. After 
chromatograms are aligned, peaks are detected and integrated so that peak areas can be 
extracted for all metabolic features that pass chromatographic and spectral noise 
thresholds and chromatographic peak width constraints.145 The resultant metabolic 
feature list is deisotoped and adduct ions may be removed to ensure that metabolic 
features are not represented more than once. Feature lists are aligned to match metabolic 
features across all data files. MZmine allows users to “gap-fill” the peak list to ensure 
that none of the algorithms used for the above process disregard metabolic features that 
are actually present in the raw data.146 Typically, metabolic feature lists are curated to 
eliminate any features that appear in blank samples and those that are not present in a 
user-specified percentage of the real samples so that the metabolic features are 
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representative of the samples included in the study. Lastly, the peak list is normalized. 
Sample data is commonly normalized to the sum of its feature abundances.145 
1.5.4 Pattern Recognition by Multivariate Analysis 
From a statistical point of view, analysis of metabolomic data sets represents a 
significant challenge, and robust approaches are necessary to handle, extract and classify 
the relevant information from the vast amount of data generated.147 Data sets can be 
explored through principal components analysis (PCA). PCA interprets and transforms 
the metabolic features into a small number of principal components that capture maximal 
variance in the data.142 Visualization of this variance assists in the discernment of data 
trends.4 As such, PCA allows the user to determine if technical variance, such as 
instrumental drift which leads to batch effects or sample carryover, will affect the 
analysis of biological variance, in addition to pointing out sample outliers. Metabolite 
concentration differences in metabolomics data sets can be as high as 5000-fold.142 
Multivariate analysis techniques are sensitive to large metabolite abundances and 
concentration differences even if they are not biologically relevant. As such, 
metabolomics data is transformed or scaled to reduce large abundances so that low 
abundances are not dwarfed and multivariate statistical analysis is more prone to identify 
pertinent biological changes.148 Different scaling or transformation methods used include 
mean-centering, autoscaling, Pareto scaling, and general logarithm transformation.149 
Supervised classification techniques such as partial least squares discriminant analysis 
(PLS-DA), soft-independent method of class analogy (SIMCA),150 and support vector 
machines (SVMs)151 are generally used to discriminate sample classes and assist in the 
interpretation of the biological information gained from metabolomics studies.152 These 
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supervised techniques incorporate sample class membership into their analysis, so that 
biological patterns in feature abundances that discriminate sample classes can be known. 
As this modeling is done with metabolic feature lists that may contain thousands of 
features, it is important to couple the statistical modeling with variable selection methods 
that extract the most important metabolic features needed for classification. Examples of 
variable selection methods are variable importance in projection (VIP) scores,151 
recursive feature elimination (RFE),153 genetic algorithms,132 sensitivity ratios,154 and S-
plots.155 Variable selection also allows metabolite identification to become more 
manageable and eliminates noisy metabolic features that do not contribute to the 
biological variation that aids in classification. Oftentimes in untargeted metabolomics 
studies, a more global assessment of perturbed metabolism is sought after, and metabolic 
features are analyzed for statistically significant differences between sample groupings. 
This can be accomplished by nonparametric statistical methods, analysis of variance 
(ANOVA), and a Student’s t Test.142 
1.5.5 Metabolite Identification and Pathway Mapping 
Metabolites responsible for class differentiation/discrimination are identified so 
that hypotheses regarding pathway perturbations can be made or identities of potential 
biomarkers can be known. Many MS-based metabolomics studies employ high-resolution 
instrumentation capable of providing accurate masses for metabolites. Generated 
elemental formulae based on the exact mass and isotopic patterns of the metabolites can 
be searched against metabolite databases,156 such as HMDB,46 METLIN,48 and the LIPID 
MAPS database.50 Despite the growth of metabolite databases over the years, a 
substantial number of metabolic features are still not matched to metabolites.157 
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Metabolites are more confidently annotated when their fragmentation patterns and 
chromatographic retention times are matched to chemical standards.156 However, 
depending on the MS instrumentation, tandem MS fragmentation spectra may be difficult 
to obtain for low concentration metabolites whose precursor ion abundance is not high 
enough for sensitive quadrupole selection and subsequent collision induced dissociation 
due to ion transmission losses.158 If a chemical standard is not available, metabolite 
fragmentation patterns can be searched against the MS/MS METLIN database48 and 
MassBank;159 literature searches can also be conducted. Although tedious, sometimes 
fragmentation patterns must be manually analyzed for metabolite identity and to 
discriminate between different isobaric species. Once metabolite identities are validated, 
databases such as KEGG49 and MetaCyc51 are utilized to determine the metabolic 
pathways in which the metabolites play a role and the upstream biological molecules to 
which they are linked. Hypotheses regarding the metabolic state of the sample classes can 
then be developed. 
1.6 Conclusion 
Metabolomics has a rich history in clinical chemistry but is continuing to add 
girth to many additional biological fields. As metabolite distributions are representative 
of phenotype, MS-based untargeted metabolomics analysis is capable of providing new 
insight into disease detection and progression as well as increasing our knowledge of 
ecological interactions in particular environmental systems. Still, shortcomings in 
metabolomics have been realized and advances in systems biology data integration and 
high-throughput analytical technologies are needed. Pairing metabolomic information 
with that acquired from other “omics” disciplines gives a more all-inclusive snapshot of 
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perturbations to metabolic pathways since it is difficult to determine causal relationships 
within metabolic networks with only metabolomic data. Additionally, chromatographic 
separation methods coupled to MS are very powerful for metabolome analysis, but they 
are not without challenges for large metabolomics studies—lengthy analysis times—so 







(1) Sardans, J.; Penuelas, J.; Rivas-Ubach, A., Ecological metabolomics: overview of 
current developments and future challenges. Chemoecology 2011, 21 (4), 191-225. 
 
(2) Dunn, W. B.; Broadhurst, D. I.; Atherton, H. J.; Goodacre, R.; Griffin, J. L., 
Systems level studies of mammalian metabolomes: the roles of mass spectrometry and 
nuclear magnetic resonance spectroscopy. Chem. Soc. Rev. 2011, 40 (1), 387-426. 
 
(3) Griffiths, W. J.; Koal, T.; Wang, Y.; Kohl, M.; Enot, D. P.; Deigner, H.-P., 
Targeted metabolomics for biomarker discovery. Angew. Chem. Int. Ed. 2010, 49 (32), 
5426-5445. 
 
(4) Dettmer, K.; Aronov, P. A.; Hammock, B. D., Mass spectrometry‐based 
metabolomics. Mass Spectrom. Rev. 2007, 26 (1), 51-78. 
 
(5) van der Greef, J.; Smilde, A. K., Symbiosis of chemometrics and metabolomics: 
past, present, and future. J. Chemom. 2005, 19 (5-7), 376-386. 
 
(6) Nicholson, J. K.; Lindon, J. C., Systems biology: metabonomics. Nature 2008, 
455 (7216), 1054-1056. 
 
(7) Dalgliesh, C. E., Two-dimensional paper chromatography of urinary indoles and 
related substances. Biochem. J. 1956, 64 (3), 481. 
 
(8) Williams, R. J., Biochemical Institute Studies IV. Individual Metabolic Patterns 
and Human Disease: An Exploratory Study Utilizing Predominantly Paper 
Chromatographic Methods, U. Texas Publication No. 5109. University of Texas: Austin, 
TX, 1951. 
 
(9) Gates, S. C.; Sweeley, C. C., Quantitative metabolic profiling based on gas 
chromatography. Clin. Chem. 1978, 24 (10), 1663-1673. 
 
(10) Young, D. S., High pressure column chromatography of carbohydrates in the 
clinical laboratory. Am. J. Clin. Pathol. 1970, 53 (5), 803-810. 
 
(11) Williams, G. Z.; Young, D. S.; Stein, M. R.; Cotlove, E., Biological and analytic 
components of variation in long-term studies of serum constituents in normal subjects I. 
Objectives, subject selection, laboratory procedures, and estimation of analytic deviation. 
Clin. Chem. 1970, 16 (12), 1016-1021. 
 
(12) Malcolm, R. D.; Leonards, R., Gas-liquid chromatographic profile of neutral and 
acidic metabolites in cerebrospinal fluid from newborns and infants. Clin. Chem. 1976, 




(13) Scott, C. D.; Chilcote, D. D.; Katz, S.; Pitt, W. W., Advances in the application of 
high resolution liquid chromatography to the separation of complex biological mixtures. 
J. Chromatogr. Sci. 1973, 11 (2), 96-100. 
 
(14) Pauling, L.; Robinson, A. B.; Teranishi, R.; Cary, P., Quantitative analysis of 
urine vapor and breath by gas-liquid partition chromatography. Proc. Natl. Acad. Sci. 
USA 1971, 68 (10), 2374-2376. 
 
(15) Dempster, A. J., A new method of positive ray analysis. Phys. Rev. 1918, 11 (4), 
316-325. 
 
(16) Aston, F. W., LXXIV. A positive ray spectrograph. Philos. Mag. 1919, 38 (228), 
707-714. 
 
(17) Horning, E. C.; Horning, M. G., Metabolic profiles: gas-phase methods for 
analysis of metabolites. Clin. Chem. 1971, 17 (8), 802-809. 
 
(18) Horning, E. C.; Horning, M. G., Human metabolic profiles obtained by GC and 
GC/MS. J. Chromatogr. Sci. 1971, 9 (3), 129-140. 
 
(19) Yamashita, M.; Fenn, J. B., Electrospray ion source. Another variation on the 
free-jet theme. J. Phys. Chem. 1984, 88 (20), 4451-4459. 
 
(20) Carroll, D.; Dzidic, I.; Stillwell, R.; Haegele, K.; Horning, E., Atmospheric 
pressure ionization mass spectrometry. Corona discharge ion source for use in a liquid 
chromatograph-mass spectrometer-computer analytical system. Anal. Chem. 1975, 47 
(14), 2369-2373. 
 
(21) Erni, F., Liquid chromatography mass spectrometry in the pharmaceutical 
industry: objectives and needs. J. Chromatogr. A 1982, 251 (2), 141-151. 
 
(22) Henion, J. D., Continuous monitoring of total micro LC eluant by direct liquid 
introduction LC/MS. J. Chromatogr. Sci. 1981, 19 (2), 57-64. 
 
(23) Henion, J. D., Drug analysis by continuously monitored liquid 
chromatography/mass spectrometry with a quadrupole mass spectrometer. Anal. Chem. 
1978, 50 (12), 1687-1693. 
 
(24) Covey, T. R.; Crowther, J. B.; Dewey, E. A.; Henion, J. D., Thermospray liquid 
chromatography/mass spectrometry determination of drugs and their metabolites in 
biological fluids. Anal. Chem. 1985, 57 (2), 474-481. 
 
(25) Games, D. E.; Alcock, N. J.; van der Greef, J.; Nyssen, L. M.; Maarse, H.; de 
Brauw, M. C. T. N., Analysis of pepper and capsicum oleoresins by high-performance 
34 
 
liquid chromatography—mass spectrometry and field desorption mass spectrometry. J. 
Chromatogr. A 1984, 294, 269-279. 
 
(26) Politzer, I. R.; Dowty, B. J.; Laseter, J. L., Use of gas chromatography and mass 
spectrometry to analyze underivatized volatile human or animal constituents of clinical 
interest. Clin. Chem. 1976, 22 (11), 1775-1788. 
 
(27) Mayron, L. W.; Kaplan, E.; Alling, S.; Becktel, J., Drug-abuse and control 
populations differentiated by a laboratory profile. Clin. Chem. 1974, 20 (2), 172-176. 
 
(28) Rhodes, G.; Miller, M.; McConnell, M. L.; Novotny, M., Metabolic abnormalities 
associated with diabetes mellitus, as investigated by gas chromatography and pattern-
recognition analysis of profiles of volatile metabolites. Clin. Chem. 1981, 27 (4), 580-
585. 
 
(29) McConnell, M. L.; Rhodes, G.; Watson, U.; Novotný, M., Application of pattern 
recognition and feature extraction techniques to volatile constituent metabolic profiles 
obtained by capillary gas chromatography. J. Chromatogr. B Biomed. Appl. 1979, 162 
(4), 495-506. 
 
(30) Blomquist, G.; Johansson, E.; Söderström, B.; Wold, S., Classification of fungi by 
means of pyrolysis-gas chromatography-pattern recognition. J. Chromatogr. A 1979, 173 
(1), 19-32. 
 
(31) van der Greef, J.; Tas, A. C.; Bouwman, J.; de Brauw, M. C. T. N.; Schreurs, W. 
H. P., Evaluation of field-desorption and fast atom-bombardment mass spectrometric 
profiles by pattern recognition techniques. Anal. Chim. Acta 1983, 150, 45-52. 
 
(32) Tas, A. C.; Van der Greef, J., Mass spectrometric profiling and pattern 
recognition. Mass Spectrom. Rev. 1994, 13 (2), 155-181. 
 
(33) Purcell, E. M.; Torrey, H.; Pound, R. V., Resonance absorption by nuclear 
magnetic moments in a solid. Phys. Rev. 1946, 69 (1-2), 37. 
 
(34) Bloch, F.; Hansen, W. W.; Packard, M., Nuclear induction. Phys. Rev. 1946, 69 
(3-4), 127-127. 
 
(35) Nicholson, J. K.; Wilson, I. D., High resolution proton magnetic resonance 
spectroscopy of biological fluids. Prog. Nucl. Magn. Reson. Spectrosc. 1989, 21 (4), 449-
501. 
 
(36) Bell, J. D.; Brown, J. C. C.; Sadler, P. J., NMR studies of body fluids. NMR 




(37) Iles, R. A.; Hind, A. J.; Chalmers, R. A., Use of proton nuclear magnetic 
resonance spectroscopy in detection and study of organic acidurias. Clin. Chem. 1985, 31 
(11), 1795-1801. 
 
(38) Williams, S. R.; Iles, R. A.; Chalmers, R. A., Spin-echo and 2-dimensional 1 H 
nuclear magnetic resonance studies on urinary metabolites from patients with 2-
methylacetocetyl CoA thiolase deficiency. Clin. Chim. Acta 1986, 159 (2), 153-161. 
 
(39) Yamaguchi, S.; Koda, N.; Eto, Y.; Aoki, K., Rapid screening of metabolic disease 
by proton NMR urinalysis. Lancet 1984, 324 (8397), 284. 
 
(40) Nicholson, J. K.; O'Flynn, M. P.; Sadler, P. J.; Macleod, A. F.; Juul, S. M.; 
Sonksen, P. H., Proton-nuclear-magnetic-resonance studies of serum, plasma and urine 
from fasting normal and diabetic subjects. Biochem. J. 1984, 217, 365-375. 
 
(41) Soga, T.; Heiger, D. N., Amino acid analysis by capillary electrophoresis 
electrospray ionization mass spectrometry. Anal. Chem. 2000, 72 (6), 1236-1241. 
 
(42) Soga, T.; Ohashi, Y.; Ueno, Y.; Naraoka, H.; Tomita, M.; Nishioka, T., 
Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J. 
Proteome Res. 2003, 2 (5), 488-494. 
 
(43) Plumb, R.; Castro-Perez, J.; Granger, J.; Beattie, I.; Joncour, K.; Wright, A., 
Ultra‐performance liquid chromatography coupled to quadrupole-orthogonal time-of-
flight mass spectrometry. Rapid Commun. Mass Spectrom. 2004, 18 (19), 2331-2337. 
 
(44) Plumb, R. S.; Granger, J. H.; Stumpf, C. L.; Johnson, K. A.; Smith, B. W.; 
Gaulitz, S.; Wilson, I. D.; Castro-Perez, J., A rapid screening approach to metabonomics 
using UPLC and oa-TOF mass spectrometry: application to age, gender and diurnal 
variation in normal/Zucker obese rats and black, white and nude mice. Analyst 2005, 130 
(6), 844-849. 
 
(45) Wishart, D. S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A. C.; Young, N.; Cheng, D.; 
Jewell, K.; Arndt, D.; Sawhney, S., HMDB: the human metabolome database. Nucleic 
Acids Res. 2007, 35 (suppl 1), D521-D526. 
 
(46) Wishart, D. S.; Jewison, T.; Guo, A. C.; Wilson, M.; Knox, C.; Liu, Y.; 
Djoumbou, Y.; Mandal, R.; Aziat, F.; Dong, E., HMDB 3.0—the human metabolome 
database in 2013. Nucleic Acids Res. 2012, 41 (suppl 1), D801-D807. 
 
(47) Wishart, D. S.; Knox, C.; Guo, A. C.; Eisner, R.; Young, N.; Gautam, B.; Hau, D. 
D.; Psychogios, N.; Dong, E.; Bouatra, S., HMDB: a knowledgebase for the human 




(48) Smith, C. A.; O'Maille, G.; Want, E. J.; Qin, C.; Trauger, S. A.; Brandon, T. R.; 
Custodio, D. E.; Abagyan, R.; Siuzdak, G., METLIN: a metabolite mass spectral 
database. Ther. Drug Monit. 2005, 27 (6), 747-751. 
 
(49) Kanehisa, M.; Goto, S., KEGG: kyoto encyclopedia of genes and genomes. 
Nucleic Acids Res. 2000, 28 (1), 27-30. 
 
(50) Sud, M.; Fahy, E.; Cotter, D.; Brown, A.; Dennis, E. A.; Glass, C. K.; Merrill, A. 
H.; Murphy, R. C.; Raetz, C. R.; Russell, D. W., Lmsd: lipid maps structure database. 
Nucleic Acids Res. 2007, 35 (suppl 1), D527-D532. 
 
(51) Caspi, R.; Foerster, H.; Fulcher, C. A.; Kaipa, P.; Krummenacker, M.; 
Latendresse, M.; Paley, S.; Rhee, S. Y.; Shearer, A. G.; Tissier, C., The MetaCyc 
Database of metabolic pathways and enzymes and the BioCyc collection of 
Pathway/Genome Databases. Nucleic Acids Res. 2008, 36 (suppl 1), D623-D631. 
 
(52) Dunn, W. B.; Ellis, D. I., Metabolomics: current analytical platforms and 
methodologies. TrAC, Trends Anal. Chem. 2005, 24 (4), 285-294. 
 
(53) Ruzsanyi, V.; Baumbach, J. I.; Sielemann, S.; Litterst, P.; Westhoff, M.; Freitag, 
L., Detection of human metabolites using multi-capillary columns coupled to ion 
mobility spectrometers. J. Chromatogr. A 2005, 1084 (1), 145-151. 
 
(54) Shurubor, Y. I.; Matson, W. R.; Willett, W. C.; Hankinson, S. E.; Kristal, B. S., 
Biological variability dominates and influences analytical variance in HPLC-ECD studies 
of the human plasma metabolome. BMC Clin. Pathol. 2007, 7 (1), 9. 
 
(55) Putri, S. P.; Yamamoto, S.; Tsugawa, H.; Fukusaki, E., Current metabolomics: 
technological advances. J. Biosci. Bioeng. 2013, 116 (1), 9-16. 
 
(56) Gomase, V.; Changbhale, S.; Patil, S.; Kale, K., Metabolomics. Curr. Drug 
Metab. 2008, 9 (1), 89-98. 
 
(57) Halket, J. M.; Waterman, D.; Przyborowska, A. M.; Patel, R. K.; Fraser, P. D.; 
Bramley, P. M., Chemical derivatization and mass spectral libraries in metabolic 
profiling by GC/MS and LC/MS/MS. J. Exp. Bot. 2005, 56 (410), 219-243. 
 
(58) Jonsson, P.; Gullberg, J.; Nordström, A.; Kusano, M.; Kowalczyk, M.; Sjöström, 
M.; Moritz, T., A strategy for identifying differences in large series of metabolomic 
samples analyzed by GC/MS. Anal. Chem. 2004, 76 (6), 1738-1745. 
 
(59) Roessner, U.; Wagner, C.; Kopka, J.; Trethewey, R. N.; Willmitzer, L., 
Simultaneous analysis of metabolites in potato tuber by gas chromatography–mass 




(60) Little, J. L., Artifacts in trimethylsilyl derivatization reactions and ways to avoid 
them. J. Chromatogr. A 1999, 844 (1), 1-22. 
 
(61) Lee, A. L.; Bartle, K. D.; Lewis, A. C., A model of peak amplitude enhancement 
in orthogonal two-dimensional gas chromatography. Anal. Chem. 2001, 73 (6), 1330-
1335. 
 
(62) Habram, M.; Welsch, T., Improvement of the detection limit in capillary gas 
Chromatographic trace analysis of C2–C4 hydrocarbons by post column cryogenic 
trapping. J. High. Resolut. Chromatogr. 1999, 22 (6), 335-338. 
 
(63) Welthagen, W.; Shellie, R. A.; Spranger, J.; Ristow, M.; Zimmermann, R.; Fiehn, 
O., Comprehensive two-dimensional gas chromatography–time-of-flight mass 
spectrometry (GC× GC-TOF) for high resolution metabolomics: biomarker discovery on 
spleen tissue extracts of obese NZO compared to lean C57BL/6 mice. Metabolomics 
2005, 1 (1), 65-73. 
 
(64) Kouremenos, K. A.; Pitt, J.; Marriott, P. J., Metabolic profiling of infant urine 
using comprehensive two-dimensional gas chromatography: application to the diagnosis 
of organic acidurias and biomarker discovery. J. Chromatogr. A 2010, 1217, 104-111. 
 
(65) Mohler, R. E.; Dombek, K. M.; Hoggard, J. C.; Young, E. T.; Synovec, R. E., 
Comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry 
analysis of metabolites in fermenting and respiring yeast cells. Anal. Chem. 2006, 78 (8), 
2700-2709. 
 
(66) Alpert, A. J., Hydrophilic-interaction chromatography for the separation of 
peptides, nucleic acids and other polar compounds. J. Chromatogr. A 1990, 499, 177-
196. 
 
(67) Tolstikov, V. V.; Fiehn, O., Analysis of highly polar compounds of plant origin: 
combination of hydrophilic interaction chromatography and electrospray ion trap mass 
spectrometry. Anal. Biochem. 2002, 301 (2), 298-307. 
 
(68) Luo, B.; Groenke, K.; Takors, R.; Wandrey, C.; Oldiges, M., Simultaneous 
determination of multiple intracellular metabolites in glycolysis, pentose phosphate 
pathway and tricarboxylic acid cycle by liquid chromatography–mass spectrometry. J. 
Chromatogr. A 2007, 1147 (2), 153-164. 
 
(69) Whitehouse, C. M.; Dreyer, R. N.; Yamashita, M.; Fenn, J. B., Electrospray 
interface for liquid chromatographs and mass spectrometers. Anal. Chem. 1985, 57 (3), 
675-679. 
 
(70) Ikonomou, M. G.; Blades, A. T.; Kebarle, P., Investigations of the electrospray 





(71) Wang, X.; Sun, H.; Zhang, A.; Wang, P.; Han, Y., Ultra‐performance liquid 
chromatography coupled to mass spectrometry as a sensitive and powerful technology for 
metabolomic studies. J. Sep. Sci. 2011, 34 (24), 3451-3459. 
 
(72) Zhang, A.; Sun, H.; Wang, P.; Han, Y.; Wang, X., Modern analytical techniques 
in metabolomics analysis. Analyst 2012, 137 (2), 293-300. 
 
(73) Evans, A. M.; DeHaven, C. D.; Barrett, T.; Mitchell, M.; Milgram, E., Integrated, 
nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem 
mass spectrometry platform for the identification and relative quantification of the small-
molecule complement of biological systems. Anal. Chem. 2009, 81 (16), 6656-6667. 
 
(74) Wilson, I. D.; Plumb, R.; Granger, J.; Major, H.; Williams, R.; Lenz, E. M., 
HPLC-MS-based methods for the study of metabonomics. J. Chromatogr. B 2005, 817 
(1), 67-76. 
 
(75) Want, E. J.; Masson, P.; Michopoulos, F.; Wilson, I. D.; Theodoridis, G.; Plumb, 
R. S.; Shockcor, J.; Loftus, N.; Holmes, E.; Nicholson, J. K., Global metabolic profiling 
of animal and human tissues via UPLC-MS. Nat. Protoc. 2013, 8 (1), 17-32. 
 
(76) Zhang, A.; Sun, H.; Han, Y.; Yan, G.; Wang, X., Urinary metabolic biomarker 
and pathway study of hepatitis B virus infected patients based on UPLC-MS system. PloS 
One 2013, 8 (5), e64381. 
 
(77) Gonzalez, E.; van Liempd, S.; Conde-Vancells, J.; Gutierrez-de Juan, V.; Perez-
Cormenzana, M.; Mayo, R.; Berisa, A.; Alonso, C.; Marquez, C. A.; Barr, J., Serum 
UPLC-MS/MS metabolic profiling in an experimental model for acute-liver injury 
reveals potential biomarkers for hepatotoxicity. Metabolomics 2012, 8 (6), 997-1011. 
 
(78) Ramautar, R.; Mayboroda, O. A.; Somsen, G. W.; de Jong, G. J., CE-MS for 
metabolomics: developments and applications in the period 2008–2010. Electrophoresis 
2011, 32 (1), 52-65. 
 
(79) Smith, R. D.; Olivares, J. A.; Nguyen, N. T.; Udseth, H. R., Capillary zone 
electrophoresis-mass spectrometry using an electrospray ionization interface. Anal. 
Chem. 1988, 60 (5), 436-441. 
 
(80) Lee, E. D.; Mück, W.; Henion, J. D.; Covey, T. R., Liquid junction coupling for 
capillary zone electrophoresis/ion spray mass spectrometry. Biomed. Environ. Mass 
Spectrom. 1989, 18 (9), 844-850. 
 
(81) Issaq, H. J.; Janini, G. M.; Chan, K. C.; Veenstra, T. D., Sheathless electrospray 
ionization interfaces for capillary electrophoresis–mass spectrometric detection: 




(82) Garcia-Perez, I.; Vallejo, M.; Garcia, A.; Legido-Quigley, C.; Barbas, C., 
Metabolic fingerprinting with capillary electrophoresis. J. Chromatogr. A 2008, 1204 (2), 
130-139. 
 
(83) Simó, C.; Ibáñez, C.; Gómez-Martínez, Á.; Ferragut, J. A.; Cifuentes, A., Is 
metabolomics reachable? Different purification strategies of human colon cancer cells 
provide different CE-MS metabolite profiles. Electrophoresis 2011, 32 (13), 1765-1777. 
 
(84) Hirayama, A.; Nakashima, E.; Sugimoto, M.; Akiyama, S.-i.; Sato, W.; 
Maruyama, S.; Matsuo, S.; Tomita, M.; Yuzawa, Y.; Soga, T., Metabolic profiling 
reveals new serum biomarkers for differentiating diabetic nephropathy. Anal. Bioanal. 
Chem. 2012, 404 (10), 3101-3109. 
 
(85) Soga, T.; Sugimoto, M.; Honma, M.; Mori, M.; Igarashi, K.; Kashikura, K.; 
Ikeda, S.; Hirayama, A.; Yamamoto, T.; Yoshida, H., Serum metabolomics reveals γ-
glutamyl dipeptides as biomarkers for discrimination among different forms of liver 
disease. J. Hepatol. 2011, 55 (4), 896-905. 
 
(86) Nemes, P.; Knolhoff, A. M.; Rubakhin, S. S.; Sweedler, J. V., Metabolic 
differentiation of neuronal phenotypes by single-cell capillary electrophoresis–
electrospray ionization-mass spectrometry. Anal. Chem. 2011, 83 (17), 6810-6817. 
 
(87) Ramautar, R.; Nevedomskaya, E.; Mayboroda, O. A.; Deelder, A. M.; Wilson, I. 
D.; Gika, H. G.; Theodoridis, G. A.; Somsen, G. W.; de Jong, G. J., Metabolic profiling 
of human urine by CE-MS using a positively charged capillary coating and comparison 
with UPLC-MS. Mol. Biosyst. 2011, 7 (1), 194-199. 
 
(88) Nevedomskaya, E.; Derks, R.; Deelder, A. M.; Mayboroda, O. A.; Palmblad, M., 
Alignment of capillary electrophoresis–mass spectrometry datasets using accurate mass 
information. Anal. Bioanal. Chem. 2009, 395 (8), 2527-2533. 
 
(89) Bedair, M.; Sumner, L. W., Current and emerging mass-spectrometry 
technologies for metabolomics. TrAC, Trends Anal. Chem. 2008, 27 (3), 238-250. 
 
(90) Kirwan, J.; Broadhurst, D.; Davidson, R.; Viant, M., Characterising and 
correcting batch variation in an automated direct infusion mass spectrometry (DIMS) 
metabolomics workflow. Anal. Bioanal. Chem. 2013, 405 (15), 5147-5157. 
 
(91) Lin, L.; Yu, Q.; Yan, X.; Hang, W.; Zheng, J.; Xing, J.; Huang, B., Direct 
infusion mass spectrometry or liquid chromatography mass spectrometry for human 
metabonomics? A serum metabonomic study of kidney cancer. Analyst 2010, 135 (11), 
2970-2978. 
 
(92) Mas, S.; Villas‐Bôas, S. G.; Edberg Hansen, M.; Åkesson, M.; Nielsen, J., A 
comparison of direct infusion MS and GC‐MS for metabolic footprinting of yeast 




(93) Takats, Z.; Wiseman, J. M.; Gologan, B.; Cooks, R. G., Mass spectrometry 
sampling under ambient conditions with desorption electrospray ionization. Science 
2004, 306 (5695), 471-473. 
 
(94) Cody, R. B.; Laramée, J. A.; Durst, H. D., Versatile new ion source for the 
analysis of materials in open air under ambient conditions. Anal. Chem. 2005, 77 (8), 
2297-2302. 
 
(95) Cajka, T.; Riddellova, K.; Tomaniova, M.; Hajslova, J., Ambient mass 
spectrometry employing a DART ion source for metabolomic fingerprinting/profiling: a 
powerful tool for beer origin recognition. Metabolomics 2011, 7 (4), 500-508. 
 
(96) Pan, Z.; Gu, H.; Talaty, N.; Chen, H.; Shanaiah, N.; Hainline, B. E.; Cooks, R. G.; 
Raftery, D., Principal component analysis of urine metabolites detected by NMR and 
DESI–MS in patients with inborn errors of metabolism. Anal. Bioanal. Chem. 2007, 387 
(2), 539-549. 
 
(97) Pan, Z.; Raftery, D., Comparing and combining NMR spectroscopy and mass 
spectrometry in metabolomics. Anal. Bioanal. Chem. 2007, 387 (2), 525-527. 
 
(98) McClay, J. L.; Adkins, D. E.; Isern, N. G.; O’Connell, T. M.; Wooten, J. B.; 
Zedler, B. K.; Dasika, M. S.; Webb, B. T.; Webb-Robertson, B.-J.; Pounds, J. G., 1H 
nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers 
for lung function. J. Proteome Res. 2010, 9 (6), 3083-3090. 
 
(99) Samuelsson, L. M.; Förlin, L.; Karlsson, G.; Adolfsson-Erici, M.; Larsson, D. J., 
Using NMR metabolomics to identify responses of an environmental estrogen in blood 
plasma of fish. Aquat. Toxicol. 2006, 78 (4), 341-349. 
 
(100) Zhou, B.; Xiao, J. F.; Tuli, L.; Ressom, H. W., LC-MS-based metabolomics. Mol. 
Biosyst. 2012, 8 (2), 470-481. 
 
(101) Shockcor, J. P.; Unger, S. E.; Wilson, I. D.; Foxall, P. J.; Nicholson, J. K.; 
Lindon, J. C., Combined HPLC, NMR spectroscopy, and ion-trap mass spectrometry 
with application to the detection and characterization of xenobiotic and endogenous 
metabolites in human urine. Anal. Chem. 1996, 68 (24), 4431-4435. 
 
(102) Albert, K., On-line use of NMR detection in separation chemistry. J. Chromatogr. 
A 1995, 703, 123-147. 
 
(103) Ludwig, C.; Viant, M. R., Two‐dimensional J‐resolved NMR spectroscopy: 





(104) Viant, M. R., Improved methods for the acquisition and interpretation of NMR 
metabolomic data. Biochem. Biophys. Res. Commun. 2003, 310 (3), 943-948. 
 
(105) Kim, E. J.; Kwon, J.; Park, S. H.; Park, C.; Seo, Y.-B.; Shin, H.-K.; Kim, H. K.; 
Lee, K.-S.; Choi, S.-Y.; Ryu, D. H., Metabolite profiling of Angelica gigas from different 
geographical origins using 1H NMR and UPLC-MS analyses. J. Agric. Food. Chem. 
2011, 59 (16), 8806-8815. 
 
(106) Siegel, R.; Ma, J.; Zou, Z.; Jemal, A., Cancer statistics, 2014. CA Cancer J. Clin. 
2014, 64 (1), 9-29. 
 
(107) Siegel, R. L.; Miller, K. D.; Jemal, A., Cancer statistics, 2015. CA Cancer J. Clin. 
2015, 65 (1), 5-29. 
 
(108) Drucker, E.; Krapfenbauer, K., Pitfalls and limitations in translation from 
biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 
2013, 4 (1), 1-10. 
 
(109) Polanski, M.; Anderson, N. L., A list of candidate cancer biomarkers for targeted 
proteomics. Biomark. Insights 2006, 1, 1-48. 
 
(110) Serkova, N. J.; Spratlin, J. L.; Eckhardt, S. G., NMR-based metabolomics: 
translational application and treatment of cancer. Curr. Opin. Mol. Ther. 2007, 9 (6), 572-
585. 
 
(111) Fossel, E. T.; Carr, J. M.; McDonagh, J., Detection of malignant tumors. New 
Engl. J. Med. 1986, 315 (22), 1369-1376. 
 
(112) Spratlin, J. L.; Serkova, N. J.; Eckhardt, S. G., Clinical applications of 
metabolomics in oncology: a review. Clin. Cancer. Res. 2009, 15 (2), 431-440. 
 
(113) Kim, Y. S.; Maruvada, P., Frontiers in metabolomics for cancer research: 
proceedings of a National Cancer Institute workshop. Metabolomics 2008, 4 (2), 105-
113. 
 
(114) Issaq, H. J.; Waybright, T. J.; Veenstra, T. D., Cancer biomarker discovery: 
opportunities and pitfalls in analytical methods. Electrophoresis 2011, 32 (9), 967-975. 
 
(115) Florian, C. L.; Preece, N. E.; Bhakoo, K. K.; Williams, S. R.; Noble, M., 
Characteristic metabolic profiles revealed by 1H NMR spectroscopy for three types of 
human brain and nervous system tumours. NMR Biomed. 1995, 8 (6), 253-264. 
 
(116) Maxwell, R. J.; Martínez-Pérez, I.; Cerdán, S.; Cabañas, M. E.; Arús, C.; Moreno, 
À.; Capdevila, A.; Ferrer, E.; Bartomeus, F.; Aparicio, A., Pattern recognition analysis of 
1H NMR spectra from perchloric acid extracts of human brain tumor biopsies. Magn. 




(117) Qiu, Y.; Cai, G.; Su, M.; Chen, T.; Zheng, X.; Xu, Y.; Ni, Y.; Zhao, A.; Xu, L. 
X.; Cai, S., Serum metabolite profiling of human colorectal cancer using GC-TOFMS 
and UPLC-QTOFMS. J. Proteome Res. 2009, 8 (10), 4844-4850. 
 
(118) Nishiumi, S.; Kobayashi, T.; Ikeda, A.; Yoshie, T.; Kibi, M.; Izumi, Y.; Okuno, 
T.; Hayashi, N.; Kawano, S.; Takenawa, T., A novel serum metabolomics-based 
diagnostic approach for colorectal cancer. PLoS One 2012, 7 (7), e40459. 
 
(119) Corominas-Faja, B.; Quirantes-Piné, R.; Oliveras-Ferraros, C.; Vazquez-Martin, 
A.; Cufí, S.; Martin-Castillo, B.; Micol, V.; Joven, J.; Segura-Carretero, A.; Menendez, J. 
A., Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a 
manner similar to the antifolate class of chemotherapy drugs. Aging 2012, 4 (7), 480. 
 
(120) Glunde, K.; Serkova, N. J., Therapeutic targets and biomarkers identified in 
cancer choline phospholipid metabolism. Pharmacogenomics 2006, 7 (7), 1109-1123. 
 
(121) Mueller-Lisse, U. G.; Swanson, M. G.; Vigneron, D. B.; Hricak, H.; Bessette, A.; 
Males, R. G.; Wood, P. J.; Noworolski, S.; Nelson, S. J.; Barken, I., Time-dependent 
effects of hormone-deprivation therapy on prostate metabolism as detected by combined 
magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn. 
Reson. Med. 2001, 46 (1), 49-57. 
 
(122) Folger, O.; Jerby, L.; Frezza, C.; Gottlieb, E.; Ruppin, E.; Shlomi, T., Predicting 
selective drug targets in cancer through metabolic networks. Mol. Syst. Biol. 2011, 7 (1), 
501. 
 
(123) Eisner, T.; Meinwald, J., Chemical ecology. Proc. Natl. Acad. Sci. U. S. A. 1995, 
92 (1), 1. 
 
(124) Prince, E. K.; Pohnert, G., Searching for signals in the noise: metabolomics in 
chemical ecology. Anal. Bioanal. Chem. 2010, 396 (1), 193-197. 
 
(125) Hay, M. E.; Kubanek, J., Community and ecosystem level consequences of 
chemical cues in the plankton. J. Chem. Ecol. 2002, 28 (10), 2001-2016. 
 
(126) Fumagalli, E.; Baldoni, E.; Abbruscato, P.; Piffanelli, P.; Genga, A.; Lamanna, 
R.; Consonni, R., NMR techniques coupled with multivariate statistical analysis: tools to 
analyse Oryza sativa metabolic content under stress conditions. J. Agron. Crop. Sci. 
2009, 195 (2), 77-88. 
 
(127) Hirai, M. Y.; Yano, M.; Goodenowe, D. B.; Kanaya, S.; Kimura, T.; Awazuhara, 
M.; Arita, M.; Fujiwara, T.; Saito, K., Integration of transcriptomics and metabolomics 
for understanding of global responses to nutritional stresses in Arabidopsis thaliana. 




(128) Jones, O. A.; Dondero, F.; Viarengo, A.; Griffin, J. L., Metabolic profiling of 
Mytilus galloprovincialis and its potential applications for pollution assessment. Mar. 
Ecol. Prog. Ser. 2008, 369, 169-179. 
 
(129) Choi, Y.; Kim, H.; Linthorst, H.; Hollander, J.; Lefeber, A.; Erkelens, C.; 
Nuzillard, J.; Verpoorte, R., NMR metabolomics to revisit the tobacco mosaic virus 
infection in Nicotiana tabacum leaves. J. Nat. Prod. 2006, 69 (5), 742. 
 
(130) Schroeder, F. C.; del Campo, M. L.; Grant, J. B.; Weibel, D. B.; Smedley, S. R.; 
Bolton, K. L.; Meinwald, J.; Eisner, T., Pinoresinol: A lignol of plant origin serving for 
defense in a caterpillar. Proc. Natl. Acad. Sci. U. S. A. 2006, 103 (42), 15497-15501. 
 
(131) Peiris, D.; Dunn, W. B.; Brown, M.; Kell, D. B.; Roy, I.; Hedger, J. N., 
Metabolite profiles of interacting mycelial fronts differ for pairings of the wood decay 
basidiomycete fungus, Stereum hirsutum with its competitors Coprinus micaceus and 
Coprinus disseminatus. Metabolomics 2008, 4 (1), 52-62. 
 
(132) Broadhurst, D. I.; Kell, D. B., Statistical strategies for avoiding false discoveries 
in metabolomics and related experiments. Metabolomics 2006, 2 (4), 171-196. 
 
(133) Dunn, W. B.; Wilson, I. D.; Nicholls, A. W.; Broadhurst, D., The importance of 
experimental design and QC samples in large-scale and MS-driven untargeted 
metabolomic studies of humans. Bioanalysis 2012, 4 (18), 2249-2264. 
 
(134) Zelena, E.; Dunn, W. B.; Broadhurst, D.; Francis-McIntyre, S.; Carroll, K. M.; 
Begley, P.; O’Hagan, S.; Knowles, J. D.; Halsall, A.; Wilson, I. D., Development of a 
robust and repeatable UPLC−MS method for the long-term metabolomic study of human 
serum. Anal. Chem. 2009, 81 (4), 1357-1364. 
 
(135) Kochhar, S.; Jacobs, D. M.; Ramadan, Z.; Berruex, F.; Fuerholz, A.; Fay, L. B., 
Probing gender-specific metabolism differences in humans by nuclear magnetic 
resonance-based metabonomics. Anal. Biochem. 2006, 352 (2), 274-281. 
 
(136) Slupsky, C. M.; Rankin, K. N.; Wagner, J.; Fu, H.; Chang, D.; Weljie, A. M.; 
Saude, E. J.; Lix, B.; Adamko, D. J.; Shah, S., Investigations of the effects of gender, 
diurnal variation, and age in human urinary metabolomic profiles. Anal. Chem. 2007, 79 
(18), 6995-7004. 
 
(137) Carraro, S.; Rezzi, S.; Reniero, F.; Héberger, K.; Giordano, G.; Zanconato, S.; 
Guillou, C.; Baraldi, E., Metabolomics applied to exhaled breath condensate in childhood 
asthma. Am. J. Respir. Crit. Care Med. 2007, 175 (10), 986-990. 
 
(138) Tiziani, S.; Emwas, A.-H.; Lodi, A.; Ludwig, C.; Bunce, C. M.; Viant, M. R.; 
Günther, U. L., Optimized metabolite extraction from blood serum for 1H nuclear 




(139) Want, E. J.; O'Maille, G.; Smith, C. A.; Brandon, T. R.; Uritboonthai, W.; Qin, 
C.; Trauger, S. A.; Siuzdak, G., Solvent-dependent metabolite distribution, clustering, 
and protein extraction for serum profiling with mass spectrometry. Anal. Chem. 2006, 78 
(3), 743-752. 
 
(140) Dietmair, S.; Timmins, N. E.; Gray, P. P.; Nielsen, L. K.; Krömer, J. O., Towards 
quantitative metabolomics of mammalian cells: development of a metabolite extraction 
protocol. Anal. Biochem. 2010, 404 (2), 155-164. 
 
(141) Masson, P.; Alves, A. C.; Ebbels, T. M.; Nicholson, J. K.; Want, E. J., 
Optimization and evaluation of metabolite extraction protocols for untargeted metabolic 
profiling of liver samples by UPLC-MS. Anal. Chem. 2010, 82 (18), 7779-7786. 
 
(142) Xia, J.; Broadhurst, D. I.; Wilson, M.; Wishart, D. S., Translational biomarker 
discovery in clinical metabolomics: an introductory tutorial. Metabolomics 2013, 9 (2), 
280-299. 
 
(143) Pluskal, T.; Castillo, S.; Villar-Briones, A.; Orešič, M., MZmine 2: modular 
framework for processing, visualizing, and analyzing mass spectrometry-based molecular 
profile data. BMC Bioinformatics 2010, 11, 395. 
 
(144) Gowda, H.; Ivanisevic, J.; Johnson, C. H.; Kurczy, M. E.; Benton, H. P.; Rinehart, 
D.; Nguyen, T.; Ray, J.; Kuehl, J.; Arevalo, B.; Westenskow, P. D.; Wang, J.; Arkin, A. 
P.; Deutschbauer, A. M.; Patti, G. J.; Siuzdak, G., Interactive XCMS online: simplifying 
advanced metabolomic data processing and subsequent statistical analyses. Anal. Chem. 
2014, 86 (14), 6931-6939. 
 
(145) Katajamaa, M.; Orešič, M., Data processing for mass spectrometry-based 
metabolomics. J. Chromatogr. A 2007, 1158 (1), 318-328. 
 
(146) Katajamaa, M.; Miettinen, J.; Orešič, M., MZmine: toolbox for processing and 
visualization of mass spectrometry based molecular profile data. Bioinformatics 2006, 22 
(5), 634-636. 
 
(147) Boccard, J.; Veuthey, J. L.; Rudaz, S., Knowledge discovery in metabolomics: an 
overview of MS data handling. J. Sep. Sci. 2010, 33 (3), 290-304. 
 
(148) van den Berg, R. A.; Hoefsloot, H. C.; Westerhuis, J. A.; Smilde, A. K.; van der 
Werf, M. J., Centering, scaling, and transformations: improving the biological 
information content of metabolomics data. BMC Genomics 2006, 7 (1), 142. 
 
(149) Parsons, H. M.; Ludwig, C.; Günther, U. L.; Viant, M. R., Improved classification 
accuracy in 1-and 2-dimensional NMR metabolomics data using the variance stabilising 




(150) Tsugawa, H.; Tsujimoto, Y.; Arita, M.; Bamba, T.; Fukusaki, E., GC/MS based 
metabolomics: development of a data mining system for metabolite identification by 
using soft independent modeling of class analogy (SIMCA). BMC Bioinformatics 2011, 
12, 131. 
 
(151) Mahadevan, S.; Shah, S. L.; Marrie, T. J.; Slupsky, C. M., Analysis of 
metabolomic data using support vector machines. Anal. Chem. 2008, 80 (19), 7562-7570. 
 
(152) Trygg, J.; Holmes, E.; Lundstedt, T., Chemometrics in metabonomics. J. 
Proteome Res. 2007, 6 (2), 469-479. 
 
(153) Guan, W.; Zhou, M.; Hampton, C. Y.; Benigno, B. B.; Walker, L. D.; Gray, A.; 
McDonald, J. F.; Fernández, F. M., Ovarian cancer detection from metabolomic liquid 
chromatography/mass spectrometry data by support vector machines. BMC 
Bioinformatics 2009, 10, 259. 
 
(154) Rajalahti, T.; Arneberg, R.; Berven, F. S.; Myhr, K.-M.; Ulvik, R. J.; Kvalheim, 
O. M., Biomarker discovery in mass spectral profiles by means of selectivity ratio plot. 
Chemometrics Intellig. Lab. Syst. 2009, 95 (1), 35-48. 
 
(155) Wiklund, S.; Johansson, E.; Sjöström, L.; Mellerowicz, E. J.; Edlund, U.; 
Shockcor, J. P.; Gottfries, J.; Moritz, T.; Trygg, J., Visualization of GC/TOF-MS-based 
metabolomics data for identification of biochemically interesting compounds using OPLS 
class models. Anal. Chem. 2008, 80 (1), 115-122. 
 
(156) Brown, M.; Dunn, W. B.; Dobson, P.; Patel, Y.; Winder, C.; Francis-McIntyre, S.; 
Begley, P.; Carroll, K.; Broadhurst, D.; Tseng, A., Mass spectrometry tools and 
metabolite-specific databases for molecular identification in metabolomics. Analyst 2009, 
134 (7), 1322-1332. 
 
(157) Patti, G. J.; Yanes, O.; Siuzdak, G., Innovation: Metabolomics: the apogee of the 
omics trilogy. Nat. Rev. Mol. Cell Biol. 2012, 13 (4), 263-269. 
 
(158) Douglas, D.; Konenkov, N., Ion source emittance influence on the transmission of 
a quadrupole operated in the second stability region. J. Am. Soc. Mass. Spectrom. 1998, 9 
(10), 1074-1080. 
 
(159) Horai, H.; Arita, M.; Kanaya, S.; Nihei, Y.; Ikeda, T.; Suwa, K.; Ojima, Y.; 
Tanaka, K.; Tanaka, S.; Aoshima, K., MassBank: a public repository for sharing mass 










CHAPTER 2. ULTRA PERFORMANCE LIQUID 
CHROMATOGRAPHY−MASS SPECTROMETRY SERUM 
METABOLOMICS DETECTION OF PROSTATE CANCER 
 
 
Reprinted with permission from 
Zang, X.‡; Jones, C. M.‡; Long, T. Q.; Monge, M. E.; Zhou, M.; Walker, L. D.; 
Mezencev, R.; Gray, A.; McDonald, J. F.; Fernández, F. M., Feasibility of Detecting 
Prostate Cancer by Ultra Performance Liquid Chromatography−Mass Spectrometry 
Serum Metabolomics. J. Proteome Res. 2014, 13 (17), 3444-3454. Copyright © 2014 
American Chemical Society. 
‡equal contributing author 
 
 
This chapter describes research conducted by multiple persons. C. M. Jones and M. Zhou 
optimized the sample preparation and UPLC-MS analysis methods in addition to 
acquiring the UPLC-MS data. C. M. Jones processed the UPLC-MS data. C. M. Jones, X. 
Zang, and M. E. Monge tentatively identified metabolites and conducted UPLC-MS/MS 
experiments. X. Zang confirmed all metabolite identifications, conducted chemical 
standard validation experiments with assistance from M. E. Monge, and determined the 
biological functions of the identified metabolites with assistance from R. Mezencev. T. Q. 




Prostate cancer (PCa) is the second leading cause of cancer-related mortality in 
men. The prevalent diagnosis method is based on the serum Prostate-Specific Antigen 
(PSA) screening test, which suffers from low specificity, over-diagnosis and over-
treatment. In this work, untargeted metabolomic fingerprinting of age-matched serum 
samples from prostate cancer patients and healthy individuals was performed using ultra 
performance liquid chromatography coupled to high resolution tandem mass 
spectrometry (UPLC-MS/MS) and machine learning methods. A metabolite-based in 
vitro diagnostic multivariate index assay (IVDMIA) was developed to predict the 
presence of PCa in serum samples with high classification sensitivity, specificity and 
accuracy. A panel of 40 metabolic spectral features was found to be differential with 
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92.1% sensitivity, 94.3% specificity, and 93.0% accuracy. The performance of the 
IVDMIA was higher than the prevalent PSA test. Within the discriminant panel, 31 
metabolites were identified by MS and MS/MS, with 10 further confirmed 
chromatographically by standards. Numerous discriminant metabolites were mapped in 
the steroid hormone biosynthesis pathway. The identification of fatty acids, amino acids, 
lysophospholipids, and bile acids provided further insights into the metabolic alterations 
associated with the disease. With additional work, the results presented here show 
potential towards implementation in clinical settings. 
2.2 Prostate Cancer Detection 
2.2.1 Current Diagnostic Methodology 
Prostate cancer (PCa) is the 2nd leading cause of cancer-related mortality in men 
worldwide, with 30,000 deaths per year in the U.S. alone.1 The prevalent diagnosis 
method is based on the triad of digital rectal examination, blood Prostate-Specific 
Antigen (PSA) measurement, and ultrasound-guided prostate biopsy. Although the 
introduction of PSA screening decreased mortality by 4% between 1994 and 2006,2 the 
use of PSA as a diagnostic serum marker still presents several drawbacks. The 
concentration of this protein in the blood stream increases during the development of 
cancer, but also can be secreted as a result of benign prostatic hyperplasia, prostatitis, or 
other traumas to prostate cells.3 Therefore, this method suffers from low specificity and 
consequent over-diagnosis and over-treatment.4-7 Moreover, approximately 15% of 
patients with PCa have PSA values lower than the commonly used cutoff point of 4.0 ng 
mL-1, leaving many cases undetected.8 
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2.2.2 Overview of Metabolic Prostate Cancer Detection 
The shortcomings of PSA as a diagnostic PCa serum biomarker have led to an 
increased interest in using untargeted metabolomic fingerprinting/profiling to discover 
new differential metabolic biomarkers that could improve the specificity of PCa 
diagnosis.9 Metabolic biomarkers are used as a routine tool in screening newborns for the 
presence of inborn errors of metabolism by means of tandem mass spectrometry;10, 11 
however, global metabolite profiling of PCa patients still remains at an early stage, and 
there is no biomarker panel currently in use for clinical testing.9 Current research has 
shown some evidence of metabolic alterations associated with PCa. Tissue sarcosine 
levels have been suggested as a potential biomarker for the aggressive form of the disease 
in a metabolomic profiling study using both liquid and gas chromatography coupled to 
mass spectrometry (LC-MS and GC-MS).12 Its concentration in prostate cancer-related 
tissue specimens was highly increased during PCa progression to metastasis, but 
differences in urine were much less marked.12 These results have been very prominent 
but somewhat controversial as other targeted studies failed in the attempt of 
differentiating healthy individuals from cancer patients based on sarcosine concentration 
in biological fluids and cancerous tissues.9, 13-15 The analysis of cancerous tissues by 
proton high-resolution magic angle spinning nuclear magnetic resonance (NMR) 
spectroscopy has shown a decrease in the concentrations of citrate and polyamines, and 
increases in cholines, glycerophospholipids, and lactate concentrations during PCa 
proliferation.16, 17 Increased levels of cholesterol as well as alterations in amino acid 
metabolism were detected in metastatic bone samples by GC-MS.18 However, all of these 
studies included too few patients to offer strong leads on the metabolic alterations 
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associated with PCa. A panel of plasma lipids that included phosphatidylethanolamines, 
ether-linked phosphatidylethanolamines, and ether-linked phosphatidylcholines was 
proposed to discriminate PCa patients from healthy groups through direct infusion 
electrospray ionization tandem MS.19 The authors demonstrated that a combination of 
multiple biomarkers with multivariate analysis and various classification algorithms 
yielded better predictive power for the diagnosis of PCa than univariate analysis of single 
lipid species. However, the predictive power was not compared with that of PSA, as this 
information was not available at the time of cohort design.19 More robust metabolic 
models still need to be developed for improved understanding of disease progression, and 
more reliable PCa detection. 
2.3 Experimental Details 
2.3.1 Chemicals 
Healthy human blood serum (S7023-50 mL) and acetic acid (≥ 99.7%) were 
purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). Omnisolv LC-MS grade 
acetonitrile, Omnisolv high purity dichloromethane and HPLC grade acetone were 
purchased from EMD (Billerica, MA, USA). LC-MS grade methanol and 2-propanol 
were purchased from J.T. Baker Avantor Performance Materials, Inc. (Center Valley, PA, 
USA). Ultrapure water with 18.2 MΩ cm resistivity (Barnstead Nanopure UV ultrapure 
water system, USA) was used to prepare mobile phases. Uric acid (≥99%), azelaic acid 
(98%), undecanedioic acid (97%), heptadecanoic acid (≥98%) and decanoic acid (≥98%) 
were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). Hexadecanedioic acid 
(98%) was purchased from Ark Pharm, Inc. (Libertyville, IL, USA). Phenylalanyl 
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phenylalanine was purchased from MP Biomedicals (Solon, OH, USA). Phenylacetyl 
glutamine was purchased from Bachem (Hauptstrasse, Bubendorf, Sitzerland). Indoxyl 
sulfate potassium was purchased from Alfa Aesar (Ward Hill, MA, USA). 1-stearoyl-2-
hydroxy-sn-glycero-3-phosphocholine/ lysoPC (18:0/0:0) was purchased from Avanti 
Polar Lipids, Inc. (Alabaster, AL, USA). 
2.3.2 Patient Cohort Description 
Age-matched blood serum samples were obtained from 64 PCa patients (age 
range 49-65, mean age 59 ± 4 years) and 50 healthy individuals (age range: 45-76, mean 
age 57 ± 7 years). At the 0.05 level, the population means were not significantly different 
with the two-sample t-test. The cohort ethnicity was as follows: 28 African American 
(24.6%); 76 Caucasian (66.7%); 5 Hispanic (4.4%); 2 Asian (1.8%); 2 Jewish ancestry 
(1.8%); and 1 unknown (0.9%). After approval by the Institutional Review Board (IRB), 
blood samples were collected at Saint Joseph´s Hospital of Atlanta (GA, USA) by 
venipuncture from each donor into evacuated blood collection tubes that contained no 
anticoagulant. Serum was obtained by centrifugation at 5000 rpm for 5 min at 4 °C. 
Immediately after centrifugation, 200 µL aliquots of serum were frozen and stored at -80 
°C for further use. The sample collection and storage procedures for PCa patients and 
healthy individuals were identical. Gleason scores based on the microscopic glandular 





2.3.3 Sample Preparation and Ultra Performance Liquid Chromatography-
Mass Spectrometry Protocols 
A stock sample of healthy human blood serum was used to develop the serum 
sample preparation protocol and ultra performance liquid chromatography-mass 
spectrometry (UPLC-MS) method. Serum samples were thawed on ice, and protein 
precipitation was performed by the addition of a mixture of acetone, acetonitrile and 
methanol (1:1:1 v/v) to 100 µL of serum in a 3:1 volume ratio. Samples were vortex-
mixed for 20 s, and centrifuged at 16000 × g for 5 min. After centrifugation, 800 µL of 
dichloromethane were added to 350 µL of supernatant, and vortex-mixed. Following the 
addition of 250 µL of deionized water, samples were vortex-mixed again to extract the 
non-polar lipid fraction. The aqueous phase was used for metabolite analysis by UPLC-
MS. Samples were randomly separated into 7 batches and consecutively analyzed. The 
instrument was calibrated before analysis and solvent and sample preparation blanks 
were jointly analyzed with the samples in a random order. 
UPLC-MS analysis was performed using a Waters ACQUITY Ultra Performance 
LC (Waters Corporation, Manchester, UK) system, fitted with a Waters ACQUITY 
UPLC BEH C18 column (2.1 × 50 mm, 1.7 µm particle size), and coupled to a high-
resolution accurate mass (HRAM) Synapt G2 High Definition Mass Spectrometry 
(HDMS) system (Waters Corporation, Manchester, UK). The Synapt G2 HDMS is a 
hybrid quadrupole-ion mobility-orthogonal acceleration time-of-flight instrument with 
typical resolving power of 20,000 FWHM M/∆m and mass accuracy of 9 ppm at m/z 
554.2615. The instrument was operated in negative ion mode with a probe capillary 
voltage of 2.3 kV, and a sampling cone voltage of 45 V. The source and desolvation 
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temperatures were 120 °C and 350 °C, respectively; and the nitrogen desolvation flow 
rate was 650 L h-1. The mass spectrometer was calibrated across the range of m/z 50-1800 
using a 0.5 mM sodium formate solution prepared in 90:10 2-propanol:water v/v. Data 
were mass corrected during acquisition using a leucine enkephalin reference spray 
(LockSpray) infused at 2 µL min-1. Data were acquired in the 50-1750 m/z range and the 
scan time was set to 1 s. Data acquisition and processing was carried out using MassLynx 
v4.1. The chromatographic method for sample analysis involved elution with acetonitrile 
(mobile phase A) and water with 0.1% acetic acid (mobile phase B) using the following 
gradient program: 0-1 min 0-10% A; 1-2.5 min 10-15% A; 2.5-4 min 15-22% A; 4-6 min 
22-38% A; 6-9 min 38-65% A; 9-12 min 65-80% A; 12-16 min 80-100% A; 16-18 min 
100% A. The flow rate was constant at 0.25 mL min-1 for 12 min. It was increased to 0.30 
mL min-1 between 12 and 16 min, and from 0.30 to 0.45 mL min-1 between 16 and 18 
min. The gradient was returned to its initial conditions over a period of 8 minutes after 
each sample injection. The column temperature was set to 35 °C, the autosampler tray 
temperature was set to 5 °C, and the injection volume was 10 µL. UPLC-MS/MS 
experiments were performed by acquiring mass spectra with applied voltages between 5 
and 50 V in the trap cell, using ultra purity argon (≥ 99.999%) as the collision gas. 
2.3.4 Data Analysis 
After UPLC-MS analysis, metabolic features (retention time (Rt), m/z pairs) were 
extracted from chromatograms using MarkerLynx XS software. This procedure involved 
chromatogram alignment, peak picking and integration, peak area extraction, and 
normalization. The matrix containing sample peak areas for each feature (Rt, m/z) was 
utilized to build a model for sample classification and to find the minimum set of 
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discriminant features by means of linear support vector machines (SVMs).20 This 
supervised classification technique is effective at handling high dimensionality data as 
those produced in the present work. For a binary classification problem, linearly-
separable samples represented as a row vector x, had membership of two classes g (= H 
or D), where H stands for healthy and D for PCa disease with labels c = -1 for class H, 
and +1 for class D. To build the classification model, 70% of the samples were randomly 
selected as a training set, and 30% as a test set. Within the training set, 10% of samples 
were used for validation and to find the minimum set of discriminant features that 
maximized accuracy in the classification through a recursive feature elimination (RFE) 
method.21 The decision function that separated the two classes, defined here as the 
IVDMIA “PCa metabolic score”, was as follows: 
𝑃𝐶𝑎 𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑐 𝑠𝑐𝑜𝑟𝑒 = 𝑏 + ∑ 𝑤𝑗𝑥𝑖𝑗
𝐽
𝑗=1
                                     [1] 
𝑔(𝒙𝑖) = 𝑠𝑔𝑛(𝒘𝒙𝑖
′  + 𝑏) = 𝑠𝑔𝑛(𝑃𝐶𝑎 𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑐 𝑠𝑐𝑜𝑟𝑒)               [2] 
where w and b are the weight and bias parameters that were determined from the training 
set and J is the total number of features. The sign of the PCa metabolic score determined 
which class a sample was assigned to: class H if negative and class D if positive. In this 
classification function, the two classes were divided in the dataspace by a 
hyperplane 𝒘𝒙′ + 𝑏 = 0 that maximized the margins between samples of different 
classes. The margin between the two classes was defined such that:  
𝒘𝒙′ + 𝑏 ≥ 1, 𝑐 = +1                                                 [3] 
𝒘𝒙′ + 𝑏 ≤ −1,        𝑐 = −1                                               [4] 
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To estimate the classification and feature selection performance, ten iterative validations 
were performed to randomly select the training and test sets. The statistical significance 
of the model was further assessed through hypothesis testing by permutation tests. No 
assumptions were made in this non-parametric approach to hypothesis testing regarding 
the data distribution, and the p-value was computed as the cumulative sum using the 
empirical distribution. Two permutation tests were performed using 100 permutation 
samples with the following null hypothesis:  
i) Null hypothesis 1: feature and labels (positive/negative) are independent (i.e. 
indifference when class labels are permutated).  
ii) Null hypothesis 2: features are independent within each class (i.e. indifference 
when value of each features are permutated within each class).   
If the p-value < α (α = 0.05), the null hypothesis H0 was rejected; otherwise the observed 
result was not statistically significant.  
Additionally, Principal Component Analysis (PCA) was used to evaluate the 
performance of all extracted metabolic features or subsets of them in an unsupervised 
manner with MATLAB R2011b (Version 7.13.0, The MathWorks, Inc., Natick, MA, 
USA) and the PLS Toolbox (v.6.71, Eigenvector Research, Inc., Wenatchee, WA, USA). 
Data were preprocessed by autoscaling. 
2.3.5 Discriminant Metabolite Identification Procedure 
Compound identification was attempted for the 40 discriminant features 
remaining after the feature selection processes. Due to the biological complexity of serum 
samples, adduct ion analysis was first performed to ensure the unambiguous assignment 
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of the signal of interest in each mass spectrum. Adduct ions corresponding to SVM-
selected variables that were investigated in the mass spectra included [M - H]-, [M + Cl]-
,[M + Br]-, [M + CH3COO]
-, [M + HCOO]-, [M + CF3COO]
- [M + Na - 2H]-, [M + K - 
2H]-, [M - H2O - H], [M + H2O - H]
- species, which are typically observed in negative 
electrospray ionization mode. The expected m/z values for common adduct species were 
calculated and compared with the experimental values from peaks within the spectra. For 
spectra in which no confirmatory adducts were present, the accurate mass of the 
candidate neutral molecule was calculated based on the assumption that the peak of 
interest corresponded to [M - H]-. Elemental formulae were generated based on the mass 
accuracy of the peak of interest and isotopic patterns with a mass error of 8 mDa, using 
MassLynx 4.1. The list of elements included in the search was C, H, N, O, P, S, Cl, and 
Br. The list of generated elemental formulae were searched against the METLIN 
database,22 HMDB,23 and MassBank24 to determine the possible endogenous metabolite 
candidates. The METLIN MS/MS database and a literature survey were subsequently 
used to confirm the identity of putative candidates. Fragmentation patterns were also 
manually analyzed to discriminate between different isobaric species. 
2.4 Prostate Cancer Detection Performance of the In Vitro Diagnostic 
Multivariate Assay 
UPLC-MS analysis in negative ion mode allowed the interrogation of highly 
complex serum samples from PCa patients and healthy individuals, revealing a total of 
480 features (Rt, m/z pairs). The extracted features were used to build a discriminant 
SVM model for sample classification. An optimum set of 51 discriminant features were 
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found to maximize classification accuracy through a RFE method,21 as illustrated in 




Figure 2.1: Evolution of classification accuracy for a validation sample subset consisting 
of 10% of the training samples as a function of the number of features retained. The 
minimum discriminant feature set that maximizes classification accuracy is highlighted 
with a dashed line. 
 
 
Out of the 51 selected features, 7 were found to be only present in less than 2% of the 
samples; 2 features were identified as acetaminophen and its sulfite adduct, and 2 
additional features were identified as adducts or fragments of other features in the subset, 
and were thus removed from further consideration. The optimum panel that best 
discriminated PCa patients from healthy individuals was thus reduced to 40 features, 
demonstrating that the feature selection process accomplished a high reduction in 
problem dimensionality.  































Figure 2.2: Visualization of the PCa metabolic scores obtained by SVMs in one out of 10 
iterative model validations based on 40 discriminant features. Green circles correspond to 
PCa patients in the training set, black triangles correspond to controls in the training set, 
red circles correspond to PCa patients in the test set built for the iteration shown, and blue 
triangles correspond to healthy individuals in the test set. The dotted line shows the 




Figure 2.2 illustrates the “PCa metabolic scores” obtained for the training and the test sets 
of randomly selected samples that were used to construct and evaluate the classification 
model, respectively. The separation of the two sample classes (H or D) was determined in 
the data space by the optimal separating hyperplane for which the margin between the 
most similar samples in each group was largest, illustrated with a dotted line in the figure. 



























Figure 2.3: Visualization of the PCa metabolic scores obtained by SVMs in 9 out of 10 
model validation iterations. Green circles correspond to PCa patients in the training set, 
black triangles correspond to controls in the training set, red circles correspond to PCa 
patients in the test set, and blue triangles correspond to healthy individuals in the test set. 




The samples with scores equal to 1 or -1 are the support vectors of the model. For the 
particular cross-validation iteration illustrated in Figure 2.2 only one sample was 
misclassified as a false negative. The remaining 9 iterative validations with their 
respective training and test sets are illustrated in Figure 2.3. Based on these 40 
discriminant features, serum samples were successfully classified as cancerous or healthy 
with 93.0% accuracy, 92.1% sensitivity, and 94.3% specificity. These values were 




































































calculated as the averages from 10 distinct test sets, illustrated in Figures 2.2 and 2.3. In 
addition, the statistical significance of the model was further evaluated through 
hypothesis testing and, at 0.05 significance level, the null hypothesis was rejected for all 
permutations generated (p-value = 0.0099). Unambiguously, the classifier did not yield a 
better leave-one-out cross-validation (LOOCV) accuracy rate than the original data. 
These results suggest a promising approach that could form the basis for a PCa IVDMIA. 
In particular, of the 40 differential features, 24 were found to increase in sera from PCa 
patients, and 16 were found to decrease in PCa, as illustrated in Figure 2.4. It is important 
to underline, however, that the strength of this IVDMIA resides in the combination of 
multiple metabolic features using an interpretation function to yield a single, patient-
specific result to be used in the disease diagnosis, and not on the average fold change of 
each differential feature. 
To evaluate the possible risk of data overfitting by SVMs,20 a simple 
unsupervised approach was also used to examine the dataset. PCA score plots were 
generated for both the 40 discriminant features set obtained by SVMs and the starting set 





Figure 2.4: Fold change of average peak areas of each discriminant feature. Positive fold 
changes are calculated as the ratio of average peak areas between PCa patients and 
healthy individuals, and negative fold changes are calculated as the negative ratio of 
average peak areas between healthy individuals and PCa patients. Features are labeled 




Using the best 40 features, three principal components containing 33.6% of the total 
variance provided a good degree of separation between classes, as illustrated in Figure 
2.5a. Sample separation in the PCA score plot was mainly achieved by the contribution of 
PC3. Loadings for PC3 are displayed in Figure 2.5b. Interestingly, Figure 2.5c shows that 
PCA does not provide any distinguishable clustering when applied to the initial set of 480 
features, further supporting the use of RFE and SVMs when handling high 
dimensionality data volumes as those in the present work. Given the clustering observed 
in PCA when using the 40 discriminant feature subset, the risk of the high classification 


































































































































Figure 2.5: Principal Component Analysis (PCA). A: PCA score plot using only the 40 discriminant features obtained by RFE-SVMs. 
B: Loadings plot obtained for PC3 using the 40 discriminant features, each labeled with their code. C: PCA score plot of the initial set 





















































































































































































































2.5 In Vitro Diagnostic Multivariate Assay Versus Prostate Specific Antigen 
Diagnosis 
The Gleason scores for the PCa patients, summarized in Table 2.1, indicate that the 
most common tumor patterns presented by the patients derived from moderate to 
aggressive cancers.  
 
 
Table 2.1: Gleason scores for PCa patients. 
 
Gleason Sum # of patients; (%) 
3+3 = 6 13; (20.3) 
3+4 = 7 27; (42.2) 
3+3 = 6; tert=4 6; (9.4) 
4+3 = 7 3; (4.7) 
3+4=7; tert=5 2; (3.1) 
4+3=7; tert= 5 2; (3.1) 
(R) 3+4 = 7; (L) 4+3 = 7 1; (1.6) 
4+5 = 9 1; (1.6) 
5+4 = 9 1; (1.6) 
(R)3+4=7; tert= 5; (L) 3+3=6 1; (1.6) 
(R)3+4=7; (L) 4+3 = 7; tert= 5 1; (1.6) 
3+5=8; tert= 4 1; (1.6) 
(R) 3+3 = 6; (L) 4+5 = 9 1; (1.6) 





However, the PSA test performed at surgery did not follow this histological evidence for 
the entire PCa cohort, as 33% of patients with PCa (n = 20) had PSA values lower than 
the commonly used cutoff point of 4.0 ng mL-1. Figure 2.6 compares PSA and IVDMIA 
results in terms of true positive and false negative outputs, highlighted in red and black, 
respectively. The IVDMIA outputs provided by the randomly-selected 10 test sets are 
visualized as box plots in the figure, and show that the IVDMIA was able to correctly 
predict 100% of the true positives that were incorrectly diagnosed as negatives by the 
PSA test. The false negative results provided by the IVDMIA derived from one sample 
that was misclassified in all test sets and 4 samples that were misclassified in at least one 
test set. The classification performance obtained with this cohort shows promise towards 
prostate cancers that would go undetected by the PSA method. The use of multiple 
discriminant features by this metabolic IVDMIA yields higher predictive power for PCa 







Figure 2.6: Comparison of IVDMIA vs. PSA diagnosis performance for 62 PCa patients. 
True positive and false negative outputs are highlighted in red and black, respectively. 
The cutoff point of 4.0 ng mL-1 used in PSA-based diagnosis is indicated with a dotted 
line. The IVDMIA score output is presented as box plots in the figure, each of which is 
generated by results obtained for each of the 10 test sets where each sample was selected 
for validation. No comparison is shown for 2 of the 64 PCa samples as they were not 




2.6 In Vitro Diagnostic Multivariate Assay Potential in Clinical Applications 
To determine the fraction of samples in which the discriminant features were 
present, and to evaluate the feasibility of implementing the PCa IVDMIA in clinical 
laboratory settings through targeted triple-quadrupole mass spectrometry-based assays, 
smaller subgroups of the optimum 40 discriminant features, subsequently referred to as 






































Table 2.2: Discriminant feature (sub)panels for PCa detection. 
 
Panel Accuracy Specificity Sensitivity 
Discriminant 
features (#) 
Discriminant Feature Codes 
% Healthy samples, 
% PCa samples 
A 93.0 94.3 92.1 40 
147, 36, 71, 211, 60, 55, 107, 409, 250, 
223, 386, 438, 157, 63, 176, 82, 393, 173, 
84, 412, 43, 376, 343, 429, 384, 76, 444, 
214, 128, 93, 398, 360, 448, 174, 153, 21, 
364, 404, 242, 237 
>0%; >0% 
B 91.2 90.6 91. 7 38 
147, 36, 71, 211, 60, 55, 107, 409, 250, 
223, 386, 438, 157, 63, 176, 82, 393, 173, 
84, 412, 43, 376, 343, 429, 384, 76, 444, 
214, 128, 93, 398, 360, 448, 174, 153, 21, 
364, 404 
>50%; >0% 
C 90.2 87.2 91.8 35 
147, 36, 71, 211, 60, 55, 107, 409, 250, 
223, 386, 438, 157, 63, 176, 82, 393, 173, 
84, 412, 43, 376, 343, 429, 384, 76, 444, 
214, 128, 93, 398, 360, 448, 174, 153 
>50%; >50% 
and >0%; >50% 
D 86.1 87.2 85.3 28 
147, 36, 71, 211, 60, 55, 107, 409, 250, 
223, 386, 438, 157, 63, 176, 82, 393, 173, 
84, 412, 43, 376, 343, 429, 384, 76, 444, 
214 
>0%; >70% 
E 84.4 80.0 85.8 25 
147, 36, 71, 211, 60, 55, 107, 409, 250, 
223, 386, 438, 157, 63, 176, 82, 393, 173, 
84, 412, 43, 376, 343, 429, 384 
>70%; >70% 
and >70%; >0% 
F 85.0 80.0 88.8 22 
147, 36, 71, 60, 55, 409, 223, 386, 438, 
157, 63, 176, 82, 393, 173, 84, 412, 43, 
376, 343, 429, 384 
>90%; >0% 
G 80.0 81.0 79.3 17 
147, 36, 71, 60, 55, 409, 386, 438, 157, 
176, 82, 393, 173, 84, 343, 429, 384 
>90%; >90% 
and >0%; >90% 
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These subpanels were chosen to provide the minimum number of features that 
collectively captured metabolic PCa patterns with a high level of accuracy, specificity 
and sensitivity. The selection of these additional subpanels was based on the fraction of 
features that were present in 50, 70 or 90% of the entire sample cohort, in either PCa 
patients or healthy controls. Table 2.2 summarizes the different panels constructed 
following these criteria, with their corresponding subset of discriminant features. These 
panels were used to build new SVM models, and cross-validated to provide average 
values of accuracy, specificity and sensitivity from 10-independent randomly-selected 
training and testing sets. Thirty eight out of 40 discriminant features were present in more 
than 50% of healthy controls (Panel B) and 35 out of 40 were present in more than 50% 
of PCa samples (Panel C), providing similar accuracy, specificity, and sensitivity as panel 
A. When the criterion for feature presence was made more stringent, from panel A to 
panel G; the accuracy, specificity and sensitivity decreased by only ~10%, suggesting the 
robust biological role that the detected features might have. In other words, the different 
feature subpanels were not highly sensitive to a reduction in the number of discriminant 
features, suggesting that the smaller number of metabolites contained in subpanel G 
could still be potentially used to build a more focused, simpler IVDMIA for PCa 
detection in a clinical setting. To further test this finding, another SVM model was 
created with only those 13 features that could be confidently assigned to metabolites in 
subpanel G by HRAM MS and MS/MS (Table 2.3). It was found that this model still 
provided high classification sensitivity (88.3%), specificity (80.3%), and accuracy 
(85.0%). The mass spectrometric assay for a model of this type would be much simpler to 
implement in a targeted fashion due to the reduced number of transitions that a UPLC-
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MS/MS triple quadrupole method would require, allowing higher analysis throughput and 
minimizing cost. 
The set of 40 SVM weights obtained for panel A from the optimal classification 
model are shown in Figure 2.7. The figure shows the individual contribution of each of 
the 40 discriminant metabolic features in the computed PCa metabolic score, i.e., the 

















Discriminant Feature Codes 
Identified in Panel G by 
HRAM MS, and MS/MS 
85.0 80.3 88.3 13 
60, 36, 84, 71, 157, 176, 55, 
343, 429, 384, 409, 386, 173 
Identified in Panel A by 
HRAM MS, and MS/MS 
91.1 91.3 90.9 31 
60, 36, 84, 71, 157, 176, 55, 
343, 429, 384, 409, 386, 173, 
223, 43, 63, 376, 250, 211, 107, 
214, 76, 444, 174, 128, 398, 93, 
153, 364, 21, 242 
Identified in Panel A by 




76.3 70.6 79.9 10 
60, 36, 71, 384, 43, 211, 76, 
174, 128, 153 
Identified in Panel A by 
HRAM MS, and MS/MS 
with xenobiotics and 
marker 63 excluded 
90.2 90.7 89.7 28 
60, 36, 84, 71, 157, 176, 55, 
343, 429, 384, 409, 386, 173, 
223, 43, 376, 250, 211, 107, 





Figure 2.7: Weights for the 40 discriminant metabolic features in panel A. Metabolic 
features are labeled with their codes. 
 
 
It is interesting to note that some features with high weights in the SVM model, such as 
feature 60, 444, 409, or 429, also have large absolute values in the PC3 loadings plot 
(Figure 2.5b). Figure 2.8 shows a comparison of the different sets of weights for the 
different panels described in Table 2.2, sorted from the largest to lowest value in panel A 
and expanded to panels B-G. The figure shows that the sign of the weights generally 
remained the same across the panels, in agreement with the fact that accuracy, specificity 
and sensitivity were highly conserved even after restricting the presence of discriminant 
features to those present in a majority of the patients within the cohort. It was seen that 
for the most restrictive panels, those features with weights equal to zero, i.e., those that 



































































































































Figure 2.8: Weights for the discriminant metabolic features from panels A-G (indicated 
in Table 2.2) obtained by the classification model using the total cohort. 
 
 
2.7 Identification of Metabolites Used in the In Vitro Diagnostic Multivariate 
Assay 
Once the robustness of the model was established, chemical identification of the 40 
discriminant metabolic features was attempted. Figure 2.9 exemplifies the procedure 
utilized for identification of feature 60. Figures 2.9a and 2.9b show the different base 
peak intensity (BPI) chromatograms obtained for serum samples of a typical PCa patient 
and healthy individual. As differences between metabolomes, and the corresponding 
features in the BPI chromatograms arise both from the presence of the disease and also 
from differences in diet, lifestyle, and the numerous other factors,25 chemical 
identification of endogenous metabolites was attempted only for the 40 discriminant 
metabolic features.  





































Figure 2.9: Base peak intensity chromatograms obtained for typical serum samples from a patient with PCa (A) and a healthy 
individual (B). (C): Extracted ion chromatogram for m/z 187.0968 ± 0.0050 generated from a PCa patient sample (red line) and a 
healthy individual (black line). These were generated from the data shown in A and B, respectively. (D): Adduct ion analysis for 
discriminant feature at m/z 187.0968. Mass errors are calculated with respect to the theoretical values for azelaic acid (C9H16O4). 
Tandem MS spectrum for the m/z 187.0968 precursor ion using a collision cell voltage of 15 V. The matching of tandem MS 
fragmentation patterns between the experimental spectrum and the metabolite candidate is illustrated by the mass errors calculated as 
differences with the values in the METLIN database. 




















































































































The high resolving power of the time-of-flight analyzer used allowed generating highly-
selective extracted ion chromatograms for each discriminant feature, as illustrated in 
Figure 2.9c. Adduct ion analysis (Figure 2.9d) was used to ensure the unambiguous 
assignment of the signal of interest in the electrospray ionization mass spectrum, and the 
isotopic pattern and accurate masses were used to generate a list of possible candidate 
elemental formulae that were searched against databases. Moreover, UPLC-MS/MS 
experiments were performed to confirm the identities of these candidate metabolites 
responsible for classification. Tandem MS spectra were compared to those in databases 
or literature, and fragmentation patterns were manually analyzed as well (Figure 2.9e). 
Finally, standards of all commercially-available metabolites were subject to UPLC-MS 
and MS/MS to verify the identity of the candidates by retention time and mass spectral 
matching. Of the 40 spectral features found in panel A, 31 were identified by HRAM MS 
and MS/MS, with 10 further confirmed chromatographically by standards. The set of 31 
metabolites provided 90.9% sensitivity, 91.3% specificity, and 91.1% accuracy; whereas 
the 10 differential metabolites confirmed by standards, when considered alone, provided 
79.9% sensitivity, 70.6% specificity, and 76.3% accuracy (Table 2.3). It should be noted 
that among the 31 identified metabolites, 1-α-amino-1H-pyrrole-1-hexanoic acid (feature 
code 63) had the highest mass error (11.4 mDa), and its identity should be viewed as 
tentative. However, a classification model built using the set of 30 metabolites excluding 





2.8 Biological Relevance of the In Vitro Diagnostic Multivariate Assay 
Metabolites 
Table 2.4 summarizes the results from the chemical identification workflow 
described above for the 40 discriminant features. Those metabolites with 
chromatographic identity confirmation by retention time matching with standards are 
shown in bold, and can be therefore viewed as the ones with the higher confidence in the 
panel. Several discriminant metabolites were identified as fatty acids, amino acids, 
lysophospholipids, and bile acids, suggesting alterations in their respective metabolism. 
Previous findings have shown abnormality in fatty acid,26 and amino acid12, 27, 28 
metabolism in PCa patients. Alterations in fatty acid metabolism through an enhanced β-
oxidation pathway have been suggested to provide bioenergy for abnormal cell 
proliferation.26 Among the different lysophospholipids identified that may play a role in 
cell signaling,29 lysoPC(18:2) and lysoPC(18:0) have been reported as biomarkers for 
PCa detection within a panel of plasma lipids.19 Uric acid has also been suggested to be a 
disease risk marker due to its pro-inflammatory properties,30, 31 and a prospective 
epidemiological study demonstrated positive association between serum uric acid levels 
and risk of PCa development.32 In addition, elevated concentrations of serum uric acid 
are often found due to tumor lysis syndrome observed as a result of cancer therapy.33 
Interestingly, indoxyl sulfate, a toxic product of dietary tryptophan metabolism that 
accumulates in the blood of patients with impaired renal function,34 was also identified 





Table 2.4: Results for the chemical identification workflow for various discriminant features. Metabolites confirmed by retention time 





















36 0.63 167.0206 [M-H]- C5H4N4O3 167.0205 0.1 uric acid 30-32 G 
71 1.95 203.0817 [M-H]- C11H12N2O2 203.0821 0.4 tryptophan 27, 36 G 
384 11.70 508.3403 [M-CH3]- C26H54NO7P 508.3403 0.0 lysoPC(18:0/0:0) 19, 37 G 








39, 40 G 
















429 9.80 578.3450 [M+CH3COO]
- C26H50NO7P 578.3458 0.8 lysoPC(18:2/0:0) 
19 G 
409 5.46 541.2639 [M-H]- C27H42O11 541.2649 1.0 cortolone-3-glucuronide 
43, 44 G 
386 6.92 511.2900 [M-H]- C27H44O9 511.2907 0.7 pregnanetriol glucuronide  G 




Table 2.4 (continued). 
393 8.12 517.3015  - - - -  G 
438 7.04 600.2572  - - - -  G 
147 0.55 266.8028  - - - -  G 
82 8.12 215.1281  - - - -  G 
43 9.56 171.1383 [M-H]- C10H20 O2 171.1385 0.2 
decanoic acid (capric 
acid) 
 F 








376 9.63 504.3081 [M-CH3]
- C26H50NO7P 504.309 0.9 lysoPC(0:0/18:2)* 
42 F 
412 8.86 545.3323  - - - -  F 













76 2.64 212.0016 [M-H]- C8H7NO4S 212.0018 0.2 indoxyl sulfuric acid 12, 51 D 










52, 53 D 
77 
 
Table 2.4 (continued). 




54, 55 D 
174 9.35 285.2059 [M-H]- C16H30O4 285.2066 0.7 hexadecanedioic acid 56 C 
128 2.69 263.1023 [M-H]- C13H16N2O4 263.1032 0.9 phenylacetylglutamine 57, 58 C 
153 14.80 269.2475 [M-H]- C17H34O2 269.2481 0.6 heptadecanoic acid 37 C 












93 6.36 229.0534 [M-H]- C10H14O4S 229.0535 0.1 
5-isopropyl-2-
methylphenol 
sulfate (carvacrol sulfate) 
60 C 
360 8.16 489.2692  - - - -  C 
448 8.51 621.3273  - - - -  C 




21 5.16 144.0471 [M-H]- C9H7NO 144.0449 2.2 indole-3-carboxaldehyde 
62, 63 B 
404 7.28 537.2501  - - - -  B 








Table 2.4 (continued). 
237 11.34 365.2680  - - - -  A 




The reason behind elevated indoxyl sulfate in serum of PCa patients is not yet fully 
understood; nevertheless, this nephrotoxic metabolite likely contributes to the disease or 
its complications via multiple mechanisms, including enhanced oxidative stress due to 
decreased levels of glutathione.51  
 Perhaps the most salient finding resulting from the chemical identification 
workflow is that many differentiating metabolites belong to the steroid hormone 
biosynthesis pathway. The pathway supplies androgens64-66 such as testosterone and 5α-
dihydrotestosterone, to support the growth of androgen-dependent PCa.67 An average 
increase of pregnanetriol and androstenedione concentrations in PCa serum suggests that 
there is a metabolic alteration of the steroid pathway that mimics congenital adrenal 
hyperplasia (CAH), a metabolic disease that is accompanied by androgen excess due to 
the diversion of 17-hydroxyprogesterone into the pathway for androgen biosynthesis.68, 69 
In addition, the average decrease of azelaic acid concentration in serum of PCa patients, 
an inhibitor of 5α-reductase,70 suggests the disinhibition of 5α-reductase, an enzyme that 
catalyzes the synthesis of highly active androgen 5α-dihydrotestosterone to support PCa 
growth. Indeed, azelaic acid, which has a large contribution in the models, has been 
postulated to be a potential antitumoral agent.35 
Table 2.4 also shows the identification of several xenobiotics that can be grouped 
into two classes according to their origin. Menthol, citronellol, carvacrol, and t-
butylhydroquinone are most likely related to food components. Assuming that both PCa 
patients and healthy individuals were equally exposed, on average, to food 
components/additives, their different metabolism could explain the different levels of 
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these xenometabolites in serum. For example, the terpenoids menthol, carvacrol and 
citronellol are metabolized by CYP2A6,71, 72 which is also involved in steroid 
metabolism. As a result, average lower concentrations of these terpenoids relative to 
healthy individuals may be suggestive of higher activity of CYP2A6 in PCa patients, 
supporting inclusion of these xenometabolites in the models. The second group of 
xenobiotics comprises indole-3-carboxaldehyde and 5'-carboxy-α-chromanol 
glucuronide, which could possibly result from the consumption of dietary supplements 
used by cancer patients. Self-medicating with an over-the-counter indole-3-carbinol (I3C) 
supplement may explain the increased average concentration of indole-3-carboxaldehyde 
in PCa serum.62 Indeed, indole-3-carboxaldehyde demonstrated activity against prostate 
cancer in both in vitro and in vivo models.63  Similarly, α-tocopherol, a form of vitamin E 
and a precursor of 5'-carboxy-α-chromanol glucuronide, have been suggested to influence 
the development of PCa due to their antioxidant activity.61 As humans do not normally 
produce indole-3-carbaldehyde or 5'-carboxy-α-chromanol, and their consideration in the 
models may reflect dietary supplementation differences rather than endogenous 
metabolic differences, PCa detection was attempted using 28 of the 31 identified 
metabolites, excluding from the SVM classification model two metabolites which might 
result from dietary supplementation and one metabolite with highest mass error (1-α-
amino-1H-pyrrole-1-hexanoic acid). This modified classification model provided 89.7% 
sensitivity, 90.7% specificity, and 90.2% accuracy (Table 2.3), indicating the three 
excluded metabolites had little effect on the overall assay performance, as supported by 




The study presented here shows the combined application of UPLC-MS/MS and 
machine learning methods to develop a metabolite-based IVDMIA that predicts the 
presence of PCa in serum samples with high classification sensitivity, specificity and 
accuracy. A panel of 40 metabolic spectral features was found to be differential with 
92.1% sensitivity, 94.3% specificity, and 93.0% accuracy. Of further significance, the 
detection performance of the IVDMIA was proven to be higher than the prevalent PSA 
test; highlighting that a combination of multiple discriminant features yields higher 
predictive power for PCa detection than the univariate analysis of a single marker. Within 
the discriminant panel, 31 metabolites were identified by HRAM MS and MS/MS, with 
10 further confirmed chromatographically by standards. Fatty acids, amino acids, 
lysophospholipids, and bile acids have been identified among the discriminant 
metabolites, suggesting alterations in their metabolism. Additionally, several metabolites 
were mapped to the steroid hormone biosynthesis pathway. These observations 
demonstrate some of the plausible metabolic alterations in PCa, and provide further 
insight into the biological pathway changes associated with the disease. The combination 
of multiple metabolites that yield a single, patient-specific result for disease detection is 
the strength of the IVDMIA presented here. When the assay is based on the 28 identified 
disease-related metabolites, PCa can still be detected with 89.7% sensitivity, 90.7% 
specificity, and 90.2% accuracy. If higher throughput analysis, and lower analysis cost 
and complexity are desired, 13 metabolites that were found to be present in 90% of the 
entire sample cohort would still provide high classification sensitivity (88.3%), specificity 
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(80.3%), and accuracy (85.0%) for cancerous and healthy samples. Therefore, this assay 
shows promise towards its implementation in the clinical laboratory setting once it is 
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Serum Profiling Detects Early-Stage High-Grade Serous Ovarian Cancer in a Mouse 
Model. J. Proteome Res. 2015, 14 (2), 917-927. Copyright © 2015 American Chemical 
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Fernández, F. M., Ultra Performance Liquid Chromatography-Mass Spectrometry 
Characterization of Serum Metabolic Phenotypes of an Early-Stage Ovarian Cancer Pilot 
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This chapter describes research conducted by multiple persons. J. Kim collected blood 
serum samples from DKO and control mice. C. M. Jones and M. E. Monge optimized all 
sample preparation protocols and UPLC-MS analysis methods and processed the UPLC-
MS data for the mouse model study. D. Gaul processed the UPLC-MS data for the human 
cohort study. T. Q. Long performed the support vector machine multivariate analysis for 
the human cohort study. C. M. Jones performed all PCA and PLS-DA multivariate 
analyses, conducted all UPLC-MS/MS and chemical standard validation experiments, 
and determined metabolite identities and biological functions. 
 
3.1 Abstract 
Ovarian cancer (OC) is the 5th leading cause of cancer-related deaths for U.S. 
women, yet it has the highest mortality rate amongst gynecological cancers. Non-specific 
symptoms, combined with a lack of early detection methods and highly specific 
biomarkers, contribute to late diagnosis and low 5-year survival rates; thus, an effective 
screening strategy for early diagnosis would be particularly advantageous since 5-year 
survival rates can be as high as 90%. Two approaches were taken to investigate metabolic 
patterns for early detection of this deadly disease. First, Dicer-Pten double knockout 
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(DKO) mice that phenocopy many of the features of metastatic high-grade serous 
carcinoma (HGSC) observed in women were studied. HGSC is the most common and 
deadliest subtype that results in 90% of OC deaths. Using ultra performance liquid 
chromatography-mass spectrometry (UPLC-MS), serum samples from 14 early-stage 
tumor (ET) DKO mice and 11 controls were analyzed in depth to screen for metabolic 
signatures capable of differentiating early-stage HGSC from controls. Iterative 
multivariate classification selected 18 metabolites that, when considered as a panel, 
yielded 100% accuracy, sensitivity, and specificity for classification. Altered metabolic 
pathways reflected in that panel included those of fatty acids, bile acids, 
glycerophospholipids, peptides, and some dietary phytochemicals. These alterations 
revealed impacts to cellular energy storage and membrane stability, as well as changes in 
defenses against oxidative stress, shedding new light on the metabolic alterations 
associated with early OC stages.  
In the second approach, serum metabolic phenotypes of an early-stage OC pilot 
patient cohort were characterized. Serum samples were collected from 24 early-stage OC 
patients and 40 healthy women, and subsequently analyzed using UPLC-MS. 
Multivariate statistical analysis employing support vector machine (SVM) learning 
methods and recursive feature elimination (RFE) selected a panel of metabolites that 
differentiated between age-matched samples with 100% cross-validated accuracy, 
sensitivity, and specificity. This small pilot study demonstrated that metabolic 
phenotypes may be useful for detecting early-stage OC and, thus, supports conducting 
larger, more comprehensive studies. 
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3.2 Ovarian Cancer 
3.2.1 Overview 
Ovarian cancer (OC) is the 5th leading cause of cancer-related deaths for U.S. 
women.1 In particular, high-grade serous carcinoma (HGSC), the subtype with the 
highest occurrence and mortality, is responsible for 90% of all ovarian cancer deaths, yet 
its origin and early progression are poorly understood.2-4 Due to the unavailability of 
reliable screening tests in clinical practice and the asymptomatic course through early 
stages of the disease, the majority of ovarian cancer cases (68%), including most HGSCs 
(>95%), are diagnosed as advanced, metastatic disease with poor survival.5, 6 The 5-year 
OC survival rate for all cases diagnosed during 2003-2009 was 44%.7 When the cancer is 
confined to the ovary at diagnosis, however, the 5-year survival is over 90%.2 Early 
detection is thus crucial in reducing ovarian cancer mortality. 
3.2.2 Current Diagnostic Methodology 
The conventional evaluation of OC patients includes physical examination, 
transvaginal ultrasonography, and measurement of levels of the serum tumor biomarker 
CA125. However, this marker is of limited utility since it can also be elevated by 
conditions unrelated to ovarian cancer, especially in premenopausal women.8 Recent 
data9, 10 have suggested that the OVA111 test, the first protein-based In Vitro Diagnostic 
Multivariate Index Assay (IVDMIA) approved by the FDA, may improve, along with 
physician clinical assessment, detection rates of malignancies among women with pelvic 
masses planning to undergo surgery. Still, OVA1 is not yet an OC screening or definitive 
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diagnostic test. Furthermore, whether this assay can detect OC at an early time point still 
remains unclear,12 and a more effective screening strategy for early diagnosis would be 
particularly advantageous for patients. 
3.2.3 Dicer-Pten Double-Knockout Mouse Model 
Traditionally, OC has been thought to originate in the ovary. The fallopian tube, 
however, has recently been proposed as an alternate site of origin, especially in women 
carrying hereditary BRCA mutations.13-15 A mouse model of HGSC where disease 
originates through this alternative route was therefore developed by conditionally 
disabling two critical genes, Dicer and Pten (Dicer flox/flox Pten flox/flox Amhr2 cre/+) in the 
fallopian tubes.16 In these Dicer-Pten double-knockout (DKO) mice, HGSCs originate 
and progressively develop in the fallopian tube before spreading to the ovary, and then 
metastasize throughout the abdominal cavity, causing ascites, and eventually killing the 
mice. Besides replicating the clinical biology of human HGSC in that tumors are 
characterized by complex papillae and irregular glands forming slit-like spaces in 
addition to solid sheets of tumor cells with pleomorphic nuclei, prominent nucleoli, and 
elevated mitotic activity, disease in these DKO mice also shows close molecular 
similarities with human HGSCs, such as upregulated folate receptor 1 (Folr1), CA125 
(Muc16), secreted phosphoprotein 1 (Spp1), and chemokine genes, therefore providing a 
simpler, better-controlled, model to study early-stage OC which could potentially be later 




3.2.4 Metabolic Ovarian Cancer Detection 
During the last decade, metabolomics has emerged as a promising discipline 
providing tools to investigate characteristic metabolic patterns of disease, with one of its 
goals being the discovery of biomarker panels for early diagnosis. Mass spectrometry 
(MS) and 1H nuclear magnetic resonance (NMR) spectroscopy in combination with 
multivariate statistical analysis have been utilized to investigate ovarian cancer-induced 
metabolome alterations in urine,17-20 plasma21, serum22-26, and tissues.27-29 Li and 
collaborators, for example, identified L-tryptophan, lysoPC(18:3), lysoPC(14:0), and 2-
piperidinone as plasma metabolites discriminating between epithelial ovarian cancer 
(EOC) patients and women with benign ovarian tumors.21 Disruption to nucleotide, 
histidine, tryptophan, and mucin metabolism pathways17, 21 and changes in amino acids 
involved in de novo purine nucleotide synthesis, have also been reported.26 However, and 
despite these advances, no widely-accepted strategy for metabolome-based OC screening 
has yet emerged.12, 30 Moreover, only a very small number of studies have focused on 
early-stage OC detection. Odunsi and collaborators24, for example, used NMR 
spectroscopy to investigate metabolome changes in early-stage patients; independent 
validation of their reported predictive statistical model resulted in 95% specificity, 68% 
sensitivity, and an area under the Receiver Operator Characteristic Curve (AUC) of 
0.949. Additionally, Xu and collaborators suggested the serum metabolite 27-nor-5β-
cholestane-3,7,12,24,25 pentol glucuronide as a potential biomarker for stage I OC 
(specificity: 77%; sensitivity: 70%; AUC: 0.750).25 A hindrance plaguing this field has 
been the poor understanding of early tumor development mechanisms, in addition to the 
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practical difficulty in obtaining access to biological fluids from sufficiently-large, well-
matched early-stage patient cohorts. 
Previous work reported by our group explored the feasibility of using MS-based 
metabolomics to detect ovarian cancer.22, 26 While successful, these studies mainly 
involved late-stage (III/IV) OC patients in which metastasis had occurred, which are 
easily detectable because the disease is systemically widespread. The current work aims 
to build upon the previous studies by probing the metabolome to determine phenotypic 
fingerprints associated with early-stage OC. 
3.3 Experimental Details 
3.3.1 Chemicals 
Healthy human blood serum (S7023-50 mL) was purchased from Sigma-Aldrich 
Corp. (St. Louis, MO, USA). FMOC-L-Proline was procured from Chem-Impex 
International, Inc. (Wood Dale, IL, USA). Leucine enkephalin was obtained from ERA 
(Golden, CO, USA). Arginyl-glycyl-aspartic acid, L-Fucose, L-Rhamnose, 1,5-
Anhydrosorbitol, D-Fucose, L-Rhamnulose, 2-Deoxy-D-glucose, and 2-Deoxy-D-
galactose were acquired from Sigma-Aldrich Corp. Bilirubin and suberic acid were 
obtained from Alfa Aesar (Ward Hill, MA, USA). Ricinoleic acid was purchased from 
MP Biomedicals (Santa Ana, CA, USA). Docosahexaenoic acid and 3-oxo stearic acid 
were acquired from Cayman Chemical Company (Ann Arbor, MI, USA). LysoPE(16:0) 
was obtained from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). LC-MS grade 
methanol was purchased from J.T. Baker Avantor Performance Materials, Inc. (Center 
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Valley, PA, USA). Ultrapure water with 18.2 MΩ cm resistivity (Barnstead Nanopure, 
Thermo Fisher Scientific Inc., Waltham, MA, USA) was used to prepare 
chromatographic mobile phases. 
3.3.2 Dicer-Pten Double-Knockout Mice 
Dicer-Pten DKO (Dicerflox/flox Ptenflox/flox Amhr2cre/+ ) mice were generated by 
mating males (Dicerflox/flox Ptenflox/flox Amhr2cre/+) with females (Dicerflox/flox Ptenflox/flox). 
Female Dicerflox/flox Ptenflox/flox (a genotype not carrying Amhr2cre/+) mice were used as 
controls. Mice were housed in a vivarium with a controlled temperature of 21 °C. They 
were fed 5053 Irradiated PicoLab® Rodent Diet 20 and had access to drinking water 
supplied in bottles. Dicerflox/flox Ptenflox/flox Amhr2cre/+ DKO mice were sacrificed for this 
study in accordance to the animal protocol approved by the Institutional Animal Care and 
Use Committee (IACUC) at Baylor College of Medicine. 
Blood samples were collected from 23 early-stage tumor (ET) and 10 late-stage 
tumor (LT) Dicer-Pten DKO mice (Dicerflox/flox Ptenflox/flox Amhr2cre/+) in addition to 21 
control mice (Dicerflox/flox Ptenflox/flox). Murine blood samples were collected into serum 
separator tubes. Serum was obtained by centrifugation at 14,000 rpm for 5 min at room 
temperature. Immediately after centrifugation, 200 µL serum aliquots were frozen and 






3.3.3 Human Cohort Description 
Age-matched blood serum samples from 24 early-stage ovarian cancer patients 
(age range 40-84, mean age 58 ± 11 years) and 40 healthy women (age range: 40-84, 
mean age 57 ± 12 years) were acquired from the Ovarian Cancer Institute laboratory at 
the Georgia Institute of Technology. The healthy women population consisted of patients 
with histology considered within normal limits (WNL), despite the fact some had 
documented cysts. All donors were required to fast and to avoid medicine and alcohol for 
12 hours prior to sampling, except for certain allowable medications (e.g., diabetics were 
allowed insulin). The mean ages of the 2 respective group populations were not 
significantly different (unpaired t-test, n = 64, p = 0.67). Blood samples were collected at 
Northside Hospital (Atlanta, GA) by venipuncture from each donor into evacuated blood 
collection tubes that contained no anticoagulant after approval by the Institutional 
Review Board (IRB). Serum was obtained by centrifugation at 5000 rpm for 5 min at 4 
°C. Immediately after centrifugation, 200 µL aliquots of serum were frozen and stored at 
-80 °C for further use. 
3.3.4 Serum Sample Preparation and Experimental Design 
Commercially available healthy human blood serum was used to optimize the 
serum sample metabolite extraction protocol and UPLC-MS method. Serum samples 
were thawed on ice prior to sample preparation. Methanol was added to 100 µL of each 
serum sample in a 3:1 ratio to precipitate proteins. Samples were vortex-mixed for 10 s 
and centrifuged at 13,000 rpm for 7 min. After centrifugation, 350 µL of supernatant 
were transferred to new microcentrifuge tubes and, after the addition of 400 µL of 
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ultrapure water, frozen at -80 °C for 2 h. Subsequently, samples were lyophilized for 24 h 
at -50 °C and 25 mTorr using a VirTis bench top freeze-dryer (SP Industries, Stone 
Ridge, NY, USA). Sample residues were reconstituted in 100 μL of water/methanol 
(80:20 v/v, initial UPLC gradient conditions), and analyzed by UPLC-MS. Blank 
samples, consisting of ultrapure water, underwent the same process as serum samples. All 
samples were randomized prior to UPLC-MS analysis. Solvent and sample preparation 
blanks were jointly analyzed with serum samples. Quality control (QC) samples (15 µM 
FMOC-L-Proline and leucine enkephalin solution in ultrapure water) were analyzed 
every 5 hours to verify that retention time, peak shape and intensity were stable for the 
duration of the analysis. The relative standard deviation of the retention times, peak areas, 
and intensities of the monoisotopic ions obtained from extracted ion chromatograms were 
less than 15% over the duration of the experiments. 
3.3.5 Metabolic Profiling via Ultra Performance Liquid Chromatography-
Mass Spectrometry 
UPLC-MS analysis was performed using a Waters ACQUITY UPLC H Class 
system fitted with a Waters ACQUITY UPLC BEH C8 column (2.1 × 100 mm, 1.7 µm 
particle size) for Dicer-Pten DKO mice experiments or a Waters ACQUITY UPLC BEH 
C18 column (2.1 × 50 mm, 1.7 µm particle size) for the human cohort experiments, and 
coupled to a Xevo G2 QTOF mass spectrometer (Waters Corporation, Manchester, UK) 
with a typical resolving power of 25,000 M/Δm FWHM and mass accuracy of 1.8 ppm at 
m/z 554.2615. The instrument was operated in negative ion mode with a probe capillary 
voltage of 2.5 kV, and a sampling cone voltage of 45 V. The ion source and desolvation 
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temperatures were 120 °C and 350 °C, respectively; the nitrogen desolvation flow rate 
was 800 L h-1, and the cone desolvation flow rate was 50 L h-1. The mass spectrometer 
was calibrated across the 50-1200 m/z range using a 0.5 mM sodium formate solution 
prepared in 90:10 2-propanol:water v/v. Data were mass corrected during acquisition 
using a leucine enkephalin reference spray (LockSpray) infused at 2 µL min-1. Data were 
acquired in the 50-1200 m/z range and the scan time was set to 1 s. Data acquisition and 
processing was carried out using MassLynx v4.1. The chromatographic method for 
sample analysis involved elution with water (mobile phase A) and methanol (mobile 
phase B) at a flow rate of 0.40 mL min-1. The following gradient program was used for 
analysis of Dicer-Pten DKO samples: 0-15 min 20-90% B; 15-19 min 90% B. The 
following gradient program was used for the analysis of human cohort samples: 0-15 min 
20-90% B; 15-23 min 90% B. Both gradients were returned to their initial conditions 
over a period of 11 min after each sample injection. Column temperatures were set to 60 
°C, the autosampler tray temperature was set to 5 °C, and the injection volume was 2 µL. 
Technical duplicates were acquired. UPLC-MS/MS experiments were performed by 
acquiring product ion mass spectra with applied voltages of 10, 20, and 30 V in the 
collision cell, using ultra high purity argon (≥ 99.999%) as the collision gas. 
3.3.6 Data Analysis for Dicer-Pten DKO Mouse Model Study 
Following UPLC-MS, spectral features (retention time (Rt), m/z pairs) were 
extracted from the data using MZmine 2.0 software.31 This procedure involved 
chromatogram alignment, peak identification and integration, peak area extraction, and 
normalization after curation of the data matrix. The data matrix curation consisted of the 
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removal of signals that were present in the blank samples, the solvent, or were not present 
in at least 50% of the serum samples. The curated data matrix was utilized to build a 
model for sample class discrimination via oPLS-DA and to down-select a smaller panel 
of discriminant features through the usage of a genetic algorithm (MATLAB Version 
7.13.0, The MathWorks, Inc., Natick, MA, USA with PLS_Toolbox v.6.71, Eigenvector 
Research, Inc., Wenatchee, WA, USA). A panel of 18 discriminant features had the 
lowest root-mean-square error of cross-validation (RMSECV) at the conclusion of the 
genetic algorithm variable selection process. The parameters for genetic algorithm 
variable selection were as follows: population size: 64, variable window width: 1, % 
initial terms (variables): 10, target minimum # of variables: 8, target maximum # of 
variables: 15, penalty slope: 0.05, maximum generations: 150, % at convergence: 79.7, 
mutation rate: 0.005, crossover: double, regression choice: PLS, # of latent variables: 6, 
cross-validation: random, # of splits: 5, # of iterations: 5, replicate runs: 20. PLS-DA 
models were orthogonalized and internally cross-validated using 10 iterations of random 
sample subsets with 5 data splits. Data were preprocessed by autoscaling prior to oPLS-
DA analysis. Principal component analysis (PCA) was also performed to inspect data 
before and after genetic algorithm variable selection (i.e., on all of the extracted spectral 
features and only the discriminant feature panel). 
3.3.7 Data Analysis for Human Cohort Study 
 Following UPLC-MS, spectral features (Rt, m/z pairs) were extracted from the 
data using MZmine 2.0 software.31 This procedure involved chromatogram alignment, 
peak identification and peak area extraction, in addition to gap-filling and normalization 
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after curation of the data matrix. The data matrix curation consisted of the removal of 
signals that were present in the blank samples and the solvent. Also, signals that were not 
present in at least 50% of the healthy samples or 50% of samples belonging to either 
ovarian cancer histological subtype used in this study (i.e., papillary serous or 
endometrioid) were eliminated from the data matrix. Linear SVMs32 in-house developed 
using LIBLINEAR33 were utilized to build multivariate sample classification models and 
to find the minimum set of discriminant features needed to differentiate the early-stage 
OC patient samples from those of the healthy women with the highest accuracy, 
specificity, and sensitivity. SVMs are effective at handling high dimensionality data as 
those produced in the present work and have been widely applied to metabolomics 
studies.22, 26, 34-36 Moreover, they are ideal for limited-size datasets since the risk of data 
overfitting is reduced.37 All data were preprocessed by autoscaling before analysis. 
For SVM analysis, linearly-separable samples represented as a row vector x, had 
membership of two classes g (= H or D), where H stands for healthy women and D for 
OC disease with labels c = -1 for class H, and +1 for class D. All of the samples were 
used to build a classification model which was internally validated using leave-one-out 
cross-validation. The decision function that separated the two classes, defined here as the 
“OC detection score”, was as follows: 
𝑂𝐶 𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛 𝑠𝑐𝑜𝑟𝑒 = 𝑏 + ∑ 𝑤𝑗𝑥𝑖𝑗
𝐽
𝑗=1
                                     [1] 
𝑔(𝒙𝑖) = 𝑠𝑔𝑛(𝒘𝒙𝑖
′  + 𝑏) = 𝑠𝑔𝑛(𝑂𝐶 𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛 𝑠𝑐𝑜𝑟𝑒)               [2] 
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where w and b are the weight and bias parameters that were determined from the SVM 
classification model and J is the total number of features. The sign of the OC detection 
score determined which class a sample was assigned to: class H if negative and class D if 
positive. In this classification function, the two classes were divided in the dataspace by a 
hyperplane 𝒘𝒙′ + 𝑏 = 0 that maximized the margins between samples of different 
classes. The margin between the two classes was defined such that:  
𝒘𝒙′ + 𝑏 ≥ 1, 𝑐 = +1                                                 [3] 
𝒘𝒙′ + 𝑏 ≤ −1,        𝑐 = −1                                               [4] 
A recursive feature elimination (RFE) method,22  structured in the SVM analysis process 
as a nested leave-one (sample)-out design, was used to find the minimum set of 
discriminant features that maximized the accuracy of the SVM classification model. The 
design consisted of two loops. The outer loop used one randomly selected sample as a 
test sample while the remaining samples constituted the inner loop training set. In the 
inner loop, one sample was iteratively left out while the remaining samples were used as 
a training set to calculate weights for each metabolic feature and predict the left-out 
sample. These weights were averaged over all inner loop iterations, and the resultant 
SVM model was used to classify the outer loop test sample. Afterwards, a different outer 
loop test sample was selected and classified after another set of inner loop iterations were 
completed. This process ensued until all samples had been used as outer loop test 
samples. Once the averaged weights resulting from each inner loop process were 
summed, the feature that ranked least important (i.e., had the lowest summed weight) was 
discarded from the remaining feature set (wi = 0), and the inner/outer loop processes 
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began again.  The aforementioned procedure was repeated until all metabolic features 
were ranked. The performance characteristics for the RFE-SVM method were generated 
based on the percentage of test samples accurately classified during each phase of the 
feature elimination procedure. From this process, a feature panel with high accuracy, 
sensitivity, and specificity was chosen and tested again across all samples. 
PLS-DA was also performed to inspect data before and after discriminant feature 
selection via RFE. PLS-DA models were orthogonalized (oPLS-DA) and internally 
cross-validated using 5 iterations of random sample subsets with 8 data splits. Data were 
preprocessed by autoscaling prior to oPLS-DA analysis. 
3.3.8 Discriminant Feature Identification Procedure 
Metabolite identification was attempted for discriminant features. Mass spectral 
ion adduct analysis was first performed to ensure the unambiguous assignment of the 
signal of interest in each mass spectrum. The adduct ions that were investigated in the 
mass spectra included [M - H]-, [M + Cl]-, [M + CH3COO]
-, [M + HCOO]-, [M + Na - 
2H]-, [M + K - 2H]-, [M - H2O - H]
-, [M + H2O - H]
-, and [2M – H]- species, which are 
usually observed in negative electrospray ionization mode. The theoretical m/z values for 
these species were calculated and compared with the experimental values from mass 
spectral signals. For spectra in which multiple adducts were not present, the accurate 
mass of the candidate neutral molecule was calculated based on the assumption that the 
m/z value observed corresponded to the [M - H]- ionic species. For mass spectra in which 
multiple adducts were present, the [M - H]- spectral signal was determined and the 
accurate mass of the metabolic candidate neutral molecule was calculated based on it. 
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Elemental formulae were generated based on the exact mass (maximum mass error of 10 
mDa) and isotopic patterns of the features using MassLynx 4.1. The elements included in 
the formulae were constrained to C, H, N, O, P, and S. The lists of generated elemental 
formulae were searched against the METLIN database,38 the LIPID Metabolites and 
Pathways Strategy (LIPID MAPS) database,39 and the human metabolome database 
(HMDB).40 MetaboSearch41 was also utilized to search the aforementioned databases 
solely using neutral masses with a mass accuracy of 20 ppm. Tandem MS data could not 
be acquired for discriminant features where the precursor ion abundance was not high 
enough for sensitive quadrupole selection and MS/MS due to ion transmission losses.42 
The MS/MS METLIN database, MassBank,43 and literature searches were used to further 
confirm the identity of the candidates for which MS/MS data was successfully acquired. 
Additionally, fragmentation patterns were manually analyzed in a few cases to 
discriminate between different isobaric species. For the Dicer-Pten DKO mouse model 
study, available chemical standards were purchased to validate tentative metabolite 
identities by chromatographic retention time matching and/or MS/MS fragmentation 
pattern matching. These chemical standards also served the purpose of eliminating 




3.4 Metabolomic Serum Profiling Detects Early-Stage High-Grade Serous 
Ovarian Cancer in a Mouse Model 
3.4.1 DKO Mouse Cohort 
Typically, between 4 and 7 months, DKO mice develop HGSCs of the fallopian 
tubes, which later spread to envelop the ovaries and at a late stage metastasize throughout 
the abdominal cavity including peritoneal tissues (Figure 3.1). For the purpose of this 
study, early-stage tumors in DKO mice were defined as those confined to the fallopian 
tube without any sign of metastasis. Eventually, all DKO mice die from metastatic 
HGSCs after developing hemorrhagic ascites, an accumulation of hemorrhagic fluid in 




Figure 3.1: Early- and late-stage high-grade serous carcinomas (HGSCs) in DKO mice 
(Dicer flox/flox Pten flox/flox Amhr2 cre/+). (A): Early fallopian tube tumors (yellow arrows) 
formed in a 6.8-month-old DKO mouse used in this study with normal ovaries (white 
arrowheads) and uterus (green arrows). (B): Massive fallopian tube tumors that engulfed 




Figure 3.2: Principal Component Analysis (PCA) scores plot of early-stage tumor Dicer-
Pten DKO (red circles), late-stage tumor Dicer-Pten DKO mice (green triangles), and 





 Initially, an exploratory experiment was conducted to determine to what extent 
UPLC-MS metabolic profiling could differentiate the blood sera of 9 ET (mean age 319 ± 
36 days) and 10 LT (mean age 309 ± 34 days) DKO mice, in addition to 10 control (mean 
age 342 ± 80 days) mice. For this experiment, DKO mice were staged based on the 
presence or lack of ascites—LT DKO mice had developed ascites while ET DKO mice 
had not. Unsupervised PCA of the resultant data showed clear separation of LT DKO 
mice from ET DKO mice and control mice along the 1st principal component (unpaired t-
test, n = 29, p = 0.002) (Figure 3.2). However, both ET DKO mice and control mice were 
clustered together. As expected, this result somewhat reflects what is clinically observed 

























Scores on PC 1 (17.54%)
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for the diagnosis of human ovarian carcinomas, i.e. late-stages in which metastasis has 
occurred are more easily detectable because the disease is systemically widespread. Yet, 
detection of early-stages is challenging since the disease is still localized and 
asymptomatic. 
At this stage the focus of the study was shifted to the detection of early-stage 
HGSC in DKO mice by comparing metabolomic profiles between DKO mice with early-
stage HGSC against control mice, as this is the equivalent of the clinically-relevant 
challenge for human HGSC detection. Therefore, a set of 14 Dicer-Pten DKO mice with 
early-stage HGSC (mean age 206 ± 19 days) and 11 control mice (mean age 211 ± 30 
days) was investigated via an alternative approach involving supervised multivariate 
analysis. To ensure complete confidence in the class membership of each mouse in the 
cohort, ET DKO mice were sacrificed after blood sample collection to confirm the early-
tumor status by ensuring that all had primary tumors located on their fallopian tubes with 
no visible metastasis. Table 3.1 describes detailed information of the mice included in 




Table 3.1: Early-Stage Tumor Dicer-Pten Double Knockout Mice and Control Mice Characteristics. 









(days) (months) (days) (months) 
310 5/8/12 181 6.0 Tumor on each oviduct 109 2/16/12 257 8.6 
312 5/8/12 181 6.0 Tumor on each oviduct 115 2/28/12 245 8.2 
315 5/8/12 181 6.0 Tumor on each oviduct 116 2/28/12 245 8.2 
252 4/16/12 199 6.6 Tumor on each oviduct 156 3/14/12 230 7.7 
255 4/16/12 199 6.6 Tumor on one oviduct 222 5/12/12 170 5.7 
215 4/10/12 204 6.8 Tumor on one oviduct 223 4/10/12 202 6.7 
216 4/10/12 205 6.8 Tumor on one oviduct 218 4/3/12 209 7.0 
217 4/10/12 205 6.8 Tumor on one oviduct 309 4/3/12 209 7.0 
219 4/10/12 205 6.8 Tumor on each oviduct 311 4/3/12 209 7.0 
205 4/8/12 206 6.9 Precursor tumor lesion on each oviduct 372 5/8/12 175 5.8 
220 4/3/12 211 7.0 Precursor tumor lesion on each oviduct 453 5/8/12 175 5.8 
256 4/16/12 217 7.2 Tumor on each oviduct     
143 3/10/12 235 7.8 
Precursor tumor lesions on each 
oviduct 
    
153 3/14/12 250 8.3 Tumor on each oviduct     
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3.4.2 Multivariate Classification Performance 
MZmine data processing extracted 934 features (Rt, m/z pairs) from the UPLC-
MS data from both control and ET DKO mice. These extracted features were utilized to 
build an oPLS-DA model which classified the respective serum samples from each class. 
Performance characteristics of the initial oPLS-DA analysis of the data matrix that 
included all 934 metabolic features (Figure 3.3a and 3.3b) were 76%, 68%, and 83% for 
the cross-validated accuracy, sensitivity, and specificity, respectively. A total of five 
murine serum samples were misclassified. This 3 latent variable model interpreted 
35.35% and 93.64% variance from the X- (feature peak areas) and Y- (mouse class 
membership) blocks, respectively. Though the model performance was not entirely poor, 
genetic algorithms were used to attain a smaller, but more robust, metabolic feature set 
that could serve to better discriminate between control and ET DKO mice with higher 
cross-validated accuracy, sensitivity, and specificity. A panel of 18 metabolic features 
with the lowest RMSECV was selected through the genetic algorithm variable selection 
process. oPLS-DA modeling with this smaller panel (Figure 3.3c and 3.3d) resulted in 
100% cross-validated accuracy, sensitivity, and specificity; therefore, no mice were 
misclassified. This model interpreted 33.12% and 98.30% of the X- and Y-block 
variances, respectively, with only 2 latent variables —one less than the model using all 
934 metabolic features. Furthermore, the captured Y-block variance was slightly higher, 
thereby, demonstrating that the down-selected panel of 18 features is more informative 




Figure 3.3: Orthogonal projection to latent structures-discriminant analysis (oPLS-DA) 
models of early-stage tumor (ET) Dicer-Pten DKO (red circles) vs. control mice (blue 
squares). (A): oPLS-DA calibration scores plot using the total initial set of 934 spectral 
features. The model consisted of 3 LVs with 35.35% and 93.64% total captured X- and 
Y-block variances, respectively. The cross-validated accuracy, sensitivity, and specificity 
were 76%, 68%, and 83%, respectively. (B): The corresponding ET cross-validated 
prediction plot for (A). There were 5 misclassified mice. (C): oPLS-DA calibration scores 
plot using the 18 discriminant metabolic feature panel obtained from genetic algorithm 
variable selection. The model consisted of 2 LVs with 33.12% and 98.30% total captured 
X- and Y-block variances, respectively. The accuracy, sensitivity, and specificity were all 










































































































Of the 18 selected features, the concentration levels of 9 metabolites were found to 
increase and 9 metabolites were found to decrease in ET DKO mice. While only 11 of 
these concentration changes were univariately significant (Mann-Whitney U test, n = 25, 
p ≤  0.05; Figure 3.4), the co-varying concentrations of all 18 metabolic features allowed 
us to distinguish the detected metabolomes of control and ET DKO mice in multivariate 
space; accordingly, they all display discriminatory power when collectively included as 
part of a joint panel. The concentration levels of those features that were not statistically 
different between ET DKO and control mice in a univariate fashion could also be a result 
of the relatively modest sample size used in this study. 
To further investigate these results, PCA was utilized to evaluate the performance 
of the 18-feature discriminant panel in an unsupervised manner. Scores plots were 
generated for both the initial set of 934 metabolic features and the 18 discriminant feature 
panel (Figure 3.5). Using the initial set, 3 principal components interpreting 46.43 % of 
the data matrix variance showed no distinct grouping of the sample classes (Figure 3.5a). 
However, better clustering was observed with the 18-feature 3-principal component PCA 
model which interpreted 53.49% of the variance (Figure 3.5b). The PCA class separation 
was statistically significant and occurred along the 1st principal component (unpaired t-






Figure 3.4: Discriminatory spectral features having statistically significant univariate 
changes between early-stage tumor (ET) Dicer-Pten DKO mice (n = 14) and control (C) 
mice (n = 11). P-values were calculated using the Mann-Whitney U test. Box plots with 
mean (square), median, upper and lower quartile, outliers, and minimum and maximum 




































































































































Figure 3.5: Principal Component Analysis (PCA) of early-stage tumor Dicer-Pten DKO 
(red circles) and control mice (blue squares). (A): PCA scores plot using the initial set of 
934 spectral features. The model consisted of 3 PCs with 46.43% total captured variance. 
(B): PCA scores plot using the 18 discriminant feature panel obtained from genetic 


























































Scores on PC 2 (18.99%)






























3.4.3 Discriminant Metabolite Identification 
Metabolite identification was attempted for the 18 discriminant feature subset 
once PCA confirmed the robustness of the oPLS-DA model. The metabolite 
identification procedure is illustrated in Figure 3.6 for feature 2501. Typical total ion 
UPLC-MS chromatograms for control and ET DKO mice are shown in Figure 3.6a and 
3.6b, respectively. The apparent similarity of these chromatograms hints that subtle 
metabolic differences occur as HGSCs initially form and begin to proliferate and 
demonstrates the need for multivariate methods to extract these differences from the 
detected metabolomes. Highly-selective accurate mass extracted ion chromatograms for 
each discriminant feature (Figure 3.6c) were generated thanks to the high resolving 
power of the time-of-flight mass analyzer utilized. The corresponding averaged mass 
spectra were used for adduct ion analysis (Figure 3.6d) to ensure that the correct exact 
mass was assigned to the spectral features of interest. The presence of multiple adducts 
for some features further assisted in chemical assignments. The ensuing isotopic patterns 
and accurate masses were used to generate lists of possible candidate elemental formulae 
that were searched against metabolite databases. Furthermore, UPLC-MS/MS 
experiments were conducted to obtain fragmentation patterns that helped confirm the 
metabolite identities of the 18 feature subset. Tandem MS spectra were compared to 
those in metabolite databases and/or scientific literature and manually analyzed as well 
(Figure 3.6e). Lastly, standards of the commercially-available metabolites were analyzed 
by UPLC-MS and UPLC-MS/MS to further verify the identity of the candidates by 





Figure 3.6: Typical total ion chromatograms obtained for serum samples from (A) a 
control mouse and (B) a Dicer-Pten early-stage tumor DKO mouse. (C): Extracted ion 
chromatogram for m/z 452.2779 ± 0.0050 generated from a control mouse sample (blue 
line) and a Dicer-Pten early-stage tumor DKO mouse (red line). These were generated 
from the data shown in A and B, respectively. (D): Mass spectrum for the discriminant 
metabolic feature with m/z 452.2779. (E): Tandem MS spectrum for the m/z 452.2779 
precursor ion using a collision cell voltage of 30 V. The matching of the experimental 
tandem MS fragmentation pattern with the metabolite candidate is illustrated by the mass 
errors calculated as differences with the values in the MassBank database, in addition to 
manual fragment analysis. 
 
  




































































m = 1.0 mDa
140.0095
m = 2.3 mDa
255.2357




















Eleven of the 18 metabolic features were identified by MS and MS/MS, while 4 
were further confirmed chromatographically by chemical standards (Table 3.2). These 4 
were ricinoleic acid (Figure 3.4; +0.23 fold change), bilirubin (Figure 3.4; -0.74 fold 
change), suberic acid (-0.42 fold change) and LysoPE(16:0) (Figure 3.4; -0.33 fold 
change). Additional identified features (Table 3.2) include di- and triglycerides, 
phospholipids, bile acids, and terpenes. Four of the features in Table 3.2 were tentatively 
matched to exogenous metabolites which have no known biofunctions, such as Peltatol A 
(lignan), and/or metabolites yet to be reported in mammals, such as (4E,8E,10E-
d18:3)sphingosine (sphingoid base). These tentative metabolite identifications are listed 





Table 3.2: Confirmed and Tentative Metabolites Identified as Discriminatory Between Early-Stage Tumor Dicer-Pten Double 
Knockout Mice and Control Mice. Metabolites confirmed by retention time matching with commercially-available standards are 


























2734 11.88 294.2410 1.23 0.0011 [M-H]- C18H33NO2 294.2439 2.9 Sphingoid base 
18, 21 


















4177 14.81 889.7234 0.36 0.0075 [M-H]- C58H98O6 889.7290 5.6 TG(55:7) 
44 
4466 13.73 625.4240 0.26 0.73 [M-H]- C42H58O4 625.4262 2.2 Lignan 
45 
2615 12.60 297.2414 0.23 0.015 [M-H]- C18H34O3 297.2435 2.1 Ricinoleic acid 27 
2489 13.37 476.2772 0.22 0.27 [M-H]- C23H44NO7P 476.2783 1.1 LysoPE(18:2) 
21, 
27, 46 
3302 11.76 163.0578 0.11 0.40 [M-H]- - - - N/A - 
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Table 3.2 (continued). 
3154 17.31 780.5530 0.061 0.77 [M-H]- C44H80NO8P 780.5550 1.9 PE(39:4) 
22, 
27, 47 
2537 13.33 219.1724 0.0059 0.40 [M-H]- C15H24O 219.1750 3.0 Terpene derivative 
48 
4509 16.85 627.5034 -0.99 0.018 [M-H]- C40H68O5 627.4994 4.0 DG(37:5) 
49 
4933 11.49 583.2555 -0.74 0.011 [M-H]- C33H36N4O6 583.2557 0.7 Bilirubin 25 
2550 14.70 711.3057 -0.63 0.025 [M-H]- - - - N/A - 
4590 1.23 345.1557 -0.52 0.29 [M-H]- 




C17H22N4O4 345.1568 1.1 Ala-Trp-Ala
4 22 
C14H26N4O4S1 345.1602 4.5 Lys-Cys-Pro
4 22 
3226 1.22 173.0810 -0.42 0.43 [M-H]- C8H14O4 173.0820 0.9 Suberic acid 27, 51 
2619 13.43 327.2295 -0.37 0.013 [M-H]- C22H32O2 327.2330 3.5 




2501 13.68 452.2783 -0.33 0.033 [M-H]- C21H44NO7P 452.2783 2.1 LysoPE(16:0) 
21, 
27, 46 






2845 0.46 402.7997 -0.33 0.0090 [M-H]- - - - N/A - 
1These reported values were obtained after data processing with MZmine 2.0 software which generates average values calculated 
using all samples. 
2Fold change was calculated as the base 2 logarithm of the average peak area ratios for ET DKO mouse samples and control samples. 
3P values calculated using Mann-Whitney U test. 
4Other polypeptide isomers are not listed; tandem MS data could not be acquired to confirm true isomer identity as their ion 
abundances were not high enough for quadrupole selection. 
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Table 3.3: Exogenous Metabolites or Metabolites Not Reported in Mammals Identified as Discriminatory Between Early-


















Tentative Metabolite Identification  
(Chemical class) 
Ref. 










2619 13.43 327.2295 [M-H]- C22H32O2 327.2330 3.5 





















Table 3.3 (continued). 



































Table 3.3 (continued). 
1These reported values were obtained after data processing with MZmine 2.0 software which generates average values 
calculated using all samples.
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3.4.4 HGSC-related Metabolic Alterations 
The identified discriminant metabolites cover a broad range of biomolecule classes 
and pathways (Figure 3.7), many of which have been individually reported to be involved 
in ovarian cancer proliferation. Table 3.2 summarizes these findings, which are discussed 
based on pathway/chemical class below. Although fold changes are reported in this 






Figure 3.7: Overview of key altered metabolic/catabolic pathways observed in early-
stage tumor (ET) Dicer-Pten DKO mice. Arrows are colored based on their 
corresponding altered pathways and represent both direct and indirect relationships 
between metabolites/metabolite classes. Metabolites from the 18 discriminant feature 
subset are italicized, and their corresponding metabolite class is in bold. Metabolites in 
red text have increased levels in ET DKO mice, while those in blue text have decreased 
levels in ET DKO mice. Metabolite relationships were derived from Kyoto Encyclopedia 




3.4.4.1 Fatty Acids and Derivatives 
 The development of hormone-related cancers, such as ovarian cancer, may be 
influenced by fatty acids.55 Fatty acids are involved in tumor cell signaling and growth, 
and are also used for energy expenditure, bulk membrane synthesis, and membrane-
targeted protein modifications.56, 57 Thus, it is not surprising that changes in fatty acid 
concentrations aid in detecting the early stages of HGSC development in the DKO mouse 
model. Five features in our discriminant subset were tentatively identified as fatty acids 
or their derivatives (Table 3.2; Figure 3.7): TG(55:7), ricinoleic acid, DG(37:5), suberic 
acid, and an unidentified possible fatty acid (C22H32O2). 
Estrogens, which play a major role in ovarian cancer proliferation,58 have been 
linked with increased hepatic triglyceride production and secretion into blood in mice,59 
chickens,60, 61 and humans.62, 63 Accordingly, increased blood serum triglyceride 
concentrations have been linked to gynecological (ovarian, endometrial, cervical) cancer 
risk,44 in agreement with our finding in ET DKO mice (Table 3.2; Figure 3.4; fold 
change: +0.36). Gercel-Taylor et al. found increased diglyceride levels in the ascites of 
late-stage ovarian cancer patients,49 which is opposite to the decrease found in this study 
in the serum from mice with early-stage tumors (Table 3.2; Figure 3.4; fold change: -
0.99). Since diglycerides are precursors to triglycerides, decreased diglyceride levels 
could be the result of increased triglyceride synthesis in the ET DKO mice, further 
demonstrating that HGSCs impact energy storage and generation. As a note, the 
identified odd-chain di- and triglycerides could also result from dietary intake, thus, 
hinting that fatty acid catabolism could be occurring at a decreased rate in ET DKO mice. 
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Suberic acid, a metabolic breakdown product of oleic acid, had decreased serum 
levels (Table 3.2; fold change: -0.42) in ET DKO mice. Menendez et al. found that oleic 
acid suppresses the transcriptional activity of the Her-2/neu oncogene in the SK-OV3 
ovarian cancer cell line by up-regulating polyomavirus enhancer activator 3 (PEA3), a 
Her-2/neu promoter transcriptional repressor.51 The detected decrease of suberic acid 
may thus be indirectly connected to the anti-cancer properties offered by oleic acid. 
Additionally, conjugated linoleic acid has been shown to suppress epidermal and 
mammary carcinogenesis in mice.64, 65 The detected increase in serum levels of ricinoleic 
acid (Table 3.2; Figure 3.4; fold change: +0.23) in ET DKO mice could thus be related to 
its increased production for further conversion into other fatty acids such as conjugated 
linoleic acid, as reported for bacteria.66, 67 In a metabolomics study, Denkert et al. 
detected decreased levels of free fatty acids (nonadecanoic acid, stearic acid, 
heptadecanoic acid) in invasive ovarian carcinoma tumors compared to borderline 
ovarian tumors.27 Correspondingly, the serum levels of the unidentified possible 
C22H32O2 fatty acid (Table 3.2; Figure 3.4; fold change: -0.37) were also decreased in the 
ET DKO mice. 
3.4.4.2 Phospholipids 
 Cancer cells need a continuous supply of phospholipids for generation and 
maintenance of membrane integrity as well as for protein modifications.68 Four features 
in our discriminant subset were tentatively identified as phospholipids (Table 3.2; Figure 
3.7): LysoPE (18:2), PE(39:4), LysoPE(16:0), and C49H93O12P [PI(O-18:0/22:2), PI(P-
18:0/22:1), PI(O-20:0/20:2), or PI(P-20:0/20:1)]. The detected changes in phospholipids 
suggest membrane degradation or morphological changes in HGSC-affected cells since 
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these lipids play a role in maintaining cellular membrane integrity. However, the 
interpretation of both increased and decreased levels is not straightforward, and could be 
the result of membrane instability and the subsequent attempt of cancer cells to repair 
them. 
 The PIK3CA oncogene, whose encoded protein phosphorylates 
phosphatidylinositols, as well as increased PI3-kinase activity have been implicated in 
ovarian carcinogenesis.52 Links between PI3-kinase activation and increased cell survival 
due to the suppression of apoptosis have also been established.69, 70 Moreover, increased 
PI3-kinase activity may aid in cancer proliferation by increasing cellular motility.52 The 
observed PI (C49H93O12P) decrease (Table 3.2; Figure 3.4; fold change: -0.33) in ET 
DKO mice could thus be attributed to increased PI3-kinase activity. As the conditional 
deletion of Pten from ET DKO mice activates the PI3-kinase signaling pathway, 
increased PI3-kinase activity could also be an artefact of the genetic manipulation of the 
mice.16 
Serum levels of PE(39:4) (Table 3.2; fold change: +0.061) were increased in ET 
DKO mice. Previous work by our group also found that a collection of 
phosphatidylethanolamines aided in combined early- and late-stage HGSC detection in 
human subjects.22 Moreover, choline kinase, an enzyme needed for the synthesis of 
phosphatidylethanolamines and phosphatidylcholines, has been shown to be increased in 
the EOC cell lines SK-OV3 and OVCAR-3.47 Lysophosphatidylethanolamine has been 
shown to increase intracellular calcium concentrations and stimulate an unknown 
membrane receptor, causing chemotactic migration and cell invasion in the SK-OV3 
ovarian cancer cell line.46 Although there are no definite conclusions to be drawn from 
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the increased (Table 3.2; fold change: +0.22) and decreased (Table 3.2; Figure 3.4: fold 
change: -0.33) levels of lysophosphatidylethanolamines detected in ET DKO mice, these 
changes could be related to the initiation of migration and invasion of HGSC to 
neighboring tissue during proliferation. Moreover, LysoPE(18:2) has recently been 
shown to aid in the detection of prostate cancer, another hormone-related cancer.34 
3.4.4.3 Sphingoid Bases 
Sphingoid bases, particularly sphingosine, have been long implicated in playing a 
role in cancer biology. One of the features in the discriminating subset was an 
unidentified C18H33NO2 sphingoid base (Table 3.2; Figure 3.7). Sphingosine facilitates 
and triggers apoptosis, while sphingosine 1-phosphate promotes cellular 
survival/profileration in response to apoptotic stress.71 Illuzzi et al. found that inhibiting 
sphingosine kinase, thereby suppressing the production of sphingosine 1-phosphate from 
sphingosine, reduced cell proliferation in ovarian cancer cell lines.72 Research by Hong et 
al. suggested that sphingosine 1-phosphate is a vital component of cellular growth and 
adhesion modulation for ovarian cancer cell lines HEY and OCC1.73 Increased levels of 
the C18H33NO2 sphingoid base in ET DKO mice (Table 3.2; Figure 3.4; fold change: 
+1.23) therefore hint at a “biochemical fight response” toward the developing carcinoma. 
Supporting this hypothesis, Fan et al. detected increased plasma levels of the 
sphingolipids phytosphingosine, ganglioside, and ceramides in a cohort combining early- 
and late-stage EOC patients that were compared to healthy controls.21 Additionally, Chen 
et al. observed an increase of phytosphingosine in the urine of a combined early- and 
late-stage EOC patient cohort.18 
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3.4.4.4 Bile Acids, Alcohols, & Derivatives 
Bile acids cause apoptosis as well as oxidative stress in cells, resulting in the 
generation of reactive oxygen species (ROS) that subsequently damage DNA. Recurring 
DNA damage can increase mutation rates of onco- and tumor suppressor genes. 
Therefore, cells exposed to bile acids can proliferate, leading to carcinogenesis.74 Two 
features in our discriminant feature subset were tentatively identified as bile acids and 
related substances (Table 3.2; Figure 3.7): 24-Nor-5β-cholane-triol and bilirubin. Serum 
levels of 24-Nor-5β-cholane-triol were found to be increased (Table 3.2; Figure 3.4; fold 
change: +0.46) in ET DKO mice. It is plausible that ROS generation by 24-Nor-5β-
cholane-triol aided in the development of ovarian carcinoma in ET DKO mice. In 
agreement with these findings, Chen et al. identified 27-nor-5β-cholestane-3,7,12,24,25 
pentol glucuronide as a serum biomarker for combined early- and late-stage EOC, which 
was also accompanied by increased levels of glycocholic acid.25 Also supporting this 
finding is previous work by our group showing that bile acids, specifically isomers of 5β-
chol-9(11)-en-24-oic acid, can aid in the detection of human HGSC.22 
Although bilirubin is not a bile acid, it is a component of bile and the end product 
of heme catabolism. Furthermore, increased bilirubin has been associated with low 
cancer mortality.75 Bilirubin acts as an endogenous antioxidant that reduces oxidative 
stress damage by scavenging peroxyl76 and hydroxyl radicals.77 Moreover, mutations in 
the tumor suppressor gene p53 can be caused by ROS,78 and p53 mutations are found in 
many cancers, including ovarian cancer.79, 80 Lowered concentration levels of bilirubin, as 
detected in the ET DKO mice (Table 3.2; Figure 3.4; fold change: -0.74), possibly imply 
diminished protection against ROS, thus leading to carcinogenesis. Supporting this 
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hypothesis, Chen et al. tentatively detected decreased levels of bilirubin in the serum of 
both early- and late-stage EOC patients, and increased levels of bilirubin mono- and di-
glucuronic acids.25 
3.4.4.5 Peptides 
One member of the discriminant feature subset was tentatively identified as a 
tripeptide isomer of Ala-Trp-Ala or Lys-Cys-Pro (Table 3.2). Tandem MS data could not 
be acquired to confirm the tripeptide sequence as the precursor ion abundances were not 
sufficiently high. Blood serum levels of these peptides were decreased in ET DKO mice 
(Table 3.2; fold change: -0.52). Previous work by our group has also found that 
tripeptides, specifically Gln-His-Ala or its isomers, aided in human HGSC detection.22 
However, a survey of the literature revealed no mechanism by which small circulating 
peptides could play a biological role in ovarian cancer. Some proteases have been 
reported to be overexpressed in ovarian carcinoma,81-83 but we would expect liberated 
peptides to have an increased concentration in ET DKO mice if their presence resulted 
from increased protease activity. 
3.4.4.6 Phytochemicals – Terpenes 
Three features in our discriminant subset were tentatively identified as terpenes 
(Table 3.2; Figure 3.7): a C15H24O terpene derivative, uroterpenol-O-glucuronide, and an 
unidentified terpene (C22H32O2). Many terpenes enter metabolic networks from food 
sources. Although both ET DKO and control mice were fed the same diet, it is plausible 
that the presence of HGSC in ET DKO mice altered the metabolism of dietary 
metabolites. Uroterpenol is a metabolic product of limonene, a terpene component of 
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citrus fruits, vegetables, herbs, and spices, and has been shown to lengthen tumor latency 
and decrease tumor yield in mice with mammary cancer.84 Interestingly, uroterpenol-O-
glucuronide has been found to have urinary excretion patterns resembling those of estriol, 
pregnanediol, and pregnanetriol, and increased excretions have been associated with 
increased placental, ovarian, or adrenal activity.50 The decreased serum levels of 
uroterpenol-O-glucuronide observed in ET DKO mice (Table 3.2; fold change: -0.52) 
might thus relate to increased ovarian activity, or to decreased serum uroterpenol 
concentrations. 
3.4.4.7 Phytochemicals – Lignans 
One feature in our discriminant subset was an unidentified C42H58O4 lignan.  
Lignans are phytoestrogens that are abundant in diets of people living in regions of low 
cancer incidence.45 An increased dietary lignan intake, measured by urinary excretion, 
has been correlated with reduced breast cancer risk.85 Ovarian cancer tumors contain type 
II estrogen binding sites,86 and it has been suggested that lignans inhibit cancer cell 
growth by competing with estradiol for type II estrogen binding sites.45 As there was a 
detected increase of the unidentified C42H58O4 lignan (Table 3.2; fold change: +0.26) in 
the serum of ET DKO mice, it is possible that binding of lignans to type II estrogen sites 





3.5 Ultra Performance Liquid Chromatography-Mass Spectrometry 
Characterization of Serum Metabolic Phenotypes of an Early-Stage Ovarian 
Cancer Pilot Patient Cohort 
3.5.1 Multivariate Classification Performance 
A total of 371 metabolic features (Rt, m/z pairs) were extracted from the UPLC-
MS acquired metabolic profiles. A SVM model was built from these extracted features to 
discriminate between serum samples from early-stage OC patients and healthy women. 
The RFE method used in the model determined that a panel of 27 features was optimal to 
discriminate both sample classes with 100% accuracy, sensitivity, and specificity (Figure 
3.8a). Of the 27 selected features, 2 were poorly resolved in the mass spectra and were 
thus removed from further consideration. The RFE method re-applied on this 25-feature 
panel led to a subgroup of 22 features that best differentiated early-stage OC patients 
from healthy women with 100% accuracy, sensitivity, and specificity (Figure 3.8b). 
Figure 3.9 shows the corresponding cross-validated “OC detection scores” obtained for 
both sample classes (H or D), which are separated by the optimal hyperplane (illustrated 
with a dotted line in the figure) that maximizes the margin between the most similar 




Figure 3.8: Evolution of classification accuracy, sensitivity, and specificity resulting 
from the recursive feature elimination (RFE) method using (A) all features and (B) the 
initial curated 25 discriminant feature set. The minimum discriminant feature set that 
maximizes the model performance characteristic is highlighted with a red dashed line. 
Accuracy values are represented by the green traces, sensitivity values are represented by 
the blue traces, and specificity values are represented by the black traces. 
 
  






















































Figure 3.9: Visualization of ovarian cancer (OC) detection scores obtained by SVMs 
using the 22-feature discriminant panel. Black squares correspond to the healthy women 
and red triangles correspond to the early-stage OC patients. The dotted line shows the 




The performance of this 22-feature discriminant panel was also investigated and 
compared to the initial set of 371 metabolic features by oPLS-DA. Misclassification plots 
were generated for both feature sets (Figure 3.10). Using the total number of features 
extracted from the UPLC-MS metabolic profiles, 4 latent variables interpreting 43.28% 
of the variance from the X- (feature peak areas) block and 73.59% of the variance from 
the Y- (class membership) block resulted in 32 sample misclassifications (Figure 3.10a). 
The cross-validated accuracy, sensitivity, and specificity were 49%, 64%, and 34%, 
respectively. However, the number of sample misclassifications was reduced to 4 with a 
22-feature 4-latent variable oPLS-DA model, which interpreted 48.49% and 80.70% X- 
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and Y-block variance, respectively (Figure 3.10b). For this model, the cross-validated 
accuracy, sensitivity, and specificity were 94%, 97%, and 91%, respectively. These 
model performance characteristics increased by 33% or more upon variable selection, 











Figure 3.10: Orthogonal projection to latent structures-discriminant analysis (oPLS-DA) 
cross-validated (CV) prediction plots of early-stage ovarian cancer (OC) patients (red 
triangles) and healthy women (black squares). (A): OC CV prediction plot for the oPLS-
DA model using the initial set of 371 spectral features. The cross-validated accuracy, 
sensitivity, and specificity of the model were 49%, 64%, and 34%, respectively. There 
were 32 misclassified samples. (B) OC CV prediction plot for the oPLS-DA model using 
the 22 discriminant feature panel. The cross-validated accuracy, sensitivity, and 
































































3.5.2 Discriminant Metabolite Identification and Biological Relevance 
Of the 22 RFE-selected discriminant features, the detected concentration levels of 
9 were increased, whereas 13 were decreased in sera of early-stage OC patients (Figure 
3.11). While only 5 of these concentration changes were univariately significant (Mann-
Whitney U test, n = 64, p ≤ 0.05; Figure 3.11), the co-varying concentrations of all 22 
discriminant metabolic features were needed to distinguish the detected metabolomes of 
OC patients and healthy women. Moreover, the concentration levels of those features that 
were not univariately statistically different between early-stage OC patients and healthy 
women could feasibly be a result of the relatively small sample size used in this pilot 
study. Although metabolite identification was attempted for all 22 discriminant features 
once oPLS-DA confirmed the robustness of the SVM classification model, only 18 of the 
22 metabolic features were identified by MS and MS/MS (Table 3.4). The majority of 
discriminant features were lipids and fatty acids (Table 3.4). Two of the features in Table 
3.4 were tentatively matched to metabolites yet to be reported in mammals, such as 
xeniasterol-a, and their identity should therefore be considered only provisional. These 
tentative metabolite identifications are detailed in Table 3.5, and the metabolite chemical 






Figure 3.11: Fold change of average peak areas of each discriminant feature. Fold 
changes are calculated as the base 2 logarithm of the average peak area ratios for early-
stage ovarian cancer samples and healthy women samples. Features are labeled with their 
codes. Features with statistically significant (p ≤ 0.05) fold changes (calculated using 


































Table 3.4: Confirmed and Tentative Metabolites Identified as Discriminatory Between Early-Stage Ovarian Cancer Patients and 





























C40H77NO8 698.5576 0.6 
738 11.41 479.2823 -0.64 0.014 [M-H]- PA(10:0/10:0) C23H45O8P 479.2779 4.4 
1533 21.07 842.5910 -0.88 0.049 [M-H]- 
PE(22:2/22:6) 
PE(22:4/22:4) 
C49H82NO8P 842.5705 20.3 





C23H32O3 355.2279 1.2 
Pro Lys Leu4 
Lys Ile Pro4 
C17H32N4O4 355.2351 8.4 
286 20.56 764.5230 -0.79 0.095 [M-H]- PE(38:5) C43H76NO8P 764.5236 0.6 
660 13.78 465.3571 -0.49 0.046 [M-H]- 
SM(d18:0/0:0) 
[LysoSM(d18:0)] 
C23H51N2O5P 465.3463 10.8 
358 15.81 491.3730 -0.15 0.46 [M-H]- Polyhydroxysterol C30H52O5 491.3742 1.2 
265 13.13 599.3195 0.18 0.93 [M-H]- PI(18:0/0:0) [LysoPI(18:0)] C27H53O12P 599.3202 0.7 
222 21.10 722.5123 -0.96 0.016 [M-H]- PE(P-16:0/20:4) C41H74NO7P 722.5130 0.7 
264 13.92 772.5492 -0.17 0.087 [M-H]- PE(P-18:1/22:6) C45H76NO7P 772.5287 20.5 
1267 16.47 833.5183 0.19 0.57 [M-H]- 
PI(16:0/18:2) 
PI(16:1/18:1) 





Table 3.4 (continued). 





C20H34O2 305.2486 0.8 
1020 12.96 557.3681 0.44 0.12 [M-H]- Gln Arg Lys Lys4 C23H46N10O6 557.3529 15.2 
405 18.31 602.4552 0.29 0.17 [M-H]- N/A - - - 





C46H87NO13 860.6105 0.4 
3718 0.76 609.2308 -0.17 0.86 
[M-
2H]2- 
N/A - - - 
273 14.19 774.5648 -0.31 0.025 [M-H]- 
PE(P-18:1/22:5) 
PE(P-18:0/22:6) 
C45H78NO7P 774.5443 20.5 




0.16 0.32 [M-H]- 
Ganglioside GM3 
(d18:1/16:0) 
C57H104N2O21 1151.7059 0.8 
803 19.27 797.6533 -0.15 0.95 [M-H]- 
SM(d18:2/23:0) 
SM(d17:1/24:1) 
C46H91N2O6P 797.6542 0.9 




C38H58O4 577.4262 3.7 
565 16.24 807.5037 0.54 0.89 [M-H]- PI(16:0/16:1) C41H77O13P 807.5029 0.8 
1These reported values were obtained after data processing with MZmine 2.0 software which generates average values calculated 
using all samples. 
2Fold change was calculated as the base 2 logarithm of the average peak area ratios for OC samples and control samples. 
3P values calculated using Mann-Whitney U test. 
4Other polypeptide isomers are not listed; tandem MS data could not be acquired to confirm true isomer identity as their ion 
abundances were not high enough for quadrupole selection. 
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C30H52O5 491.3742 1.2 
439 18.11 379.3571 -0.64 0.082 [M-H]- 
(Monounsaturated fatty acid) 
Pentacosenoic acid 
Mycolipenic acid 
C25H48O2 379.3581 1.0 
1These reported values were obtained after data processing with MZmine 2.0 software which generates average values 
calculated using all samples. 
2Fold change was calculated as the base 2 logarithm of the average peak area ratios for OC samples and control samples. 




Five discriminant metabolites are sphingolipids involved in ceramide-mediated 
metabolic pathways. Sphingolipid metabolism alterations have been implicated in cancer 
pathogenesis and progression.21, 87  Ceramides aid in cell cycle arrest, terminal cell 
differentiation, and apoptosis,88, 89 but have been reported to be decreased in OC tumors 
compared to normal ovarian tissues,90 thereby, aiding OC proliferation. Decreases of two 
sphingomyelins (SM(d18:0/0:0) and SM(d18:2/23:0) or SM(d17:1/24:1)) and increases 
of a cerebroside (glucosylceramide (d18:1/16:0) or galactosylceramide (d18:1/16:0)), 
Ganglioside GM3, and a globoside (lactosylceramide (d18:1/16:0) or galabiosylceramide 
(d18:1/16:0)) were observed in the sera of early-stage OC patients (Table 3.4; Figure 
3.11). Sphingomyelins can be hydrolyzed to form ceramides, which may account for their 
observed decrease. The resultant ceramides can be incorporated into cerebrosides 
(precursors to gangliosides), thereby supporting their observed increase in the early-stage 
OC patients.  Supporting our observations, elevated levels of glucocerebrosides in the 
multi-drug resistant OVCAR-3, an OC cell line, have been reported.91 Additionally, Fan 
et al. found that the plasma concentration levels of a ganglioside were increased in 
combined early- and late-stage OC patients when compared to healthy women.21 Our 
findings suggest that the early-stage OC patients included in this study have decreased 
levels of ceramides, which are essential in the apoptotic response of cancer cells to death 
inducers such as hypoxia and DNA damage.92 Sphingolipid metabolism was also found 
to be modified in Dicer flox/flox Pten flox/flox Amhr2 cre/+ double-knockout mice with early-
stage ovarian cancer.93 
Phosphatidylinositols (Table 3.4; Figure 3.11) were identified as discriminant 
metabolites with increased levels in the early-stage OC patients, in agreement with the 
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fact that the phosphatidylinositol 3-kinase (PI3K)-AKT pathway has long been 
implicated in ovarian carcinogensis.94 The activation of the PI3K oncogene, whose 
encoded protein phosphorylates phosphatidylinositols, has been linked to increased cell 
survival due to the suppression of apoptosis.69, 70 Although our data only represents a 
small snapshot of the underlying biochemical processes occurring after the onset of OC, 
it is plausible that activity of PTEN, a PI3K-AKT pathway regulator, was enhanced in an 
attempt to stifle cellular growth of OC cells, thereby, increasing the levels of 
phosphatidylinositols in the early-stage OC patients. While PTEN levels are known to 
decline during the progression of OC,95 they have a strong inverse correlation with PI3K-
AKT activity.96 A second group of phospholipids with decreased levels in the early-stage 
OC patients was identified in the discriminant panel as phosphatidylethanolamines (Table 
3.4; Figure 3.11). Previous work by our group found that a collection of 
phosphatidylethanolamines aided in combined early- and late-stage OC detection.22 
Additionally, alterations in the metabolism of phosphatidylethanolamines were also 
detected in Dicer flox/flox Pten flox/flox Amhr2 cre/+ double-knockout mice with early-stage 
ovarian cancer.93 Human phosphatidylethanolamine-binding protein 4 (hPEBP4), a 
known protein overly expressed in the CaoV-3 OC cell line,97, 98 has been shown to 
inhibit tumor necrosis factor-α (TNF-α) induced apoptosis.99 Binding of hPEBP4 to 
phosphatidylethanolamines could account for their decreased levels in the early-stage OC 
patients.  Phosphatidic acid was an additional identified discriminant metabolite (Table 
3.4; Figure 3.11). This compound plays a direct role in the metabolism of 
lysophosphatidic acid (LPA),which activates proliferative growth signaling cascades and 
suppresses apoptotic cell death in OC when it is altered.100 Since these phospholipids play 
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a role in maintaining cellular membrane integrity, alterations in their metabolism also 
suggest membrane degradation or morphological changes in OC-affected cells. 
Furthermore, membrane phospholipid translocation is an early indicator of apoptosis.101, 
102 These findings add to the growing body of scientific evidence that shows apoptosis is 
gravely disturbed during ovarian carcinogenesis. 
Animal and in vitro studies have shown that n-3 fatty acids, such as 
docosahexaenoic acid (DHA), inhibit carcinogenesis in hormone-related cancers.103 
Though several mechanisms by which this inhibition occurs have been postulated, one is 
via suppression of arachidonic acid (AA)-derived eicosanoids.104 These eicosanoids can 
alter immune responses to cancer cells in addition to inhibiting apoptosis,105 stimulating 
cellular proliferation and metastasis,106 and promoting tumor angiogenesis.107 14-
Hydroxy docosahexaenoic acid (14-HDoHE), an oxidation product of DHA metabolism, 
was detected in higher concentrations in the early-stage OC patients (Table 3.4; Figure 
3.11), thus, suggesting that DHA may not be able to inhibit carcinogenesis by 
suppression of AA-derived eicosanoids during the early stages of OC. Furthermore, 
dihomo-γ-linolenic acid (DGLA), which is involved in the biosynthesis of AA, was 
detected at lower levels in the early-stage OC patients (Table 3.4; Figure 3.11), hinting 
that AA-derived eicosanoids may be increased in the early stages of ovarian 
carcinogenesis if the decrease of DGLA is due to increased synthesis of AA. DGLA is 
also an activator of peroxisome proliferator-activated receptor-δ (PPARδ), which is a 
cellular proliferation inducer and promoter of cancer progression.104, 108 
2-Hexaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinol, a ubiquinone 
derivative, had lower levels in the early-stage OC patients (Table 3.4; Figure 3.11). 
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Ubiquinone is an electron carrier and, thus, an antioxidant. Studies have shown that 
ubiquinone levels are increased in precancerous tissue changes and decrease below 
normal tissue levels when cancer is fully developed. These changes imply that levels of 
ubiquinone are affected as cells respond to the increased oxidative stress caused by 
carcinogenesis.109, 110 
3.5.3 Discriminant Metabolite Differences Between Early-Stage Papillary 
Serous and Endometrioid Ovarian Carcinoma 
The early-stage OC patient cohort in this study was comprised of patients having 
either papillary serous (n = 12) or endometrioid (n = 12) histological subtypes of OC 
(Table 3.6).  
 
 













Papillary serous carcinoma 12 7 5 49-84 63 
Endometrioid carcinoma 12 11 1 40-70 54 





Serous ovarian carcinoma is the most common type of epithelial OC, while endometrioid 
accounts for 10-20% of all epithelial OC cases.111 Serous OC mainly originates from the 
mesothelial surface lining of the ovarian cortex or cortical inclusion cysts, and the onset 
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of endometrioid OC is greatly associated with ovarian endometriosis.112, 113  Since 
microarray gene expression analysis has shown that the etiology of OC histological 
subtypes may be different due to the activation and deregulation of different pathways,113 
metabolome differences were explored in these subtypes as well within the 22-feature 
panel.  However, only 2 discriminant features of the panel presented significantly 
different concentration levels between serous and endometrioid OC. Because the SVM 
model aimed to differentiate both OC histological subtype groups from the healthy 
women, they were grouped together to find common features for sample discrimination, 
and presumably, the features selected by RFE would not differ between the two OC 
histological subtypes. Feature 1016 (14-HDoHE) had higher concentration levels in 
serous OC patients (fold change: 2.5), whereas feature 3718 (unidentified) had lower 
concentration levels in serous OC patients (fold change: -1.1) (Figure 3.12). Perhaps 
DHA is metabolized at a higher rate in early-stage papillary serous OC patients, thereby, 
limiting its ability to incorporate into cellular membranes and replace AA— the 






Figure 3.12: Discriminatory spectral features having statistically significant univariate 
changes between papillary serous ovarian cancer (S) patients (n = 12) and endometrioid 
ovarian cancer (E) patients (n = 12). P values were calculated using the Mann−Whitney 
U test. Box plots with mean (square), median, upper and lower quartile, outliers, and 
minimum and maximum (whiskers) data values are displayed. Feature ID numbers are 
indicated on top of each case. Fold change was calculated as the base 2 logarithm of the 
average peak area ratios for early-stage papillary serous ovarian cancer samples and 






This chapter details the success of two systems used to investigate metabolic 
patterns for early detection of OC. In the first system, early-stage HGSC was successfully 
detected in a Dicer-Pten DKO mice model utilizing UPLC-MS untargeted metabolic 
fingerprinting. After down-selection of spectral features with maximum discriminatory 




































control mice with 100% accuracy, sensitivity and specificity. Altered metabolic pathways 
included those of fatty acids, bile acids and alcohols, glycerophospholipids, peptides, and 
phytochemicals. These alterations impact cellular energy storage and membrane stability, 
as well as defenses against oxidative stress. This work is the first step toward 
understanding the underlying metabolic changes resulting from the progression of early 
HGSCs originating in the fallopian tube, but an exploration of the overlap between DKO 
mice and humans at early stages of HGSC development is needed. Building upon 
previous work, the second system studied showed that early-stage OC detection in 
humans employing UPLC-MS untargeted metabolic profiling is feasible. After down-
selection of spectral features with maximum discriminatory power by RFE, 22 
metabolites differentiated 24 early-stage OC patients from 40 healthy women with 100% 
cross-validated accuracy, sensitivity, and specificity. Although this is a small pilot 
study—poor early diagnosis currently complicates collection of large patient cohorts for 
more detailed studies—it demonstrates that metabolic information can be useful for 
detecting early-stage OC. Larger, more focused studies will be needed to further validate 
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Karenia brevis is a toxic dinoflagellate known to exude allelopathic compounds 
that directly inhibit the growth of species with whom it competes for resources. Yet, 
brevetoxins produced by K. brevis, which are responsible for shellfish and marine 
mammal deaths, are known not to be allelopathic.  K. brevis allelopathic compounds have 
not yet been identified, and their metabolic effects are poorly understood.  In this work, 
the combined power of metabolomics and proteomics was exploited to explore how 
chemically mediated interactions between K. brevis and two diatom competitors, 
Asterionellopsis glacialis and Thalassiosira pseudonana, impact competitor physiology. 
This integrated systems biology showed that K. brevis allelopathy distinctively perturbed 
the metabolisms of these two competitors. A. glacialis had a more robust metabolic 
response to K. brevis allelopathy which may be a result of its repeated exposure to K. 
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brevis blooms in the Gulf of Mexico. However, K. brevis allelopathy disrupted energy 
metabolism and obstructed cellular protection mechanisms including altering cell 
membrane components, inhibiting osmoregulation, and increasing oxidative stress in T. 
pseudonana. This work highlights the ability of systems biology to shed light onto the 
nature of complex ecological interactions. 
4.2 Marine Plankton Competition 
4.2.1 Chemically Mediated Competition 
 Fifty percent of net primary production is generated by marine phytoplankton.1 
Higher trophic levels require primary production for survival; however, interactions 
among marine planktonic species affect the movement of the produced biomass and 
nutrients in the water column.2 Numerous interactions among marine planktonic species, 
such as competition3, 4 and the capture of prey,5 are mediated by chemical signals and 
cues. Consequently, chemically mediated ecological interactions may impact large-scale 
ecosystem processes. 
 Allelopathy, an interference competition method through which species release 
biochemical compounds that kill or inhibit the growth of competitors, is capable of 
modifying the composition of terrestrial6 and benthic aquatic communities.7, 8 
Allelopathic interactions among marine planktonic species can cause immense 
competitor death9 or induce apoptosis.10 Conversely, allelopathy can also cause sublethal 





4.2.2 Karenia brevis 
Karenia brevis is a red tide dinoflagellate that exudes brevetoxins during red tide 
blooms in the Gulf of Mexico. These brevetoxins cause fish and marine mammal death in 
addition to neurotoxic shellfish poisoning in humans.14 Although brevetoxins are lethal, 
they are known not to be allelopathic.3, 15-17 K. brevis also exudes a set of polar 
biochemical compounds16 of unknown identity that harmfully impacts the physiology of 
certain competitor phytoplankton species.3, 17 These unidentified allelopathic compounds 
inhibit competitor growth and photosynthetic processes as well as cause increased cell 
membrane permeability.17 Interestingly, competitor species are differentially affected by 
K. brevis allelopathy and the degree to which competitors are affected is in part 
facilitated by ecological context.3 Still, the cellular targets of K. brevis allelopathy remain 
unknown.  
4.2.3 Omics Integration 
The aim of systems biology is to reconstruct cellular network interactions to 
predict and characterize physiological responses to stimuli. Data from systems biology 
fields must be combined to accomplish such a vast task. It has been suggested that omics 
integration has the potential to identify basic concepts of cellular function that are 
currently unknown.18 As proteins are responsible for cellular signals, structural integrity, 
and catalysis of most biochemical reactions including the production and conversion of 
the vast array of metabolites required for cellular survival, integrating findings from 
metabolomic and proteomic analyses gives more global insight into cellular behavior. 
Although metabolomics and proteomics have been used in the past to examine diatoms 
adapting to various stressors,19-22 the presented work represents the first instance of 
162 
 
metabolites and proteins measured simultaneously to understand the effects of allelopathy 
or in fact any form of competition. 
4.3 Experimental Methods 
Experimental details for phytoplankton culturing and monitoring, the experimental 
co-culture design and preparation, nutrient analyses, harvest, extraction, and processing 
of phytoplankton cultures, and NMR spectral acquisition and processing can be found 
elsewhere.23 
4.3.1 Ultra Performance Liquid Chromatography-Mass Spectrometry Data 
Acquisition 
 Prior to UPLC-MS analysis, all diatom polar extracts were reconstituted in 250 
µL of H2O. UPLC-MS analysis was performed using a Waters Xevo G2 mass 
spectrometer (Waters Corporation, Manchester, UK) coupled to a Waters ACQUITY 
UPLC H Class system, fitted with a Waters ACQUITY UPLC BEH C18 column (2.1 × 
50 mm, 1.7 µm particle size; Waters Corporation, Milford, MA, USA). The Xevo G2 
mass spectrometer has a characteristic resolving power of 25,000 M/Δm (FWHM) and 
mass accuracy of 1.8 ppm at m/z 554.2615. The instrument was operated in negative 
electrospray ionization mode with a probe capillary voltage of 2.5 kV, and a sampling 
cone voltage of 45 V. The source and desolvation nitrogen gas temperatures were 120 °C 
and 350 °C, respectively. The nitrogen desolvation flow rate was 800 L h-1. The mass 
spectrometer was calibrated across the 50-1200 Da mass range using a 0.5 mM sodium 
formate solution prepared in 90:10 2-propanol/water (v/v). A leucine enkephalin 
reference spray (LockSpray) infused at 3 µL min-1 was utilized for mass correction 
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during data acquisition. Data were acquired in the 50-1200 m/z range with a scan time of 
1 s. Data acquisition and processing was carried out using MassLynx v4.1. UPLC-
MS/MS experiments were performed by acquiring mass spectra with applied voltages of 
10, 20, 30 and 40 V in the T-wave collision cell using ultra high purity argon (≥ 
99.999%) as the collision gas. 
Chromatographic separation solvents for sample analysis were H2O with 0.1 % 
acetic acid (mobile phase A) and acetonitrile (mobile phase B). The following mobile 
phase gradient was utilized: 0–1 min, 0% B; 1–3 min, 0–61% B; 3–5 min, 61% B; 5–6 
min, 61–62% B; 6–8 min, 62% B; 8–10 min, 62–100% B; 10–15 min, 100% B. The flow 
rate was held constant at 0.3 mL min-1. The injection volume was 7 µL. The 
chromatographic method for re-equilibrating the column after each sample injection was 
as follows: 0–1 min, 0% A; 1–1.5 min, 0–100% A; 1.5–2.5 min, 100–0% A; 2.5–3.5 min, 
0–100% A; 3.5–5 min, 100% A. The flow rate was held constant at 0.3 mL min-1 during 
the re-equilibration period. The column and autosampler tray temperatures were 35 °C 
and 5 °C, respectively. 
4.3.2 Ultra Performance Liquid Chromatography-Mass Spectrometry Data 
Processing 
Following UPLC-MS data acquisition, metabolic features (retention time, m/z 
pairs) were extracted from chromatograms using MarkerLynx XS software (Waters 
Corporation, Manchester, UK). This procedure involved chromatogram alignment, peak 
picking and integration, peak area extraction, and normalization of all data. Technical 
duplicate data were acquired for all samples and the resulting feature peak areas were 
averaged to obtain the finalized peak area list for each biological replicate. Metabolic 
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features detected in K. brevis blank culture extracts in addition to media blank culture 
extracts were excluded from the feature list. 
4.3.3 Metabolomics Statistical Analyses 
 PCA was used to initially examine differences in diatom metabolomes between 
treatment and controls of the same species (MATLAB with PLS Toolbox v.7.03). To 
determine statistical differences between PCA scores of treatment and control extracts, t 
tests were performed (MATLAB). PCA models for both the T. pseudonana and A. 
glacialis experiments are provided in Figure 4.3, but these were only used as an 
exploratory tool. PLS-DA data models used to investigate metabolome differences for 
both experiments are shown in Figure 4.2. UPLC-MS data were preprocessed by 
autoscaling prior to statistical analyses. PLS-DA data models were orthogonalized and 
internally cross-validated using the venetian blinds method with 7 data splits in an effort 
to extract all relevant class-discriminatory information from the first latent variable, 
ensure accuracy, and assess for any overfitting.  
 For NMR data, after PLS-DA, the weights on latent variable 1 were used to 
ascertain which chemical shifts (i.e., metabolites) within extracts were responsible for 
distinguishing between K. brevis exposed and media exposed cultures. For UPLC-MS 
data, forward interval PLSDA (iPLSDA) variable selection was used to enhance the 
accuracy of the PLS-DA models and simplify their complexity. The iPLSDA number of 
intervals and step size were chosen automatically, while the interval size was set to one, 
and the maximum number of latent variables was ten. Additionally, for the T. 
pseudonana experiment, selectivity ratios (the ratio of a feature’s explained and residual 
variance)24 were employed to assist in the determination of useful metabolic features that 
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had discriminatory power between K. brevis-exposed and media-exposed species. 
Forward iPLSDA variable selection only provided one metabolic feature (2.68 min, m/z 
701.0880) responsible for discrimination, so selectivity ratios were used to extract more 
informative metabolic information from the T. pseudonana data set. Metabolic features 
with selectivity ratios greater than 1.5 were used. However, selectivity ratios were not 
utilized for the A. glacialis experiment since there were no metabolic features with 
selectivity ratios greater than one.  
As the biological hypotheses presented in this work were based on multivariate 
analysis via PLS-DA, changes in concentration of single metabolites were combined into 
a discriminating panel that was used for the separation of K. brevis-exposed and media-
exposed cultures. P-values are noted in Table 4.2 to present a view of the univariate 
difference in metabolite concentrations, even if the univariate difference alone was not 
significant (p ≤ 0.05). 
4.3.4 Metabolite Annotation 
 Chemical identification was attempted for all discriminant features. 
Representative extracts from each experiment were used to collect 2D NMR spectral data 
(standard HSQC and TOCSY experiments, 500 MHz) to aid in annotation. The Kyoto 
Encyclopedia of Genes and Genomes (KEGG)25 was also used to aid in identification of 
particular pathways involving critical metabolites. For UPLC-MS, because numerous 
adduct ions can be detected for a single compound with electrospray ionization, adduct 
ion analysis was initially conducted to ascertain correct metabolite identifications. The 
adduct ions that were investigated in the mass spectra included [M-H]-, [M+Cl]-, [M+Br]-
, [M+ CH3COO]
-, [M+HCOO]-, [M+Na-2H]-, [M-H2O-H]
- and [2M-H]- species, which 
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are commonly observed in negative electrospray ionization mode. The theoretical m/z 
values for typical adduct species were calculated and compared with the experimental 
values from mass spectral signals. For spectra in which multiple adducts were not 
present, the accurate mass of the candidate neutral molecule was calculated based on the 
assumption that the m/z value for the metabolic feature of interest corresponded to [M-
H]-. For mass spectra in which multiple adducts were present, the [M-H]- spectral signal 
was identified and the accurate mass of the candidate neutral molecule was calculated 
based on it. Molecular formulae were generated based on the mass accuracy of the 
discriminant metabolic features of interest, in addition to their isotopic patterns, using 
MassLynx 4.1.  
The lists of generated molecular formulae and chemical shifts were searched 
against the METLIN database,26 KEGG,25 LIPID Metabolites and Pathways Strategy 
(LIPID MAPS) database,27 the Madison-Qingdao Metabolomics Consortium Database 
(MMCD),28 the Human Metabolome Database (HMDB),29 and Chenomx Profiler, as well 
as literature searches used to annotate spectra and tentatively identify metabolites. 
MetaboSearch30 was also utilized to search the aforementioned databases solely using 
neutral masses with a mass accuracy of 20 ppm. Tandem MS data could not be acquired 
for all discriminant features as their ion abundances were not intense enough for sensitive 
quadrupole mass selection due to ion transmission losses.31 Acquired fragmentation 
patterns from MS/MS data could not be utilized for further identification due to the co-
elution of compounds with the features of interest. Some of the discriminatory metabolic 
features were matched to metabolites specific to plants. In such cases, the metabolites 
were described by compound class, and are included in the metabolite identification 
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tables in italics (Tables 4.3 and 4.5). As numerous compounds are still being discovered 
in microalgae,32 it is plausible that isomers of known specific plant metabolites could 
exist in diatoms. 
4.3.5 Protein Sample Preparation 
Two biological replicate samples from each T. pseudonana treatment and three 
biological replicates from each A. glacialis treatment were collected for proteomic 
analyses (450 ml culture each). Cells were pelleted (10,000 g; 10 min) on ice and lysed 
using a titanium microtip sonicating probe. Each sample received 10 sonication events 
(10-15 s each) in 0.2% PPS silent surfactant33 (Agilent Technologies) in 50 mM 
ammonium bicarbonate. The details of the digestion were per the manufacturer’s 
guidelines. Disulfide bonds were reduced with dithiothreitol and alkylated with 
iodoacetamide. Each sample received trypsin at an enzyme to protein ratio of 1:50, 
vortexed, and incubated on a Thermomixer (800 rpm) 4 h at 37 oC. Peptide 
concentrations were measured for each sample using a Thermo Scientific NanoDrop 
2000/2000c spectrophotometer. The peptide bond absorbance was monitored at 205 nm 
and samples were diluted to yield a final concentration of 100 μg protein mL-1.    
4.3.6 Mass Spectrometry-Based Proteomics 
Samples were separated and introduced into the mass spectrometer by reversed-
phase chromatography using a 30 cm-long, 75 μm i.d. fused silica capillary column 
packed with C18 silica particles (Magic C18AQ, 100 Å, 5 m; Michrom, Bioresources, 
Inc., CA) fitted with a 2 cm long, 100 μm i.d. precolumn (Magic C18AQ, 200 Å, 5 m; 
Michrom).19 Peptides were eluted using an acidified (formic acid, 0.1% v/v) 
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water/acetonitrile gradient (2-35% acetonitrile over 90 min). Mass spectrometry was 
performed on a Thermo Fisher (San Jose, CA) QExactive (QE). Based on peptide 
concentrations, a total of 1 µg of peptide digest in 10 µl of 2% ACN, 0.1% formic acid 
was sampled per LC-MS analysis. Biological duplicates were analyzed from the 
treatment and the control group of T. pseudonana using data-dependent acquisition 
(DDA).  Biological triplicates of A. glacialis controls and treatment were analyzed using 
DDA on the QExactive.   To determine relative expression of proteins with respect to the 
alternate cell state, QSpec software was utilized to provide statistical significance.34 
4.3.7 Protein Database Searching and Mass Spectrometry Data Interpretation 
Tandem mass spectrometry results were searched and interpreted with SEQUEST 
(PVM v.27 20070905). SEQUEST parameters included: reverse concatenated sequence 
database search, trypsin enzyme specificity, cysteine modification of 57 Da (resulting 
from iodoacetamide), and modifications on methionine of 15.999 Da (oxidation). 
Minimum protein and peptide thresholds were set at p > 0.95 on ProteinProphet and 
PeptideProphet.35, 36 Protein identifications from whole cell lysates were accepted by 
ProteinProphet if the above mentioned thresholds were passed, two or more peptides 
were identified (PeptideProphet), and at least one terminus was tryptic. Using 
concatenated target-decoy database searches, false discovery rates (FDR) were calculated 
according to Elias and Gygi 200737 and were all < 1%.  The protein database used for 
correlating spectra from the T. pseudonana experiment with protein identification was 
generated by combining the latest release of the T. pseudonana proteome (12914 
proteins) and 50 common contaminants.  Since the genome of A. glacialis has not been 
described, we first searched the A. glacialis data as for T. pseudonana. Second, we 
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assembled a database to search for confident peptide matches to spectra from protein 
sequences associated with diatoms in the National Center for Biotechnology Information 
database (www.ncbi.nlm.nih.gov). Using the "nrdb90" script provided by Holm and 
Sander 38 at a 95% identity threshold on the input diatom database of 93,744 protein 
sequence entries reduced redundancy and size down to 64,752 sequence entries.39 
ProteinProphet and PeptideProphet were set at a higher threshold of p > 0.99, to increase 
confidence in peptide and protein assignments. Proteins from the A.glacialis treatments 
and controls were considered present if one of the biological replicates identified two or 
more unique peptides and the termini were tryptic. 
 To determine relative expression of proteins expressed in treatments with respect 
to the control cell state, QSpec software was utilized to provide statistical significance.34 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) v. 6.7 
was used to examine enriched biological terms in the sets of proteins identified to be 
significantly enhanced or suppressed relative to control cell state.40, 41  P-values <1E-3 are 
reported for DAVID analyses on T. pseudonana data. 
4.4 Karenia brevis Allelopathy Impacts Competitor Metabolism 
Although previous studies3, 17 have shown that K. brevis allelopathy reduces the 
growth of competitor species, the current study demonstrates the impact of allelopathy on 
global cellular function and indicates that metabolism was altered even in the case of 






Figure 4.1: Effects of exposure to exudates of live Karenia brevis on the growth of 
Asterionellopsis glacialis and Thalassiosira pseudonana. (A) A. glacialis (red) in vivo 
and T. pseudonana (blue) in vivo fluorescence (arrow indicates day of harvest for 
metabolomics and proteomics). The solid lines indicate fluorescence of diatom-only 
controls, and the dashed lines indicate fluorescence of diatoms exposed to K. brevis. 
Initial K. brevis (red open circles for A. glacialis experiment; blue open circles for T. 
pseudonana experiment) concentrations from cultures used to fill dialysis tubes (n = 1), 
final concentrations from experimental flasks at time of harvest (n = 15). (B) Calculated 
percent growth of competitors A. glacialis (red) and T. pseudonana (blue) relative to their 
own controls after 8 and 6 days exposure to K. brevis, respectively. The dotted line 
indicates growth equivalent to control. n = 15. P < 0.0001 indicated by asterisk (*), 




K. brevis allelopathy differentially affected growth of the two competitors (Figure 4.1), 
which was reflected in both the metabolomes (Figures 4.2, 4.3) and proteomes (Table 
4.1) of each competitor. In the presence of K. brevis, T. pseudonana growth was reduced 
by 85% (Figure 4.1b, n = 15, p < 0.0001). Growth suppression and subsequent population 
decline was observed after four days of co-culture with both species physically separated 







Figure 4.2: Orthogonal projection to latent structures-discriminant analysis (oPLS-DA) 
shows effects of Karenia brevis allelopathy on the metabolomes of competitor diatoms. 
oPLS-DA calibration scores plot of (A) UPLC-MS metabolic features and (B) 1H NMR 
spectral data for Thalassiosira pseudonana exposed to K. brevis (filled squares) or dilute 
media control (empty squares) with cross-validated accuracies of 87% and 100%, 
respectively. oPLS-DA calibration scores plot of (C) UPLC-MS metabolic features and 
(D) 1H NMR spectral data for Asterionellopsis glacialis exposed to live K. brevis (filled 
circles) or dilute media controls (empty circles) with cross-validated accuracies of 57% 
and 63%, respectively. 
 
 






























































































Figure 4.3: Principal component analysis (PCA) shows effects of Karenia brevis 
allelopathy on the metabolomes of competitor diatoms. PCA scores plot of (A) UPLC-
MS metabolic features and (B) 1H NMR spectral data for Thalassiosira pseudonana 
exposed to K. brevis (filled squares) or dilute media control (empty squares) showing 
significant separation along the 2nd and 1st principal components, respectively (MS: 
unpaired t-test, n = 30, p = 0.002; NMR: unpaired t-test, n = 9-14, p < 0.0001). PCA 
scores plot of (C) UPLC-MS metabolic features and (D) 1H NMR spectral data for 
Asterionellopsis glacialis exposed to live K. brevis (filled circles) or dilute media controls 
(empty circles) with only the 1H NMR spectral data showing significant separation (5th 
principal component, unpaired t-test, n = 9-11, p = 0.033). 
 
  




































































































Scores on PC 1 (17.28%)
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Analysis of the T. pseudonana metabolome (Table 4.2; Figure 4.2) and proteome (Table 
4.1) revealed that K. brevis allelopathy impacts multiple metabolic pathways, with some 
cellular responses possibly used to compensate for negative effects of allelopathy. In 
contrast, the overall growth of A. glacialis was only reduced by 35% when exposed to K. 
brevis allelopathy—an effect that was not statistically significant (Figure 4.1b, n = 15, p 
= 0.089) and, at most, indicative of a weak allelopathic effect of K. brevis on A. glacialis 
in this experiment. In the A. glacialis experiment, final K. brevis cell concentrations in 
flasks averaged 15.3 x 103 cell mL-1, whereas mean K. brevis concentrations were 8.3 x 
103 cell mL-1 at the time of harvest in the T. pseudonana experiment (Figures 4.1a). 
Nutrients were not limiting in these experiments, suggesting that the negative effects of 
K. brevis on competitor growth were mediated by allelopathy rather than exploitation 
competition. Overall, it is clear that based on both the proteomic and metabolomic data, a 
sensitive competitor exposed to allelopathy operates in a functionally compromised 





Table 4.1: Metabolic pathways and cellular functions from Biological Process and 
Molecular Function Gene Ontology categories for proteins in Thalassiosira pseudonana 
whose concentrations increased (red triangle) or decreased (blue triangle) in response to 







▲ Generation of precursor metabolites and energy 25 8.9E-12 
▲ Metabolic process 101 3.2E-10 
▲ Cellular carbohydrate metabolic process 16 2.0E-08 
▲ Monosaccharide metabolic process (hexose and 
glucose) 
14 2.1E-08 
▲ Alcohol metabolic process 15 3.6E-08 
▲ Energy coupled proton transport, down 
electrochemical gradient 
10 4.7E-07 
▲ ATP metabolic process 11 1.7E-06 
▲ Oxidative phosphorylation 10 3.8E-06 
▲ Nucleoside triphosphate metabolic process 11 4.5E-06 
▲ Cellular metabolic process 73 5.7E-06 
▲ Proton-transporting ATPase activity, rotational 
mechanism 
9 9.7E-10 
▲ H-ion transport ATP synthase activity, rotational 
mechanism 
8 2.2E-08 
▲ Catalytic activity 96 4.2E-08 
▲ ATPase activity, coupled to transmembrane 
movement of ions 
10 9.3E-08 
▲ Hydrolase activity, acting on acid anhydrides, 
catalyzing transmembrane movement of 
substances 
11 8.2E-07 
▲ Lyase activity 15 2.2E-06 
▲ Cofactor binding 19 3.3E-06 
▼ Photosynthesis 12 7.7E-11 
▼ Generation of precursor metabolites and energy 13 1.3E-09 
▼ Chromatin assembly 8 1.6E-09 
▼ Cellular macromolecular complex subunit 
organization 
8 3.5E-07 
▼ Cellular component biogenesis 9 8.5E-07 
▼ Electron carrier activity 6 1.3E-03 
▼ Iron ion binding 6 2.8E-03 
▼ 4 Iron, 4 sulfur cluster binding 3 3.0E-03 
▼ Metal cluster binding 4 4.3E-03 
1# of proteins represents the number of proteins that correlate to the annotation category. 




Table 4.2: Candidate metabolites tentatively identified by NMR spectra and UPLC-MS to increase in concentration (red arrows) or 




Candidate Metabolite Biological Sub-category 
Fold 
Change1 
Method of Detection p value2 
Cell Protection          
▲ Lipid (C31H42O9)3 Membrane constituent +10.3 UHPLC/MS 6.9E-17 
▲ Phospholipid (C24H47O12P)3 Membrane constituent +10.3 UHPLC/MS 6.9E-17 
▲ Sarcosine4 Glycine metabolism/Osmoregulation +0.32 
 
1H-HSQC NMR 4.9E-1 
▼ Mannan5,6 Cell wall constituent -3.4 UHPLC/MS 9.8E-16 
▼ Phospholipid (C26H43O9P)7 Membrane constituent -1.4 UHPLC/MS 2.5E-15 
▼ Lipid (C26H42O11)7 Membrane constituent -1.4 UHPLC/MS 2.5E-15 
▼ Terpene glycoside Membrane constituent -1.2 UHPLC/MS 6.9E-15 
▼ Betaine Osmoregulation -0.58 1H-HSQC NMR 2.9E-3 
▼ Myo-inositol8 Osmoregulation  -0.41 1H-HSQC NMR 6.2E-1 
▼ Homarine Osmoregulation  -2.5 1H-HSQC NMR 3.0E-5 
▼ Polyphenol5 Oxidative stress -3.4 UHPLC/MS 9.8E-16 




Table 4.2 (continued). 
Energy 
Metabolism 
         
▲ Acetate Carbon Metabolism/Glycolysis  +0.92 1H-HSQC NMR 1.8E-2 
▲ Dimethylamine4 Glycine metabolism/Osmoregulation  +0.32 1H-HSQC NMR 4.9E-1 
▼ Alanine Amino Acid metabolism  -0.48 1H-HSQC NMR 1.1E-1 
▼ Stachyose5,6 Carbon metabolism -3.4 UHPLC/MS 9.8E-16 
▼ Cellotetraose5,6 Carbon metabolism -3.4 UHPLC/MS 9.8E-16 
▼ Maltopentaose9 Carbon metabolism -3.2 UHPLC/MS 3.3E-20 
▼ Amylopectin9 Carbon metabolism -3.2 UHPLC/MS 3.3E-20 
▼ Cellopentaose9 Carbon metabolism -3.2 UHPLC/MS 3.3E-20 
▼ Verbascose9 Carbon metabolism -3.2 UHPLC/MS 3.3E-20 
▼ Glucose8 Carbon Metabolism/Glycolysis  -0.41 1H-HSQC NMR 2.1E-1 
▼ Glycerate Photorespiration  -0.024 1H-HSQC NMR 9.2E-1 




         
▲ Glutamate Amino Acid metabolism/ 
osmoregulation 
 +1.22 1H-HSQC NMR 1.4E-3 
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Table 4.2 (continued). 
▲ Proline Amino Acid metabolism/ 
osmoregulation 
 +0.052 1H-HSQC NMR 8.8E-1 
1Fold change was calculated as the base 2 logarithm of the average peak area ratios for exposed T. pseudonana samples and control 
samples; 2P values calculated using unpaired, two-tailed t-test; 3isobars; 4metabolites share observed chemical shifts; 5isobars; 




4.5 Response of Asterionellopsis glacialis to Allelopathy 
To date, metabolomics and proteomics are under-utilized tools for investigating 
the impacts of ecological interactions on organism physiology.  This study revealed that 
metabolomic and proteomic analyses of competitors can demonstrate the species-specific 
effects of K. brevis allelopathy. The diatom A. glacialis appeared to maintain a relatively 
robust metabolism in response to K. brevis, which resulted in mild allelopathic effects on 
growth (Figure 4.1, Figure 4.2c and 4.2d). Using multivariate analysis [orthogonal 
projection to latent structures-discriminant analysis (oPLS-DA)], we identified groups of 
metabolites whose co-varying concentrations allowed us to distinguish metabolomes of 
K. brevis-exposed and control cultures of A. glacialis. While concentrations of these 
compounds may not have significantly differed between treatments and controls when 
each compound was considered alone, these compounds displayed explanatory power 
when part of a discriminating panel.42 oPLS-DA analysis suggested that concentrations of 
only a few aliphatic metabolites were enhanced in A. glacialis by exposure to allelopathy 
(i.e., glycerophosphocholine and lactose or polysaccharides, as well as two unidentified 
compounds; Table 4.3). However, only 6-9% (Figure 4.2c and 4.2d) of the observed 
among-culture variation in the A. glacialis metabolome was due to K. brevis allelopathy, 
indicating that this species maintains relatively normal functioning in response to K. 
brevis. Additionally, only one protein increased in abundance when exposed to K. brevis 
allelopathy according to differential expression protein analyses (ATP synthase) whereas 
five proteins were significantly suppressed (e.g., cytochrome b559, photosystem II 












































The strain of A. glacialis used in this experiment was originally isolated from the Gulf of 
Mexico, where K. brevis blooms regularly occur.14 Thus, A. glacialis may have evolved 
partial resistance to K. brevis allelopathy due to its potential for frequent exposure to K. 
brevis blooms.44 Conversely, T. pseudonana used in the current study was from the North 
Atlantic Ocean where K. brevis does not occur. It is possible that the robust metabolome 
of A. glacialis has resulted from multiple metabolic adaptations that mitigate allelopathic 
impacts, allowing A. glacialis cells to function when challenged by K. brevis allelopathy. 
4.6 Response of Thalassiosira pseudonana to Allelopathy 
Because of its sensitivity to K. brevis allelopathy (Figure 4.1), T. pseudonana 
serves as a suitable model for exploring mechanisms by which allelopathy affects 
competitor physiology. From our integrated systems biology approach we found T. 






Figure 4.4: Network of cellular pathways, enzymes, and metabolites in the diatom 
Thalassiosira pseudonana impacted by exposure to Karenia brevis allelopathy, derived 
from NMR and MS metabolomics and proteomics. Pathways and metabolites enhanced 
by allelopathy are indicated by red arrows and compound names, respectively. Blue 





An observed significant increase of acetate concentrations (+0.92-fold), as well as 
decreased myo-inositol and/or glucose concentrations, as distinguished by oPLS-DA 
(Table 4.2, Table 4.4), with concomitant increased concentrations of glycolysis enzymes 
(e.g., pyruvate kinase +3.0-fold; Table 4.1, Dataset 4.2), suggests that glycolysis was 
enhanced in T. pseudonana. Starch stores were depleted, as indicated by significantly 
lowered concentration of maltopentose, amylopectin, cellopentose, and/or verbascose (-
3.2-fold) (Table 4.2, Table 4.5), whereas concentrations of small (e.g., C8-C10) fatty acids 
increased (Table 4.4). Several fatty acid biosynthesis and metabolism enzymes (Table 
4.1) were more abundant in T. pseudonana in response to K. brevis allelopathy, including 
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acetyl CoA carboxylase (+2.3 fold) and acyl CoA dehydrogenase (+3.0 fold) (Dataset 
4.2). Together, this suggests that allelopathy caused enhanced glycolysis in T. 
pseudonana, while also stimulating synthesis and β-oxidation of fatty acids. Allelopathy 
may have altered the photosynthetic capability of T. pseudonana, as evidenced by the 
decreased abundance of 12 photosynthetic proteins, even though the abundance of 
RuBisCO, the key enzyme responsible for carbon fixation, remained unchanged (Table 
4.1, Dataset 4.2). The reduction in photosystem complexes and surge in fatty acid β-





Table 4.4: Candidate metabolites identified from 1H and HSQC NMR spectra of 
Thalassiosira pseudonana exposed to Karenia brevis allelopathy. Chemical shifts in bold 
indicate observed signals in T. pseudonana extracts, while non-bold shifts indicate 
signals not observed due to overlap in that spectral region. Chemical shift values that 
were not observed are reported from either Boroujerdi et al.45 or the human metabolome 
database (HMDB). Metabolic pathways reported from KEGG. 
 
Metabolite 
















0.85, 1.27, 1.53, 2.16 
37.3 
 
39.5, 27.9, 30.9, 






fatty acid metabolism 
Sarcosine1 2.72, 3.59 35.6, 53.5 enhanced nitrogen metabolism 
Glutamate 2.07, 2.14, 2.35, 3.78 







2.05, 2.07, 2.36, 
3.35, 3.43, 4.15 
26.5, 31.7, 31.6, 






Taurine 3.29, 3.43 51.7, 38.3 suppressed  
Alanine 1.45, 3.80 19.1, 53.6 suppressed  
Betaine 3.28, 3.91 56.2, 68.8 suppressed osmoprotectant 





3.33, 3.36, 3.53, 
3.59, 3.57, 3.76, 
3.79, 3.87, 3.92, 
3.93, 4.66, 5.25 
79.6, 76.3, 78.3, 
75.9, 75.0, 74.0, 
63.5, 74.0, 63.1, 





3.33, 3.59, 3.57, 
3.75, 3.75, 4.08 
79.6, 75.9, 74.0, 




Glycerate 3.70, 3.79, 4.17 67.7, 67.7, 77.8 suppressed photorespiration 
Homarine 






1 indicates metabolites share observed chemical shifts 




Table 4.5: Candidate metabolites tentatively identified from UPLC-MS data of Thalassiosira pseudonana exposed to Karenia 

























  Phospholipid C24H47O12P 3.5   Membrane lipid 
47 
4.54 581.2994 Unknown C31H42N4O7 1.3 [M-H]
- Enhanced - 
4.30 529.2555 PG(20:5/0:0) C26H43O9P 1.7 [M-H]
- Suppressed Membrane lipid 47 
  Lipid C26H42O11 9.9   
Membrane 
constituent 46 




  Mannan C24H42O21 3.3   
Cell wall 
component 49 
  Stachyose C24H42O21    
Galactose 
metabolism1 
  Cellotetraose C24H42O21    
Starch & sucrose 
metabolism1 





2.77a 827.2672 Maltopentaose C30H52O26 0.2 [M-H]





Table 4.5 (continued). 
  Amylopectin C30H52O26    
Glucose/starch 
storage 53 
  Cellopentaose C30H52O26    
Starch & sucrose 
metabolism1 










1biological function information obtained from KEGG 
athe chlorine adduct of this metabolic feature was also selected as a discriminant feature 
italics indicate compounds not previously described from marine planktonic organism
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4.6.1 Cell Protection Pathways Impacted 
In previous work, K. brevis exudates were found to increase cell membrane 
permeability of several competitors, via unknown mechanisms.17 In the current study, 
metabolic and biosynthetic activities associated with cell membranes were altered in T. 
pseudonana in response to K. brevis allelopathy, as evidenced by decreased mannan and 
C26 phospholipid or C31 lipid concentrations, as well as an increase in a C24 phospholipid 
or C26 lipid (Table 4.2, Table 4.5). This is suggestive of membrane restructuring and a 
possible increase in permeability since mannans and phospholipids are primary 
membrane components of T. pseudonana49 and other photosynthetic organisms.55 These 
changes could be the result of membrane instability and the subsequent attempt of T. 
pseudonana to alter membrane phospholipid content via increased biosynthesis. 
Recently, Martin et al. revealed that phosphorus-deprived T. pseudonana substitute 
betaine lipids and sulfolipids for phospholipids in cellular membranes.47 In addition, 
Riekhof et al. demonstrated that betaine lipid synthesis is associated with the degradation 
of membrane phospholipids.56 These coordinated pathways provide a possible 
explanation to the significantly reduced betaine concentrations (-0.58-fold) since betaine 
would be consumed to build betaine-based lipids (Table 2, Table 4.4). Enzymes involved 
in sulfolipid biosynthesis were present in higher concentrations in T. pseudonana 
responding to K. brevis (e.g., sulfolipid biosynthesis protein; Dataset 4.2), suggesting a 
modification of T. pseudonana’s content via an increase in sulfolipids. Although 
phosphate was not limiting to T. pseudonana in this experiment, it is possible that K. 
brevis allelopathy reduced the capacity of T. pseudonana to utilize nutrients present in the 
media. Plankton lipids mediate a number of important ecological interactions, including 
187 
 
grazing,57 susceptibility to viral infection,58 and toxin sensitivity.59 Thus, future 
experiments testing how phytoplankton competition alters lipid biochemistry and 
membrane stability could lead to discovery of cascading ecological effects on other types 
of interactions.  
Another critical aspect of membrane structure and function is the ability of a cell 
to control solute osmosis. From the current study it is apparent that osmotic regulation 
was impacted by K. brevis allelopathy: concentrations of homarine (-2.5-fold) and 
betaine were suppressed when T. pseudonana was exposed to K. brevis (Table 4.2, Table 
4.4) and are recognized osmolytes in marine planktonic organisms.60, 61 T. pseudonana 
may respond to K. brevis allelopathy by compensating for impeded osmotic regulation by 
enhancing or maintaining concentrations of both proline and dimethylamine (Table 
4.2).21, 62 
  When T. pseudonana was exposed to K. brevis allelopathy, multiple enzymes 
involved in critical pathways related to oxidative stress were enhanced. In addition, 
several enzymes responsible for mitigating high oxidative stress were more abundant. 
Fifteen oxidoreductases increased in abundance, including manganese superoxide 
dismutase and ascorbate peroxidase (Table 4.1, Dataset 4.2). Our oPLS-DA model 
suggests glycerate concentrations were reduced, as part of a group of compounds whose 
concentrations covaried, in T. pseudonana exposed to K. brevis indicating that 
photorespiration was disrupted (Table 4.2), which would also likely increase oxidative 
stress.63, 64 Recently, Schlegel et al. proposed that an increase in oxidative stress may 
force cells to reduce the abundance of photosynthetic and electron carrier enzymes.48 
Consistent with that prediction, in the current study proteins involved in electron carrier 
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activity were suppressed, whereas proton transport activity was enhanced, suggesting 
potential compensation within T. pseudonana cells (Table 4.1, Dataset 4.2). Seven 
proteins involved in the pentose phosphate pathway, a side-step to glycolysis that yields 
reducing equivalents of NADPH,19 yielded heightened abundances (Table 4.1, Dataset 
4.2). Recent findings also show that diatoms experiencing oxidative stress lose their 
ability to assimilate nitrogen, due to either altered redox states of critical nitrogen 
assimilation enzymes, or the loss of reducing equivalents (e.g. NADPH).65 This suggests 
that in the current study, oxidatively stressed T. pseudonana may have been forced to 
recycle internal nitrogen stores as a downstream effect of exposure to K. brevis 
allelopathy. We also observed alterations in the concentrations of several amino acids 
(increased concentrations of glutamate and proline; decreased concentrations of taurine; 
Table 4.2, Table 4.4) and an unidentified alkaloid (Table 4.2, Table 4.5), suggesting a 
reshuffling and possible recycling of internal nitrogen stores. Together, this suggests that 
T. pseudonana was responding to increased oxidative stress as a result of K. brevis 
allelopathy.  
4.6.2 Cells in Crisis 
 Overall, it appears that T. pseudonana cells exposed to K. brevis allelopathy 
experienced substantially disrupted metabolic processes indicative of heightened stress 
(Figure 4.4). In addition to the metabolic and proteomic changes described above, we 
observed a fourfold increase in the abundance of the diatom’s trypsin with a concomitant 
increase in the abundance of an anti-trypsin protease inhibitor as well as reduced 
concentrations of a serine protease inhibitor (Dataset 4.2). For trypsin annotation, a total 
of 19 unique peptides were identified, none of which resembled the pure porcine trypsin 
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used for digestion during sample preparation. These findings suggest that protein 
degradation pathways were induced which may approach conditions typically observed 
for programmed cell death response in diatoms.66 In addition, concentrations of several 
DNA replication enzymes, as well as eight chromatin assembly proteins were suppressed 
(e.g., histone-3: -3.4 fold; Table 4.1, Dataset 4.2), consistent with a strong negative 
impact of allelopathy on T. pseudonana growth (Figure 4.1).  
Mucins, gel-like glycoproteins, were in higher abundance in T. pseudonana 
exposed to allelopathy (Dataset 4.2). While largely unexplored for phytoplankton, in 
other organisms mucins have been found to reduce adherence of bacteria.67 If diatom 
mucins prevent colonization by harmful bacteria or aggregation of diatom cells, this may 
represent a valuable defense mechanism or a response to stress. Furthermore, if mucins 
are shown to be involved in diatom aggregation, then allelopathy may directly influence 
the flux of particulate carbon from the water column to depth in the ocean. Mucins have 
also been found to demonstrate antiapoptopic activity.68, 69 Previous studies on T. 
pseudonana have found ascorbate peroxidase genes to be up-regulated in iron-limited 
situations, whereas mucin genes were down-regulated, demonstrating a balance between 
ROS reducing mechanisms and the initiation of programmed cell death pathways in 
stressful situations.70 This balancing act ultimately allows acclimation to stress, which 
may be disrupted by allelopathy.  
4.7 Conclusion 
Whole cell metabolomic and proteomic analyses revealed differing responses of 
planktonic competitors to K. brevis allelopathy, suggesting that co-occurring species may 
have evolved partial resistance to allelopathy via robust metabolic pathways. In contrast, 
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a “naïve” competitor, T. pseudonana, which does not co-occur with K. brevis blooms, 
suffered greater metabolic disruption and growth suppression when exposed to K. brevis 
allelopathy. Critical metabolic processes including glycolysis, photosynthesis, cell 
membrane maintenance, osmoregulation, and responses to oxidative stress were all 
impacted in this sensitive competitor. If other sensitive competitors are also found to 
undergo similarly altered metabolic pathways, then allelopathy among phytoplankton 
may affect ecosystem level processes even more than previously believed due to the 
importance of phytoplankton on carbon fixation and nutrient dynamics in the world’s 
oceans. This interdisciplinary systems biology approach provides an unbiased 
opportunity to establish novel, testable hypotheses towards understanding the 
mechanisms by which allelopathy alters species composition in plankton communities, 
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CHAPTER 5. TRANSMISSION MODE DIRECT ANALYSIS IN 
REAL TIME MASS SPECTROMETRY FOR FAST UNTARGETED 
METABOLIC FINGERPRINTING 
 
Adapted with permission from 
Jones, C. M.; Fernández, F. M., Transmission Mode Direct Analysis in Real Time Mass 
Spectrometry for Fast Untargeted Metabolic Fingerprinting. Rapid Commun. Mass 
Spectrom. 2013, 27 (12), 1311-1318. Copyright © 2013 John Wiley & Sons, Ltd. 
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Although current hyphenated mass spectrometry (MS) techniques are very 
powerful for metabolomics studies, there is a clear need for more rapid, high-throughput 
MS approaches. A rapid metabolic fingerprinting method that utilizes a new transmission 
mode direct analysis in real time (TM-DART) sampling technique coupled with 
quadrupole time of flight mass spectrometry (QTOF MS) is presented. In this approach, 
the sample is deposited directly on a stainless steel mesh that is held in the ionization 
region by a custom-built module. As a result, the DART plasma gas stream interacts with 
the sample in a flow-through fashion, which maximizes the sample-ionizing species 
interaction and minimizes variance in sample positioning. The optimization of TM-
DART parameters directly affecting metabolite desorption and ionization, such as sample 
position and ionizing gas desorption temperature, was critical in achieving high 
sensitivity and detecting a broad mass range of metabolites. Ramping the ionizing gas 
desorption temperature further enhanced analysis by adding a simple separation 
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dimension to this ambient approach. In terms of reproducibility, TM-DART compared 
favorably with traditional probe mode (PM-) DART analysis, with coefficients of 
variation as low as 16%. The longer-lasting TM-DART signals enabled the acquisition of 
full scan and product ion accurate mass spectra in a single experiment, resulting in 
greater confidence in metabolite identification. TM-DART MS proved to be a powerful 
analytical technique for rapid metabolome analysis of human blood sera and was adapted 
for exhaled breath condensate (EBC) analysis. To determine the feasibility of utilizing 
TM-DART for metabolomics investigations, TM-DART was interfaced with traveling 
wave ion mobility spectrometry (TWIMS) time-of-flight (TOF) MS for the analysis of 
EBC samples from cystic fibrosis (CF) patients and healthy controls. TM-DART-
TWIMS-TOF MS was able to successfully detect CF in this small sample cohort. 
5.2 Metabolic Fingerprinting by Direct Analysis in Real Time Mass 
Spectrometry 
5.2.1 Direct Analysis in Real Time 
 Direct Analysis in Real Time (DART)1 belongs to the growing family of direct 
sampling “ambient” ionization techniques. Ambient MS techniques make use of well-
established ionization principles, such as electrospray ionization (ESI), chemical 
ionization (CI), and photo-ionization (PI), in an open air format which allows high 
throughput experiments to be performed with minimal sample preparation. Non-
destructive surface analysis, spatially-resolved analyte detection, multi-analyte 
fingerprinting, matrix-less molecular imaging, and selective ionization enhancement by 
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means of specific gas-phase chemical reactions are possible with ambient MS 
approaches.2 
 DART uses a DC point-to-plane atmospheric pressure electric discharge in the 
glow regime to generate metastable species from a flowing gas in a chamber that is 
physically separated from the analyte ionization region. The gas stream with metastables 
is heated and directed through a set of one or more grid electrodes that prevent most 
plasma ionic species from interacting directly with the sample, and minimize ion-ion and 
ion-electron recombination of ionic species generated within the external ionization 
region. The metastable species formed within the discharge supporting gas, generally He 
or N2, generate protonated water clusters by Penning ionization of atmospheric gases, 
which act as reactant ions that chemically ionize thermally-desorbed analyte molecules 
through proton-transfer reactions.3 The thermal conductivity of the gas used for 
desorption is a critical parameter affecting the sensitivity due to the thermal desorption 
step, with He being approximately one order of magnitude more conducting than N2. In 
the majority of applications, the utilization of DART has mainly been focused on analytes 
below 1 kDa, which is well suited for most metabolomic experiments.4-8  
In the traditional probe mode (PM)-DART sample introduction method, liquid 
samples are deposited on a melting point capillary, allowed to dry, and then introduced 
into the ionization region mechanically or manually. In this approach, a multitude of 
geometric variables affect analyte desorption, ion transmission, and the reproducibility of 
the experiments, as the sample capillary itself creates turbulence while being introduced 
into the ionization region.9 To minimize the variance introduced by the various DART 
geometric factors, our group was first to propose a transmission mode (TM)-DART 
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geometry 10 as an alternative to the PM method. TM operation is highly advantageous as 
the sample can be deposited directly on a stainless steel mesh that is held in the ionization 
region by a custom-built module placed directly in between the ion source and the mass 
spectrometer inlet. TM operation enables the DART plasma gas stream to interact with 
the sample in a flow-through fashion, therefore maximizing interaction with ionizing 
species, and minimizing variance in sample positioning. 
5.2.2 Direct Analysis in Real Time in Metabolomics 
DART applications in the field of metabolomics have shown a steady growth 
since the first reports in 2010,4, 11 and are expected to become more prominent. Compared 
to analytical tools used routinely in metabolomics such as continuous infusion 
electrospray ionization (ESI)-MS, capillary electrophoresis (CE)-MS, liquid 
chromatography (LC)-MS and gas chromatography (GC)-MS,12-14 DART-MS is 
attractive due to several reasons: (1) sample analysis can be completed in a few minutes 
without chromatographic separation, (2) memory effects are minimized because all parts 
in contact with the sample are disposable, (3) analytes with a broad spectrum of polarities 
are ionized because of the acidity of the chemical ionization reagent ions involved,15 and 
(4) simpler spectra than ESI are produced, as a minimal number of adducts/multimers is 
generated.7, 11 However, the lack of chromatographic separation increases the probability 
of overlapping chemical features and ionization suppression, making the use of high mass 
resolution instrumentation a necessity to achieve the required peak capacity and find 




5.2.3 Ion Mobility Spectrometry 
Ion mobility spectrometry (IMS) techniques are appealing for their ability to 
separate ionized analytes, even isobars, on a millisecond timescale based on differences 
in their gas-phase mobility within an electric field, which is affected by mass, charge, 
field strength, and collisional cross section.17 Each analyte has a characteristic drift 
velocity (vd) that is proportional to the applied electric field strength (E) and ion mobility 
constant (K):  
𝑣𝑑 = 𝐾𝐸                                            [1] 
Ion mobility values are typically normalized to standard temperature and pressure 
conditions and reported as reduced mobility (K0). The time required for analytes to reach 
the detector (drift time, td) can be used to determine ion mobility values: 
𝐾 =  
𝐿2
𝑡𝑑𝑈
                                           [2] 
where L is the drift length and U is the potential difference of the electric field. The 











                [3] 
where z is the charge state of the ion, e is the elementary charge, N is the drift gas number 
density, µ is the reduced mass of the ion-neutral drift gas pair, kB is the Boltzmann 
constant, and T is the gas temperature. Collision cross sections, which are indicative of 
size and shape, provide characteristic structural information for analytes.  
IMS coupled to MS provides a separation dimension for the analysis of complex 
biological samples. IM-MS has been successfully employed for metabolomics studies.19-
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21 While not completely orthogonal to MS, IMS has been shown to increase the peak 
capacity of MS sixfold.20 The coupling of DART to high-resolution ion mobility TOF 
MS may also alleviate the lack of chromatographic separation in DART metabolomics 
studies. Various IMS techniques are currently available, including drift tube IMS,22 
differential mobility spectrometry (DMS),23 and traveling wave ion mobility 
spectrometry (TWIMS),24 each offering varying degrees of separation power and signal-
to-noise ratio enhancement. A traveling voltage wave is applied to a stacked ring ion 
guide in the TWIMS technique (Figure 5.1). Adjacent electrodes have radially confining 
radiofrequency voltages applied. Ions are propelled axially by a transient direct current 
voltage that is applied to each electrode in succession (i.e., the traveling wave).24, 25 Ions 
with short drift times traverse the ion guide while being ‘carried’ by the wave. In 







Figure 5.1: TWIMS schematic. A traveling voltage wave (T-wave) applied to a series of 
electrically connected ring electrodes (stacked ring ion guide: SRIG) pushes ions through 
the device. For a given wave speed and magnitude, ions carried forward by the T-wave 
have short drift times (red), while ions that roll over the T-wave take longer to exit the 
device (blue). RF, radiofrequency. Reprinted with permission from ref 25. Copyright © 




5.3 Experimental Details 
5.3.1 Transmission Mode Direct Analysis in Real Time Metabolic 
Fingerprinting Method Development 
5.3.1.1 Chemicals 
D-erythro-sphingosine was obtained from Avanti Polar Lipids, Inc. (Alabaster, 
AL, USA). Anhydrous pyridine and acetone were purchased from EMD Chemicals 
(Gibbstown, NJ, USA).  Polyethylene glycol standard 400 and 600 (PEG 400, 600) were 
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purchased from Fluka Chemical Corp. (Milwaukee, WI, USA). Healthy human serum 
(S7023-50 mL) and quinine were procured from Sigma-Aldrich Corp. (St. Louis, MO, 
USA). Analytical grade isopropanol and N-trimethylsilyl-N-methylfluoroacetamide 
(MSTFA) containing 0.1% trimethylchlorosilane (TMCS) were acquired from Thermo 
Fisher Scientific, Inc. (Waltham, MA, USA).  Ultra high purity helium (99.999 %) was 
purchased from Airgas, Inc. (Atlanta, GA, USA). 
5.3.1.2 Serum Sample Preparation 
Prior to analysis, healthy human serum samples were taken from a -80 °C freezer 
and thawed on ice. Two hundred µL serum aliquots were mixed with 1 mL of a chilled (-
18 °C) and degassed 2:1 (v/v) acetone/isopropanol mixture, vortex-mixed, and stored 
overnight at -18 °C  to precipitate proteins. Centrifugation of samples at 13,000 x g for 5 
min followed. The supernatant was transferred to a new centrifuge tube, and the solvent 
was evaporated in a Savant DNA 110 speed vacuum concentrator. The remaining solid 
residue was dissolved in 25 µL of anhydrous pyridine in a N2-purged glove box and 
shaken for 1 h at room temperature for complete dissolution. Fifty µL of MSTFA 
containing 0.1% TMCS were added to samples in the glove box.  The mixture was 
incubated at 55 °C for 1 h, resulting in trimethylsilane derivatization of amide, amine, 
carboxyl, and hydroxyl groups.  The derivatized serum samples were subjected to DART-
MS analysis as described in Section 5.3.1.4. 
5.3.1.3 Mass Spectrometry Instrumentation 
MS analysis was performed with a DART SVP 100 source (IonSense, Saugus, 
MA, USA) coupled to a hybrid QTOF mass spectrometer (Bruker micrOTOF-Q II; 
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Bremen, Germany). Prior to coupling, the mass spectrometer interface was modified with 
the addition of a custom-built gas-ion separator tube (GIST) connected to a Vacuubrand 
2C diaphragm pump (Vacuubrand, Wertheim, Germany) to reduce the amount of  
discharge gas flowing into the mass spectrometer atmospheric pressure inlet. A DART 
helium flow rate of 1 L min-1 heated to 250 °C was chosen for all experiments unless 
otherwise indicated. The exit grid voltage was set at +350 V. The settings for the QTOF 
mass spectrometer were as follows: inlet capillary voltage, -1500 V, end plate offset, -500 
V, drying gas (nitrogen) flow rate, 2.0 L min-1, drying gas temperature, 150 °C, ion 
funnel 1 RF, 150 Vpp, ion funnel 2 RF, 200 Vpp, hexapole RF, 100 Vpp, quadrupole ion 
energy, 5 eV, collision cell transfer time, 77 µs, collision cell pre pulse storage, 5 µs. All 
experiments were conducted in positive-ion mode. Spectra were acquired at 1.0 Hz in the 
35 – 1000 m/z range. Tandem MS experiments were conducted utilizing nitrogen as the 
collision gas with 10 and 30 eV collision energies. The instrument was mass calibrated 
before conducting experiments using a 1:1 solution (v/v) of PEG 400 and 600. Mass 
spectral data processing, signal averaging, and background subtraction were performed 
using DataAnalysis 4.0, the built-in mass spectrometer software. SmartFormula and 
SmartFormula 3D, DataAnalysis 4.0 modules, were used to attain elemental formulas for 
MS and MS/MS experiments. 
5.3.1.4 Direct Analysis in Real Time Setup 
For PM-DART analysis, 0.8–1.1 o.d. x 90 mm-long glass capillary probes 
(Kimble Chase, Vineland, NJ, USA) were used. One µL of sample was deposited on the 
closed end of the glass probes. Probes were placed on a custom built holder (“module”) 
mounted on a software-controlled linear rail (IonSense, Saugus, MA, USA) positioned 
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between the DART ion source and the GIST (Figure 5.2). An automated DART software 
method was utilized for sample introduction. This method had a waiting period of 5 s, 
after which the probe was moved towards the ionization region at 10 mm s-1. Before 
entering into the ionization region, the movement of the probe was paused. Following a 
speed change to 0.4 mm s-1, the probe was moved an additional 7 mm and was stopped in 
front of the DART source for data acquisition. The DART software method was started 








 Stainless steel (SS) mesh type 304 (IonSense) and type 316 (TWP Inc., Berkeley, 
CA, USA) were employed as sample substrates for TM-DART experiments. Samples 





Linear Rail Probe Module 
Gas-ion Separator Tube 
(leading to MS inlet) 
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T316). The SS mesh substrates had the following characteristics: wire diameter, 0.004 in 
(SS mesh strips) or 0.0075 in (SS mesh discs), mesh size, 74 x 74 wires in-1 (SS mesh 
strips) or 60 x 60 wires in-1 (SS mesh discs), open area, 52.7% (SS mesh strips) or 30% 
(SS mesh discs). A 1 in long SS mesh strip or individual 1 cm (diameter) SS mesh discs 
were placed in the mesh holder module having 10 open slots available for sample 
deposition (Figure 5.3). The exposed mesh areas in these slots were 33 mm2. No sample 
was deposited on the first slot, followed by deposition of 2 µL of derivatized serum 
solution on the central point of the exposed mesh in the second slot. Deposition of 





Figure 5.3: Photograph of the automated TM-DART system. The top panel displays the 
module used to hold the stainless steel mesh strip or discs, as well as a stainless steel 
mesh strip. The bottom panel shows the automated TM system during an analysis placed 




As with PM-DART, an automated DART software method was used. This method had 
no waiting period. The module was moved towards the ionization region at 10 mm s-1 and 
stopped when the first exposed mesh was in front of the DART source. The module 
advanced to adjacent exposed areas at 10 mm s-1.  
For all data shown, mass spectrometric signals were only averaged for the first 45 
s of the analysis time and experiments were carried out in triplicate. Optical microscope 
images of samples spotted on meshes were acquired with an Olympus BX41 laboratory 
microscope equipped with an Olympus DP12 digital microscope camera (Olympus 
America Inc., Melville, NY, USA). A FLIR T-Series Infrared Camera (FLIR Systems, 
Inc., Boston, MA, USA) was used to acquire images of the TM-DART experimental 
setup.  
The identity of metabolites was tentatively annotated by matching accurate 
masses against a custom built database encompassing entries for endogenous human 
metabolites found in the Human Metabolome Database (HMDB).26 Entries for 
compounds reacting with the MSTFA/TMCS reagent mixture were manually expanded to 
take into account mono-, di-, tri-, tetra-, penta-, and/or hexa-trimethylsilane (TMS) 
derivatives. Matching metabolites not found in human blood sera were excluded. The 
matching of experimental data to database accurate mass records was performed using 
the SearchFromList application included in the Mass Spec Tools suite of programs 
(ChemSW, Fairfield, CA, USA) using a tolerance of 10 mDa and a relative intensity 




5.3.2 Application of Transmission Mode Direct Analysis in Real Time for 
Cystic Fibrosis Detection 
5.3.2.1 Chemicals 
Omnisolv LC-MS grade acetonitrile was purchased from EMD (Billerica, MA, 
USA). Ultrapure water with 18.2 MΩ cm resistivity (Thermo Scientific Barnstead 
Nanopure UV ultrapure water system, Marietta, OH, USA) was used in sample 
preparation protocols. 
5.3.2.2 Exhaled Breath Condensate Sample Collection and Preparation 
EBC samples from 5 healthy controls and 4 patients diagnosed with cystic fibrosis 
(CF) were collected under the guidelines approved by the Georgia Institute of 
Technology and the Emory University Institutional Review Boards (approval number 
IRB00000372). EBC was collected using an R-Tube collector (Respiratory Research, 
Inc., Austin, TX, USA) and kept frozen at -80 °C until processed.  Prior to analysis, EBC 
samples were thawed, and 2 mL aliquots were placed into separate vials, stored at -80 °C 
for a minimum of 2 h, and freeze-dried overnight using a VirTis bench top freeze-dryer 
(SP Industries, Stone Ridge, NY, USA). The remaining residues were reconstituted, 
without derivatization, in 100 μL of acetonitrile:water 80:20 v/v (concentration factor = 
20) and analyzed by TM-DART-TWIMS-TOF MS in the negative ion mode to test the 
feasibility of this technique in metabolomics investigations. 
5.3.2.3 Traveling Wave Ion Mobility Mass Spectrometry Instrumentation 
TWIMS-TOF MS was performed in negative ion mode on a Synapt G2 High 
Definition Mass Spectrometry system (Waters Corporation, Manchester, UK), a hybrid 
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quadrupole-ion mobility-orthogonal acceleration TOF mass spectrometer with a typical 
resolving power of 20,000 m/∆m (FWHM) and mass accuracy of 9 ppm at m/z 554.2615.  
TWIMS parameters were as follows: wave height ramped between 10–40 V; wave 
velocity ramped between 400–1000 m s-1, IMS gas flow rate: 40 mL min-1; helium gas 
flow rate: 180 mL min-1.  The mass spectrometer was calibrated across the range of m/z 
50–1000 using a 0.5 mM sodium formate solution prepared in 90:10 2-propanol:water 
v/v.  Raw data were evaluated using MassLynx v4.1. 
5.3.2.4 Transmission Mode Direct Analysis in Real Time Setup 
A DART SVP 100 ion source and transmission module (IonSense, Saugus, MA) 
were used to conduct TM-DART experiments at a 1 L min-1 He gas flow rate. The 
discharge gas was heated to 300 °C.  A custom-built flange and gas-ion separator tube 
(GIST), connected to a Vacuubrand 2C diaphragm pump (Vacuubrand, Wertheim, 
Germany), was used to couple the DART ion source to the mass spectrometer interface to 
reduce the amount of discharge gas flowing into the mass spectrometer atmospheric 
pressure inlet.  The exit grid voltage was set at 300 V.  Individual 1 cm stainless steel 
mesh discs were placed within the 10-position transmission module and 4 µL of sample 
(i.e. solvent blank or EBC concentrate) was deposited in the center of the exposed mesh 
area and allowed to dry for approximately 5 min.  Three technical replicates were 
analyzed for each sample, leaving a blank mesh positioned before every deposited sample 
spot.  An automated method was used to introduce the transmission module into the 
DART ionization region at 10 mm s-1, and each position was held within the DART 
ionization region for 2 min.  To avoid disturbing the DART ionizing gas stream, only a 1 
s hold time was used when the transmission module was advanced to the next position. 
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5.3.2.5 Data Analysis 
 Metabolic features were extracted from TWIMS-TOF MS data as drift time-m/z 
pairs using MZmine 2.10.27  Although originally designed for extracting chromatographic 
data, the drift time function of the acquired TWIMS-TOF MS data could be analyzed 
similarly using MZmine 2.10, as the ion mobility chronograms obtained from DART 
experiments resemble typical chromatograms.  The feature extraction workflow consisted 
of mass detection followed by the generation, deconvolution, de-isotoping, alignment, 
and integration of extracted ion mobility chronogram peaks.  Due to the nature of ion 
separations in IM-MS experiments, where different adduct species do not necessarily 
coincide in drift time, mass spectral adduct ion analysis was not performed. EBC sample 
data were curated against corresponding solvent blank data to determine EBC-specific 
features, where features with peak areas ≥10× those present in solvent blanks were 
deemed EBC-specific. 
 The resulting matrix from metabolic spectral feature extraction of TM-DART 
TWIMS-TOF MS data from 5 healthy controls and 4 CF patients was utilized to build a 
model for sample class discrimination via oPLS-DA and to down-select a smaller panel 
of highly-discriminant features through the usage of a genetic algorithm (MATLAB 
Version 7.13.0, The MathWorks, Inc., Natick, MA, USA with PLS_Toolbox v.6.71, 
Eigenvector Research, Inc., Wenatchee, WA, USA).  A panel of 9 discriminant features 
had the lowest root-mean-square error of cross-validation (RMSECV) at the conclusion 
of the genetic algorithm variable selection process.  The parameters for genetic algorithm 
variable selection were as follows: population size: 64, variable window width: 1, % 
initial terms (variables): 15, target minimum # of variables: 1, target maximum # of 
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variables: 8, penalty slope: 0.005, maximum generations: 150, % at convergence: 79.7, 
mutation rate: 0.005, crossover: double, regression choice: PLS, # of latent variables: 4, 
cross-validation: random, # of splits: 3, # of iterations: 5, replicate runs: 10.  PLS-DA 
models were orthogonalized and internally cross-validated using leave-one-out cross-
validation.  Data were preprocessed by mean-centering prior to oPLS-DA analysis.  
Principal component analysis (PCA) was also performed to inspect data before and after 
genetic algorithm variable selection (i.e., on all of the extracted spectral features and only 
the discriminant feature panel). 
MetaboSearch28 was utilized to search the METLIN database,29 the LIPID 
Metabolites and Pathways Strategy (LIPID MAPS) database,30 and the human 
metabolome database (HMDB)26 for endogenous metabolite candidates solely using 
neutral masses with a mass accuracy error no greater than 15 mDa.  
5.4 Optimization of Transmission Mode Direct Analysis in Real Time 
Experimental Variables 
A typical TM-DART mass spectrum of MSTFA-derivatized human blood serum, 
along with microscopic images of the sample spot before and after analysis, is shown in 






Figure 5.4: Microscopic image of a dried, derivatized human serum sample (a) before 
and (b) after TM-DART analysis with the (c) corresponding background-corrected 
positive ion mode mass spectrum in the 50 – 850 m/z range. The inset details the signals 





It was observed that, once dried, samples “sat” on the SS mesh instead of being 
interspersed around the SS strands which constitute the mesh (Figure 5.4a). Exposure to 
the heated DART stream resulted in desorption of the entire sample (Figure 5.4b) after 45 
seconds. The ensuing mass spectrum was highly complex (Figure 5.4c) as many 
metabolite-related features were detected. Closer investigation of this TM-DART mass 
spectrum (Figure 5.4c, inset) revealed that many less-dominant ion signals also existed. 
Table 5.1 shows elemental formulas assigned to species present in the spectrum shown in 
Figure 5.4, and their tentative annotations based on matches to entries in the HMDB. 
An investigation of the sources of sensitivity drift in TM-DART was carried out 
to better understand what experimental variables should be controlled for ensuring 
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optimum coefficients of variation (CV) values. In initial exploratory experiments using 
SS mesh strips, a progressive increase in the total ion current (TIC) was observed for 




Table 5.1. Tentative annotation of peaks selected from the chemically derivatized human blood serum mass spectrum shown in 

























189.1211 189.1113 9.8 C7H15N3O3 Homocitrulline HMDB00679 
204.1434 [M+2TMS+H]+ 59.0565 59.0483 8.2 CH5N3 Guanidine HMDB01842 
221.1288 [M+TMS+H]+ 148.0814 148.0735 7.9 C6H12O4 Mevalonic acid HMDB00227
a 
250.1344 [M+TMS+H]+ 177.0870 177.0789 8.1 C10H11NO2 5-Hydroxytryptophol HMDB01855
b 
263.1405 [M+2TMS+H]+ 118.0536 118.0629 9.3 C5H10O3 3-Hydroxyvaleric acid HMDB00531
c 



















Table 5.1 (continued). 
 
 
442.2507 [M+4TMS+H]+ 153.0848 153.0789 5.9 C8H11NO2 Dopamine HMDB00073
f 
461.1880 [M+3TMS+H]+ 244.0616 244.0695 7.9 C9H12N2O6 Uridine HMDB00296
g 
461.1880 [M+4TMS+H]+ 172.0220 172.0136 8.4 C3H9O6P Glycerol 3-phosphate HMDB00126
h 
468.2395 [M+4TMS+H]+ 179.0735 179.0793 5.8 C6H13NO5 Glucosamine HMDB01514
i 













513.2819 513.2760 5.9 C26H43NO7S Sulfolithocholylglycine HMDB02639 
526.2593 [M+4TMS+H]+ 237.0934 237.0861 7.2 C9H11N5O3 Biopterin HMDB00468
k 
700.3462 [M+2TMS+H]+ 555.2593 555.2692 9.9 C28H37N5O7 Enkephalin L HMDB01045 
700.3462 [M+6TMS+H]+ 267.1012 267.0954 5.8 C9H17NO8 Neuraminic acid HMDB00830 
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Table 5.1 (continued). 
 
a1 isomer found with source ID HMDB12140; b1 isomer found with source ID HMDB12490; c10 isomers found with source IDs 
HMDB02011, HMDB00351, HMDB00410, HMDB00642, HMDB01863, HMDB00354, HMDB00396, HMDB00407, 
HMDB01987, HMDB00754; d3 isomers found with source IDs HMDB13311, HMDB02266, HMDB00393; e1 isomer found 
with source ID HMDB03148; f1 isomer found with source ID HMDB04825; g1 isomer found with source ID HMDB00767; h1 
isomer with source ID HMDB02520; i1 isomer found with source ID HMDB02030; j1isomer found with source ID 




Figure 5.5: Total ion chronogram observed during TM-DART analyses of a derivatized 
serum sample showing an increase in the abundance of detected ions for each successive 







Figure 5.6: Thermal IR images of the TM-DART ion source and sampling module 
assembly during the analysis of a derivatized serum samples. The DART cap (1) in the IR 
images rests in close proximity of the module (2) where the sample is spotted for 
analysis. Two previously-analyzed mesh holder samples positions (3) are shown on the 
left, and two mesh positions in the queue (4), waiting to be analyzed, on the right. The 
color scale displays the measure temperature in Celsius. The set DART temperature was 
250 °C. 
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As metabolite ion intensities were monitored, this phenomenon greatly impacted the 
reproducibility of TM-DART analyses. To investigate possible origins of this temporal 
drift effect, the TM-DART experimental set-up was thermally imaged with an IR camera 
during the analysis of a serum sample (Figure 5.6). A temperature increase in parts of the 
TM module surrounding the spot being analyzed was observed. Additionally, the sections 
of the SS mesh strip exposed in the two spots adjacent to the spot being sampled were 
also observed to be heated to higher-than-ambient temperature (~52°C) due to the good 
thermal conductivity of stainless steel. It is likely that this heat gain could allow for some 
extent of sample carryover (or loss) from one sampled spot to the next one during TM-
DART analyses. Moreover, fringe heating of a sample prior to its analysis could cause 
premature melting, leading to a subsequent redistribution of the sample on the mesh. It is 
also plausible that desorption and ionization processes would be more efficient on a “pre-
heated” sample, causing a progressive increase in signal as samples placed later in the 
analysis queue were interrogated. In an effort to mitigate these potential thermal effects, 
SS mesh discs instead of strips were used for TM experiments. As an additional 
cautionary measure, samples were deposited in an alternating manner, leaving one SS 
mesh disc void of sample between each SS mesh disc being analyzed. 
As the key step in the DART ionization mechanism involves proton transfer 
reactions from protonated water cluster reagent ions to desorbed analyte neutrals, the 
intensities of various reagent ions (H2O)nH
+ (n = 5, 6, 8, 11, 13) were monitored to 
determine if these species were consistently available during successive same sample 
analyses (Figure 5.7). Data was collected immediately after the DART corona-glow 
discharge was activated. As shown, the intensities of the monitored reagent ions 
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increased for at least 30 minutes before stabilizing, despite the fact that the temperature 
of the ionization region stabilized within 1 minute and the relative humidity in the 
environment was constant.  Therefore, part of the observed increase in TIC for repeat 
serum sample analyses during this “warm up” period seemed to correlate with observed 
changes in reactant ion abundances, indicating that, under these conditions, a finite time 
is needed for species in the DART plasma and/or ionization region to reach a steady state 
which would ensure that subsequent experiments are reproducible.  Because proton 
transfer reactions of basic polar molecules under atmospheric pressure conditions are 
under kinetic control, following pseudo-first order reaction kinetics, changes in the 
reactant ion population are bound to change reaction rate constants. Upon investigation, it 
was found that the original vendor TM-DART software methods deactivated and 
reactivated the DART corona-glow discharge prior to the TM module entering into the 
ionization region. Consequently, any efforts to maintain reagent ion signal stability using 
a “warm up” period were negated. New software methods that did not deactivate the 
DART corona-glow discharge were subsequently created to solve this problem. The 
aforementioned implementation of SS mesh discs in TM-DART experiments, 
modification of the software sample insertion methods for ensuring stabilization of the 
reagent ion population, and leaving SS mesh discs void of sample between serum 






Figure 5.7: Extracted ion chronograms for selected reagent water cluster ions present in 
the DART ionization regions for a period of ~50 minutes after application of high voltage 





As a primary aim of untargeted metabolic profiling is to acquire maximum 
coverage for detected metabolites both in terms of sensitivity and mass range, the key 
DART experimental variables affecting metabolite desorption and ionization were 
optimized. First, the sensitivity and reproducibility of TM-DART MS for liquid and dried 
blood serum samples were investigated via 3 sample deposition/introduction strategies: 
(A) serum sample introduced into the ionization region without prior drying, (B) serum 
sample dried with heated nitrogen from the DART source with the discharge deactivated, 
and (C) serum sample self-dried on mesh before introduction into the ionization region 
(Figure 5.8). For the monitored ionic species (m/z  315.1042, C13H23O5Si2
.
 , m/z  
416.2246, C19H38NO5Si2
., m/z  640.3391, C33H54N3O4Si3
., m/z 714.3601, 
C29H60N7O6Si4
.), the sample deposition methods that involved a drying step before 
analysis (B and C) had CVs of 30% and 18.3%, respectively. Utilizing a non-dried serum 
sample resulted in less precise results (CV: 26.3%) than the self-dried serum sample. 
 







TIC after turning on HV_1.d: EIC 199.160000±0.01 +All MS TIC after turning on HV_1.d: EIC 235.180000±0.01 +All MS
TIC after turning on HV_1.d: EIC 145.090000±0.01 +All MS TIC after turning on HV_1.d: EIC 91.050000 +All MS







































Interestingly, the intensities of the lower mass ionic species (m/z < 600) were higher 
when samples were first dried, while the higher mass species (m/z > 600) showed an 
inverse behavior.  Although this observation is not yet completely understood, a 
“splattering” effect may be the probable cause of this observed trend.  The non-dried 
serum sample may begin to splatter when exposed to the DART gas stream, so a loss of 
the more volatile, lower mass species could more easily occur as a result of thermal 
losses during the desorption process. Higher mass species may benefit from desorption 
from a “wet” sample, as the solvent removes intermolecular interactions which reduce 






Figure 5.8: Effect of serum sample deposition strategy (A: liquid sample; B: sample 
dried with heated N2 from DART source; C: self-dried sample) on sensitivity and 
reproducibility of successive TM-DART analyses for mass spectrometric signals at m/z = 
315.1042, C13H23O5Si2, m/z = 416.2246, C19H38NO5Si2, (top panel) and signals at m/z = 




 Experiments also showed that the position of the DART gas outlet relative to the 
SS mesh greatly affects the intensity and information content of the observed signal from 
serum samples analyzed by TM-DART MS (Figure 5.9). Sensitivity was greatly reduced 
when the DART gas outlet was not in close proximity of the SS mesh holder (ii > 1 mm 
in Figure 5.9a). This effect is most likely caused by excessive cooling leading to poor 
thermal desorption. Therefore, only the effect of mesh-to-GIST distance (indicated as “i” 
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in Figure 5.9a) on sensitivity was investigated. The current TM-DART set-up limits 





Figure 5.9: The sensitivity of TM-DART MS analysis is influenced by the position of the 
SS mesh substrate in the ionization region. Two parameters (a) determine this position: 
the distance from the GIST to the SS mesh (i) and the distance from the mesh to the 
DART cap (ii). The effect of varying distance “i” on the sensitivity for untargeted 




Higher intensities for metabolite ions were obtained at mesh-GIST distances of 5 and 12 
mm. Coverage for detected metabolites extended to 800 m/z for these distances. A major 
decrease in intensity occurred at 19 mm and not many metabolite ions beyond 700 m/z 
were detected. The shorter mesh-GIST distances probably allowed for enhanced fluid 
dynamic focusing of the ions toward the GIST, as previously shown by fluid dynamic 
simulations.10  These simulations showed that in TM-DART, the heated gas plume is 
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channeled almost completely through the sample area when the DART cap is in close 
proximity to the module. Since this is also likely occurring in the current system, the 
farther away the mesh is positioned from the GIST, the poorer the ion transmission due to 
divergence of the gas stream and the resultant observed sensitivity. 
Figure 5.10a demonstrates the effect of increasing the set DART temperature on 





Figure 5.10: Effect of helium gas temperature on TM-DART MS sensitivity for 
untargeted metabolic profiling of derivatized serum: (a) absolute intensities of monitored 
signals in the low mass range and (b) absolute intensities of monitored signals at higher 
masses. Intensities were monitored at DART set temperatures of 100, 150, 200, 250, 300, 




Lower temperatures were efficient enough to desorb lower mass metabolites from 
samples with the best sensitivity. Increasing the temperature beyond 200 °C conceivably 
allowed for thermal degradation of low mass metabolites.31 Conversely, the intensity of 
higher-mass ionic species (m/z > 600) increased with increasing temperature before 
beginning to stabilize at 300 °C (Figure 5.10b).  Higher temperatures resulted in more 
efficient desorption of higher mass metabolites as the amount of thermal energy required 
for their volatilization is higher compared to that of lower mass metabolites. Increasing 
the temperature beyond 350 °C most likely increased the thermal degradation rate of all 
metabolites. 
An advantage of hyphenated platforms for metabolic profiling is the reduced 
potential for ion suppression effects. As the DART analyte desorption process is thermal, 
temperature ramping can be used to partially separate metabolites in time based on their 
volatility.32, 33 A pseudo-separation dimension can be incorporated to the analyses while 
maintaining the high throughput nature of DART. Figure 5.11 shows extracted ion 
chronograms for several ionic species produced from a blood serum sample for a three 
minute temperature ramping experiment starting at 150 °C and ending at 450 °C. Varying 
desorption profiles were observed for the ionic species. Generally, the intensities of lower 
mass metabolic ionic species began to decay after 30 seconds, while intensities of higher 






Figure 5.11: Effect of ramping the set helium gas temperature on intensities of monitored 
mass spectrometric signals in the low (top panel) and high (bottom panel) mass ranges. 




Increasing the flow rate of the ionizing gas from 0.5 to 1.0 L min-1 resulted in an 
upward trend for the intensities of all of the monitored metabolic ionic species (Figure 
5.12). Increased flow rates resulted in more reactive species interacting with serum 
samples in a set time period, thereby, allowing for enhanced ionization. As the ionizing 
gas stream additionally aids in ion transport to the GIST, sensitivity was also enhanced 
through this secondary effect.  Flow rates higher than 1.0 L min-1 resulted in slightly 
decreased intensities for all of the monitored metabolic ionic species and undesirable 






































Figure 5.12: Effect of helium gas flow rate on TM-DART MS sensitivity for 
untargeted metabolic profiling of derivatized serum: (a) absolute intensities for selected 
ions below m/z = 600, (b) absolute intensities for selected ions above m/z = 600. 




5.5 Comparison of Probe Mode Direct Analysis in Real Time and 
Transmission Mode Direct Analysis in Real Time 
The antimalarial quinine was used as a test compound to investigate the precision 
of both PM- and TM-DART operational modes in the absence of matrix effects. An 
internal standard was not used due to the difficulties associated with assessing the type of 
compound that should be utilized when analyzing a large number of unknown 
metabolites and evidence of the occurrence of major ion suppression when an internal 
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standard was added to serum samples (data not shown). It was found that CV values for 
the [M+H]+ quinine ion were lower for TM-DART than PM-DART (Table 5.2), thus 
supporting the hypothesis that minimal variance in sample positioning, and minimization 




Table 5.2: Reproducibility comparison between automated PM- and TM-DART 
experiments. The absolute intensities of [M+H]+ quinine ions were monitored (n = 3) at 








Repeat PM-DART analysis of the 10 µM quinine solution resulted in a CV of 92%.  
Upon further inspection of the data, an outlier data point was detected. If this outlier was 
removed from the data set, the CV was reduced to 50%, which was still greater than TM-
DART.  During this work, we commonly encountered outliers with PM-DART. The 
smaller diameter of the probes utilized for PM-DART caused the sample deposition 
process to be more difficult and less reproducible. Manually depositing samples on the 
same probe position for all experiments is exceedingly difficult, and sample dispersion 
(wetting) on the probe is often observed. Overall, we found that TM-DART required less 
technical replicates and post-analysis user intervention than PM-DART. 
Absolute Intensity 10 µM 15 µM 
  Average CV% Average CV% 
Transmission Mode 6.2x103 21 1.1x104 16 
Probe Mode 1.4x105 92 1.6x105 35 
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Quinine calibration curves generated by TM-DART were found to have a better 





Figure 5.13: Signal linearity for TM-DART (left) and PM-DART (right). The absolute 
intensity of the [M+H]+ quinine ion was monitored (n = 3) for 1 (PM), 10, 15, 25, 75 
(TM), 100 (TM), and 150 (TM) µM solutions. The experimental data was linearly fitted 
to a 𝑦 = 𝑚𝑥 + 𝑏 model.  The regression parameters for each DART operational mode are 




Due to the thermal desorption processes involved in DART ionization, the sensitivity 
observed in both modes was directly related to the thermal conductivities of the substrate 
materials over which the sample was deposited (glass: 1 W m-1 K-1, stainless steel: 15 W 
m-1 K-1).34, 35 During TM-DART analyses, stainless steel more efficiently dissipates the 
heat from the helium plasma plume, resulting in less thermal energy focused on the 
sample for analyte desorption. As the glass probes are thermally insulating, the heating 
Quinine Concentration (µM)
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rate for analyte desorption in PM-DART is higher, thus leading to a more transient and 




Figure 5.14: Extracted ion chronograms of the [M+H]+ (m/z 325.1920) ion observed 




5.6 Transmission Mode Direct Analysis in Real Time Tandem Mass 
Spectrometry 
A distinct aspect of TM-DART is the long-lasting ion signal observed (Figure 
5.14), with a duration much greater than that for PM-DART.  These long lasting signals 
allow tandem MS experiments with more constant precursor ion intensity, thus enabling 
more confident metabolite identification.36, 37  High mass accuracy product ion spectra 
not only enable down-selecting likely metabolites from a list of candidates, but also 
increase the confidence of a given match by determining whether a significant fraction of 
the fragment ions’ elemental formulae are “contained” in the candidate elemental formula 
of the precursor ion. 





10TSM3D3_G_Pos3_04mmsec_1uL_2.d: EIC 195.0 +All MS










Figure 5.15: TM-DART full scan MS (a) and 30 eV product ion spectrum (b) for D-





 As an initial assessment of the tandem MS capabilities of the TM-DART 
approach, we tested the system on a model lipid species. Particularly, sphingolipids are 
involved in the regulation of cellular proliferation and death through their role as 
signaling molecules.38, 39 Due to their structural diversity, many sphingolipids share the 
same elemental formula. D-erythro-sphingosine (C18H37NO2), was fragmented using the 
TM-DART MS/MS method (Figure 5.15). The [M+H]+ precursor ion derived from the 
survey spectrum had two elemental formula matches when a tolerance of 15 ppm was 
used: C18H38NO2 and C16H36N4O (Table 5.3), with C18H38NO2 having the best score 




Table 5.3: Elemental formula result generated by SmartFormula from the full DART MS 










Incorporating fragmentation data resulted in three elemental formula possibilities within a 
15 ppm error (Table 5.4). Both C18H38NO2 and C16H36N4O explained the same 
Measured m/z: 300.2919 




C18H38NO2 100 300.2897 -7.3 17.1 
C16H36N4O 32 300.2883 -11.8 11.1 
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percentage of the fragment peaks, but C18H38NO2 remained the best match as it had the 
best mass accuracy (error of -2.6 ppm) and isotopic pattern matching (lowest mSigma 
value). Incorporating the fragmentation data lowered the mSigma value of C18H38NO2 
relative to that of C16H36N4O. In this case, the additional metabolite fragmentation data 
enabled better down-selection of the correct precursor ion elemental formula candidate. 
Data of this nature is immensely valuable for metabolomic studies in which the 




Table 5.4: Elemental formula results generated by SmartFormula 3D from the 10 eV 















C18H38NO2 300.2897 -2.57 74.2 25.0 
C16H36N4O 300.2883 -7.04 79.8 25.0 
C14H34N7 300.2870 -11.52 85.8 12.5 
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5.7 Application of Transmission Mode Direct Analysis in Real Time 
Metabolic Fingerprinting 
TM-DART was interfaced with TWIMS-TOF MS to investigate the feasibility of 
utilizing TM-DART for metabolomics investigations. Experiments have shown that TM-
DART-TWIMS-MS adds to the chemical diversity of metabolites detected in exhaled 
breath condensate (EBC) (data not shown: experimental data is currently being analyzed 
by Fernández research group member José J. Pérez), so TM-DART-TWIMS-MS EBC 
metabolomics was employed for cystic fibrosis (CF) detection. CF is an autosomal 
recessive disorder caused by a mutated cystic fibrosis transmembrane conductance 
regulator (CFTR) gene. CFTR is a voltage-gated chloride channel.40 Metabolomics has 
the potential to expose metabolic alterations associated with CF pathology and aid in the 
discovery of biomarkers for which new CF therapeutics can target.41 TM-DART-
TWIMS-TOF MS metabolic profiles were acquired from the exhaled breath condensate 
(EBC) of 4 CF patients and 5 healthy controls. A total of 66 metabolic features (unique 
dt, m/z pairs) were extracted from the acquired metabolic profiles. An oPLS-DA model 
built from these extracted features was used to discriminate EBC samples from CF 
patients and healthy controls. Two latent variables interpreting 46.43% of the data matrix 
variance from the X- (feature peak areas) block and 93.79% of the variance from the Y- 
(class membership) block resulted in 1 sample misclassification (Figure 5.16a and 5.16b). 
The cross-validated accuracy, sensitivity, and specificity were 88%, 100%, and 75%, 
respectively. Although the oPLS-DA model performance was not entirely poor, genetic 
algorithms were used to attain a smaller, yet more robust, metabolic feature set that could 
serve to better discriminate between CF patients and normal controls. A set of 9 
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metabolic features was selected through the genetic algorithm variable selection process 
as having the lowest RMSECV. The oPLS-DA model generated with this smaller panel 
(Figure 5.16c and 5.16d) resulted in 100 % cross-validated accuracy, sensitivity, and 
specificity; hence, no samples were misclassified. This model interpreted 84.24% and 
94.29% of the X- and Y-block variances, respectively. The captured X-block variance 
was 1.8 times greater, thereby, demonstrating that the down-selected set of 9 features was 






Figure 5.16: Orthogonal projection to latent structures-discriminant analysis (oPLS-DA) 
models for the discrimination of CF patients (orange circles) from healthy controls (black 
squares).  (a): oPLS-DA calibration scores plot using the total initial set of 66 spectral 
features.  The model consisted of 2 LVs with 46.43% and 93.79% total captured X- and 
Y-block variances, respectively. The cross-validated accuracy, sensitivity, and specificity 
were 88%, 100%, and 75%, respectively.  (b): The corresponding CF cross-validated 
prediction plot for (a).  There was 1 misclassified CF EBC sample.  (c): oPLS-DA 
calibration scores plot using the 9 discriminant metabolic feature panel obtained from 
genetic algorithm variable selection.  The model consisted of 2 LVs with 84.24% and 
94.29% total captured X- and Y-block variances, respectively.  The accuracy, sensitivity, 
and specificity were all 100%.  (d): The corresponding CF cross-validated prediction plot 













































































































Figure 5.17: Principal Component Analysis (PCA) of cystic fibrosis (CF) patients 
(orange circles) and healthy controls (black squares).  (a): PCA scores plot using the 
initial set of 66 spectral features.  The model consisted of 2 PCs with 72.89% total 
captured variance.  (b): PCA scores plot using the 9 discriminant feature panel obtained 
from genetic algorithm variable selection.  The model consisted of 2 PCs with 84.49% 

























































Scores on PC 1 (57.59%)
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 To further investigate these results, PCA was utilized to evaluate the performance 
of the set of 9 discriminant features in an unsupervised manner. Scores plots were 
generated for both the initial set of 66 metabolic features and the set of 9 discriminant 
features (Figure 5.17). Using the initial set, 2 principal components interpreting 72.89% 
of the data matrix variance showed some clustering of sample classes, but each class 
contained outliers (Figure 5.17a). However, better clustering of CF patients was observed 
with the 9-feature 2-principal component PCA model that interpreted 84.49 % of the 
variance (Figure 5.17b), providing further evidence of the robustness of the set of 9 
discriminant features. TM-DART-TWIMS-TOF MS was able to successfully detect CF 
in this small sample cohort. 
Although not all of the discriminant metabolites tentatively identified (Table 5.5) 
have been reported to be present in EBC, two have been linked to research focusing on 
CF. Grasemann et al. found that asymmetric dimethylarginine is increased in the airways 
of CF patients and may contribute to airway obstruction by reducing nitric oxide 
formation.42 The authors suggested the endogenous hormone melatonin could aid in the 
reduction of asymmetric dimethylarginine in CF airways as in vivo experiments in rats 
have shown that melatonin treatment can decrease concentrations of asymmetric 
dimethylarginine in the liver, kidney, and blood plasma and increase nitric oxide 
formation.43-45 Higher levels of N-acetylserotonin sulfate, a melatonin metabolite, were 
observed in our cohort of CF patients (Table 5.5), suggesting that melatonin was more 
rapidly metabolized by the CF patients. Bacteria species belonging to the genus 
Inquilinus have been isolated from CF patients. Chiron et al. found that one isolated 
strain was able to use valeric acid as its sole carbon source during assimilation testing.46 
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2-Hydroxyvaleric acid, a valeric acid oxidation product, was detected as a CF 
discriminatory metabolite in this study (Table 5.5). Many discriminant metabolites were 
flavonoids and other dietary metabolites with endogenous functions. Flavonoids have 
been shown to increase the chloride conductance of CFTR with the ∆F508 mutation 

































217 2.68 184.0532 -2.96 0.043 [M-H]- - - - N/A 
240 3.28 243.1788 -1.93 0.08 [M-H]- 
C17H24O 243.1754 3.4 Panaxynol 
C12H24N2O3 243.1714 7.4 
Isoleucyl-Leucine (& 
isomers) 




273 3.36 297.0575 0.83 0.26 [M-H]- 
C12H14N2O5S 297.0550 2.4 
N-Acetylserotonin 
sulfate 
C13H14O8 297.0615 4.1 
Benzoyl glucuronide 
(Benzoic acid) 














Table 5.5 (continued). 
328 2.30 117.0452 0.77 0.12 [M-H]- 


































Table 5.5 (continued). 







1Fold change was calculated as the base 2 logarithm of the average peak area ratios for CF samples and control samples. Entries 







TM-DART MS is a powerful analytical technique for metabolic fingerprinting. 
With optimal desorption temperatures and gas flow rates for efficient ionization and ion 
transmission, this approach detects a broad mass range of species. Furthermore, TM-
DART MS has the ability to acquiring fragmentation data along with full scan MS data in 
a single experiment which minimizes sample consumption and allows for improved 
elemental formula assignment confidence. TM-DART coupled to TWIMS-TOF MS 
successfully detected CF in a small sample cohort, thereby, demonstrating it can be 
employed for probing metabolome changes.  Comparing data acquired by TM-DART MS 
to that of the more commonly used chromatographic-MS platforms will provide a better 
perspective on the relevance and amount of biochemical information derived from TM-
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CHAPTER 6. CONCLUSIONS AND OUTLOOK 
 
6.1 Abstract 
This chapter presents a summary of the results pertaining to the use of mass 
spectrometry (MS)-based metabolomics for cancer detection and the study of ecological 
interactions in addition to the development of TM-DART for metabolomic fingerprinting 
discussed in this dissertation. Additionally, potential future directions for continuation of 
this work are given. 
6.2 Ultra Performance Liquid Chromatography-Mass Spectrometry Serum 
Metabolomics for Cancer Detection 
6.2.1 Summary of Accomplishments 
 The major finding in the work presented in this dissertation is the feasibility of 
MS-based untargeted metabolomics for prostate (PCa) and ovarian cancer (OC) 
detection. A metabolite-based in vitro diagnostic multivariate index assay (IVDMIA) 
created from UPLC-MS/MS serum metabolomic analysis of 64 PCa patients and 50 
healthy individuals coupled to machine learning methods predicted the presence of PCa 
with high classification sensitivity, specificity and accuracy. A panel of 40 metabolic 
features was found to be differential with 92.1% sensitivity, 94.3% specificity, and 93.0% 
accuracy. Of further significance, the IVDMIA was able to correctly predict 100% of the 
true positives that were incorrectly diagnosed as negatives by the conventional PSA test; 
highlighting that a combination of multiple discriminant features yields higher predictive 
power for PCa detection than the univariate analysis of a single biomarker. Within the 
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discriminant panel, 31 metabolites were identified by high-resolution accurate mass MS 
and MS/MS, with 10 further confirmed chromatographically by standards. Fatty acids, 
amino acids, lysophospholipids, and bile acids have been identified among the 
discriminant metabolites, suggesting alterations in their metabolism. Additionally, several 
metabolites were mapped to the steroid hormone biosynthesis pathway. These 
observations demonstrate some of the plausible metabolic alterations in PCa, and provide 
further insight into the biological pathway changes associated with the disease. If higher 
throughput analysis, and lower analysis cost and complexity are desired, 13 metabolites 
that were found to be present in 90% of the entire sample cohort would still provide high 
classification sensitivity (88.3%), specificity (80.3%), and accuracy (85.0%) for 
cancerous and healthy samples. 
Two systems were used to investigate metabolic patterns for early detection of 
OC. In the first system, early-stage HGSC was successfully detected in a Dicer-Pten 
double knockout (DKO) mouse model utilizing UPLC-MS untargeted metabolic 
fingerprinting. After down-selection of metabolic features with maximum discriminatory 
power, 18 metabolites differentiated 14 DKO mice with early-stage tumors from 11 
control mice with 100% accuracy, sensitivity and specificity. Altered metabolic pathways 
included those of fatty acids, bile acids and alcohols, glycerophospholipids, peptides, and 
phytochemicals. These alterations impact cellular energy storage and membrane stability, 
as well as defenses against oxidative stress. Building upon previous work, the second 
system studied showed that early-stage OC detection in humans employing UPLC-MS 
untargeted metabolic fingerprinting is feasible. After down-selection of metabolic 
features with maximum discriminatory power by recursive feature elimination, 22 
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metabolites differentiated 24 early-stage OC patients from 40 healthy women with 100% 
cross-validated accuracy, sensitivity, and specificity. Although this was a small pilot 
study—poor early diagnosis currently complicates collection of large patient cohorts for 
more detailed studies—it demonstrates that metabolic information can be useful for 
detecting early-stage OC. 
6.2.2 Moving Forward 
 While the presented PCa and OC metabolic fingerprinting studies demonstrate the 
applicability of MS-based untargeted metabolomics for cancer detection, additional 
studies are needed to further validate and test the robustness of the proposed metabolite-
based detection panels. The following studies are recommended for future research: 
1. A drawback of the PCa and OC studies is the number of patients involved. 
Larger-scale studies are needed to prove that these metabolites are indeed 
indicators of these cancers across a broad population. According to formulas 
proposed by Arkin and Wachtel, a biomarker discovery study that aims to have a 
fixed specificity of 95% and sensitivity of at least 95% (±0.05) at the 95% 
confidence interval should include 73 diseased patients at minimum.1 Xia et al. 
advises matching each diseased patient to four random healthy controls for low-
prevalence diseases such as OC which affects 1.3% of women.2, 3 The authors also 
suggest multiplying the minimum sample size by 1.5 if multivariate models will 
be cross-validated. Therefore, using the OC metabolomics detection work as an 
example, at least 110 early-stage OC patients and 440 controls (healthy 
individuals) are needed for biomarker discovery studies. Currently, David Gaul (a 
research scientist in the Fernández research group) is pursuing an additional 
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metabolomics study for detection of early-stage OC in a larger patient cohort that 
builds upon what was demonstrated in the pilot human study presented in Chapter 
3. Additionally, María Eugenia Monge (a prior research scientist in the Fernández 
research group) has engaged in a collaboration with Hospital Italiano de Buenos 
Aires to determine if the findings presented in Chapter 2 still hold when applied to 
a cohort of 500 PCa patients of Argentine descent. 
2. The cancer detection studies presented were based on untargeted metabolomic 
fingerprinting methodology, but translation to a clinical setting will require the 
development of targeted assays. Tandem MS (as used for newborn screening of 
inherited metabolic disorders) provides the specificity and sensitivity needed for 
such targeted assays.4 Selected reaction monitoring (SRM) or multiple reaction 
monitoring (MRM) can be utilized to detect only user-specified precursor 
metabolite ions and the corresponding fragment product ion(s) (referred to as 
transitions). Experiments must be conducted to detect and ascertain the transitions 
of the discriminant metabolites determined in these studies to facilitate their use in 
a clinical setting. 
3. Only a fraction of the metabolic information that was amassed during these cancer 
detection studies was utilized. While primary aims were focused on 
demonstrating the efficacy of using metabolomics for biomarker discovery/cancer 
detection, the wealth of information garnered should also be utilized to investigate 
the biological processes and proliferative molecular mechanisms of these cancers. 
Instead of focusing on metabolite panels, all detected metabolites with significant 
concentration changes between groups should be mapped to further understand 
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the impact each cancer has metabolic pathways. A better understanding of the 
biological processes and proliferative molecular mechanisms can lead to more 
targets for chemotherapeutics. In this vein, this work also stands to benefit 
majorly from the integration of this data with other omics data such as 
proteomics. 
4. Preliminary MS imaging experiments of DKO mice oviduct tissue sections 
performed my Martin Paine (a postdoctoral researcher in the Fernández research 
group) have shown that chemically imaging metabolite abundances may provide 
useful information regarding tumor formation-associated metabolite abundance 
changes. Conducting similar experiments with cancerous tissue samples from 
humans may help in understanding the underlying metabolic perturbations caused 
by tumor development in both OC and PCa. 
For the OC Dicer-Pten DKO mouse model work specifically, an exploration of the 
shared metabolome overlap between DKO mice and humans at early stages of HGSC 
development is needed to further understand how relevant scientific findings resulting 
from research using this mouse model can carry over to the diseased human population. 
Moreover, as metabolomics is actively used to understand the molecular mechanisms by 
which chemotherapeutic drugs attack and destroy cancerous cells in addition to assessing 
the efficacy of treatment, the Dicer-Pten DKO mice can be used to gather metabolic 
fingerprints related to the efficacy of new chemotherapeutic drugs or to gain insights 
regarding the molecular mechanisms of their interaction with their targets since these 
mice provide a simpler, better-controlled model to study these effects. 
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6.3 Metabolic Impacts of Chemically Mediated Competition on Marine 
Plankton 
6.3.1 Summary of Accomplishments 
The work presented in Chapter 4 represents the first instance of metabolites and 
proteins measured simultaneously to understand the effects of allelopathy or any form of 
competition among diatoms. Whole cell metabolomic and proteomic analyses revealed 
differing responses of planktonic competitors to Karenia brevis allelopathy, suggesting 
that co-occurring species may have evolved partial resistance to allelopathy via robust 
metabolic pathways. In contrast, a “naïve” competitor, Thalassiosira pseudonana, which 
does not co-occur with K. brevis blooms, suffered greater metabolic disruption and 
growth suppression when exposed to K. brevis allelopathy. Critical metabolic processes 
including glycolysis, photosynthesis, cell membrane maintenance, osmoregulation, and 
responses to oxidative stress were all impacted in T. pseudonana. This interdisciplinary 
systems biology approach provided an unbiased opportunity to establish novel, testable 
hypotheses towards understanding the mechanisms by which allelopathy alters species 
composition in plankton communities, and, thus, the roles of chemical cues in mediating 
important ecological interactions. 
6.3.2 Moving Forward 
 K. brevis blooms pose threats to human health and destroy endangered marine 
mammal populations at an estimated cost of more than $18 million per bloom.5, 6 
Knowledge of the mechanisms by which allelopathy alters species composition in 
plankton communities, and, thus, the roles of chemical cues in mediating important 
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ecological interactions potentially allow for a deeper understanding of bloom dynamics 
that may lead to prediction and mitigation strategies to alleviate their harmful effects. 
While this work exemplified how the integration of data from systems biology fields can 
characterize physiological responses to stimuli and generate hypotheses related to cellular 
function, more can be done to further understand how K. brevis allelopathy affects 
competitor species. The following studies are recommended for future research: 
1. The presented work focused primarily on polar metabolites (i.e., non-lipids). Yet, 
plankton lipids mediate a number of important ecological interactions, including 
grazing,7 susceptibility to viral infection,8 and toxin sensitivity.9 Thus, future 
experiments testing how phytoplankton competition alters lipid biochemistry are 
needed. These experiments could lead to discovery of cascading ecological effects 
on other types of interactions. Remy Poulin (a graduate student in the Kubanek 
research group) has begun these experiments using NMR metabolomics. 
2. Thus far, the impact of K. brevis allelopathy on diatom metabolism was only 
investigated for one co-occuring competitor species—Assterionellopsis glacialis. 
Experiments should be conducted to understand the metabolic impacts on other 
co-occuring competitor species such as Skeletonema grethae, Odontella aurita, 
and Stephanopyxis turris.10 These experiments can produce further findings that 
generate hypotheses towards understanding the mechanisms by which allelopathy 





6.4 Transmission Mode Direct Analysis in Real Time for Metabolic 
Fingerprinting 
6.4.1 Summary of Accomplishments 
Although current hyphenated MS techniques are very powerful for metabolomics 
studies, there is a clear need for more rapid, high-throughput MS approaches. TM-DART 
MS was shown to be a powerful, rapid analytical technique for metabolic fingerprinting. 
With optimal desorption temperatures and gas flow rates for efficient ionization and ion 
transmission, this approach detects a broad mass range of metabolite ionic species. 
Ramping the ionizing gas desorption temperature further enhanced analysis by adding a 
simple separation dimension to this ambient approach. Furthermore, TM-DART MS has 
the ability to acquire fragmentation data along with full scan MS data in a single 
experiment which minimizes sample consumption and allows for improved elemental 
formula assignment confidence. In terms of reproducibility, monitored TM-DART 
signals from a quinine standard resulted in coefficients of variation as low as 16%. 
Moreover, TM-DART coupled to TWIMS-TOF MS successfully detected CF in a small 
sample cohort, thereby, demonstrating it can be employed for probing metabolome 
changes.   
6.4.2 Moving Forward 
 While TM-DART was successfully used to probe metabolome changes, more 
experiments are needed to establish the technique as viable for large-scale metabolomics 
studies. The following studies are recommended for future research: 
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1. Similarly to GC-MS analysis, serum samples used in the TM-DART method 
development work were derivatized via silylation reactions. Chemical 
derivatization reactions can create undesirable artifacts and also have varying 
degrees of efficiency as sterically hindered analytes may only be partially 
derivatized.11, 12 Moreover, this added sample preparation step decreases sample 
throughput, thus, increasing analysis time which may reduce the advantage of the 
inherent rapidness of the technique. As the EBC analyses did not require a 
derivatization sample preparation step, experiments should be conducted to 
evaluate the ability of TM-DART to analyze non-derivatized serum samples. 
2. Many biological sample types are utilized for metabolomic fingerprinting studies. 
The ability of TM-DART MS to acquire discriminant metabolic information from 
a multitude of sample types should be evaluated. This can be used to further show 
the applicability of TM-DART for many different metabolomic fingerprinting 
studies. 
3. Data acquired by TM-DART MS should be compared to that of the more 
commonly used chromatographic-MS platforms so that a better perspective on the 
relevance and amount of biochemical information derived from TM-DART MS 
experiments can be provided. José J. Pérez, a graduate student in the Fernández 
research group, is currently comparing the chemical information acquired from 
TM-DART MS analysis of EBC samples to that of direct infusion ESI and APCI 
MS. But, an evaluation of how TM-DART MS fares in comparison to LC-MS in 
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